Effective Dose Gradients in Lung Radiotherapy: Setting Target Margins and Monitoring Dose Deviations for Image-Guided Adaptive Strategies by Foster, William Kyle
Effective Dose Gradients in Lung Radiotherapy: Setting
Target Margins and Monitoring Dose Deviations for
Image-Guided Adaptive Strategies
by
William Kyle Foster
A thesis
presented to the University of Waterloo
in fulfillment of the
thesis requirement for the degree of
Doctor of Philosophy
in
Physics
Waterloo, Ontario, Canada, 2016
© William Kyle Foster 2016
Author’s Declaration
I hereby declare that I am the sole author of this thesis. This is a true copy of the thesis, including
any required final revisions, as accepted by my examiners.
I understand that my thesis may be made electronically available to the public.
ii
Abstract
Organ motion is a major source of geometric uncertainty in the delivery of external beam radi-
ation therapy. Organ motion that occurs during the delivery of radiation therapy is referred to
as intrafraction organ motion. Intrafraction motion is most predominant in the lungs due to the
respiratory motion of the diaphragm and lungs. This intrafraction motion presents a substantial
challenge to physicists and clinicians interested in the accurate prescription and delivery of a
dose in radiation treatment.
The convolution model of target motion described in this work was used to assess the impact
of respiratory motion on the delivered dose distribution. This model predicts the dose distribu-
tion that will be delivered in the presence of motion by performing a mathematical convolution
between the planned dose distribution and a probability distribution describing the target motion.
The model was modified from its original form to include the gradient of the probability density
function, which provides additional insight into the effect of target motion. The validity of the
convolution model in the context of intrafraction motion was established based on an analysis
of the model assumptions as well as experimental validation of the model predictions using ra-
diochromic film measurements. It is shown that the model makes useful predictions for a wide
range of regular and irregular breathing patterns.
Breathing trace recordings acquired during four dimensional computed tomography scans of
iii
502 unique patients were used in conjunction with the convolution model to simulate the effect
of target motion using MATLAB code developed in house. The motion effect on dose coverage
was simulated for each breathing trace on a range of target sizes in order to establish trends
which can be used to guide margin selection. The required margins were found to have a clear
dependence on the standard deviation of the probability distribution describing the target motion.
A method for calculating the margin required to maintain target dose coverage is presented. A
table of margin recommendations for a range of breathing patterns and target sizes is presented.
The effect of motion was also simulated on clinical treatment plans including a 3-field, a 4-field
and a volumetric modulated arc treatment. The clinical treatment plans demonstrate the interplay
between the static dose gradients seen in a clinical setting and the loss of dose coverage due to
breathing motion.
The validity of the technique is demonstrated for an extreme case of a small lung target
undergoing large amplitude motion. This result represents the full use of the proposed method-
ology. The process demonstrates that using the margins recommended in this work will ensure
target dose coverage, but that compromises will be made relative to the plan with unmodified
margins. The target dose coverage comes at the expense of increased target volume and poten-
tially increased dose to nearby organs at risk. An analytical approximation of lung target motion
and static dose distributions using Gaussian functions is used to demonstrate the limit of the
technique for small fields and the sensitivity of the model to its key parameters.
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Chapter 1
Introduction
1.1 Overview
The objective of radiotherapy is to deliver a lethal absorbed dose of radiation to the cells within
a prescribed target volume containing the tumour, while sparing the surrounding healthy tissues
as much as possible. Today this is achieved in radiotherapy centres using highly specialized
medical imaging systems, advanced software packages for dose calculation in treatment planning
systems, and medical linear accelerators (LINACs) to deliver the radiation. Each of the aspects
of a radiotherapy treatment are attended to by many well trained individuals and teams.
A radiotherapy treatment is usually delivered with an external beam of high energy X-rays or
electrons. When the radiation interacts with the atoms of the patient’s tissue, it imparts some of
its energy to those atoms. The energy that is absorbed by tissue causes chemical changes to the
atoms and molecules within the irradiated cells. These chemical changes can cause biological
damage which can ultimately result in the death of the cell. It is the objective of radiotherapy to
cause the death of cancerous cells while sparing healthy tissues as much as possible.
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The first step towards the development of a radiotherapy plan is the diagnosis of the disease.
This can be accomplished with diagnostic imaging tests such as ultrasound, X-ray computed to-
mography (CT) scans, positron emission tomography (PET) scans [5], or multi-modality imaging
such as a PET-CT scan [6]. Once the disease has been diagnosed, the development of a radiother-
apy treatment plan can begin in earnest. The major steps are laid out in Figure 1.1. The process
begins with careful imaging of the disease site within the patient [7]. This step involves immo-
bilizing the patient in a position which can be reliably replicated later at the time of treatment.
The imaging is typically performed using X-ray computed tomography (CT). This generates a
detailed map of the patient anatomy which includes the tissue density information required for
accurate dose calculation. Great care is taken during the initial simulation CT scan to position the
patient in a manner which is as easily reproducible and as comfortable as possible for the patient,
because the patient will be repeatedly set up in the same position for all treatment fractions.
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Figure 1.1: The steps involved in the development and delivery of a radiotherapy treatment plan.
After acquiring the patient image, the 3D image data is sent to the treatment planning com-
puters. The relevant target volumes and healthy organs are then delineated on the patient image
using specialized treatment planning software. After these structures have been defined within
the patient, the X-ray beam angles and shapes are selected in order to deliver the prescribed dose
to the target. This is a complicated procedure during which the planner is constantly trying to
balance the requirement to deliver the prescribed dose to the target while sufficiently sparing
the healthy tissues and organs. Great care must be taken during the treatment planning stage to
account for geometric uncertainties, such that the final plan can reliably deliver the prescribed
dose. These uncertainties are discussed in more detail below. Finally, the treatment plan data is
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transferred to the treatment delivery system. The dosimetry of many plans is confirmed prior to
delivering the treatment as part of a regular quality assurance (QA) program.
The final step is the delivery of the treatment. The delivery typically occurs over the course
of several days, with the delivery of a single ‘fraction’ each day. In order to help ensure accurate
delivery of the treatment, verification imaging of the patient setup is often acquired on the treat-
ment unit prior to delivering the radiation. Each step in the radiotherapy treatment plays a crucial
role in ensuring that the treatment is delivered as planned and, therefore, has the best chance of
attaining a positive patient outcome.
1.2 Geometric Uncertainties
From a technical perspective, a key objective of a radiotherapy treatment is the geometrically
accurate delivery of the prescribed radiation dose. Patient setup errors and organ motion are the
two main factors that could lead to a geometric miss of the dose delivery.
Setup errors result from the difficulty of reproducing the patient’s position relative to the
original planning CT before each treatment fraction. Many tools are used to assist the radiation
therapists with the task of reproducing the planning position of the patient on treatment day.
The most common approaches seek to immobilize the patient in the treatment position. This
can be accomplished using devices such as vacuum molded bags, which conform to the exterior
of the patient then stay rigid for future fractions. When treating head and neck cancers, patient
immobilization may be achieved using a plastic mesh mask. The mesh is pliable when heated and
can be formed to the patient’s face. The mask is also affixed to a frame which can be accurately
positioned on the treatment unit. The positioning of a patient on the treatment unit is also guided
by the use of fixed, wall mounted lasers. The patient can be aligned to the positioning lasers
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using external marks on the patient. As a rule of thumb, a treatment volume will be expanded by
a margin of 5 mm in all directions in order to reliably accommodate setup errors.
Organ motion generally falls into two categories: interfraction motion and intrafraction mo-
tion. Interfraction motion is organ motion that occurs in between treatment fractions. This may
result from changes in organ filling or changes in patient anatomy as a result of the radiotherapy
(e.g. a shrinking tumour). Interfraction motion will often manifest as change in the position of
a target volume (or organ) relative to the rest of the patient anatomy. Intrafraction motion is or-
gan motion occurring during the delivery of a fraction of a radiotherapy treatment. Intrafraction
motion typically results from motion that the patient has little or no control over, such as the
breathing motion of the lungs or the beating motion of the heart. The management of target mo-
tion during external beam radiation therapy (EBRT) is crucial for ensuring agreement between
prescribed and delivered dose to the patient and hence successful treatment outcomes.
Of particular interest to this thesis is the large intrafraction motion of the lungs caused by res-
piration. Other authors have described the motion of targets in the lung due to respiratory motion
[8, 9, 10]. It is generally noted that target motion in the lung is largest in the superior-inferior (SI)
direction, although each patient presents with a unique motion direction and amplitude. It has
also been shown that target motion resulting from patient respiration can cause the displacement
of lesions in the lung by up to 2 cm in some cases [11]. Organ motion of this magnitude falls well
beyond the typical 5 mm margin used to account for setup uncertainty, and therefore requires
additional consideration in the treatment planning process.
1.3 Motion Management of Lung Targets
A report by the American Association of Physicists in Medicine (AAPM) task group TG-76 [12]
highlights several different methods for managing respiratory motion, these include: motion
5
encompassing techniques (margin and target volume definitions), breath-hold techniques, gated
treatment delivery and real time target tracking methods. Each of these methods is discussed in
more detail in Chapter 3. The use of any of these techniques requires consideration of trade-
offs between dose conformality, technical feasibility, demand on clinical resources and patient
condition.
The least technically demanding (and therefore most widely used) of these approaches is to
define treatment volumes that account for the expected motion of the target. Within this approach
to motion management there are several different methods which can be used to define treatment
volumes. Widely accepted motion encompassing techniques include: margin expansion [13, 2,
1], the use of an internal target volume (ITV) determined by the range of target motion [14,
15] and probabilistic approaches to volume definition [16]. Since, by definition, the expansion
of treatment volumes is accompanied by an increase in normal tissue complication probability
(NTCP), a balance must be struck between improving target dose coverage with larger treatment
volumes and potential complications to healthy tissues.
Historically the motion of targets in lungs was studied with the use of fluoroscopic imaging
[17, 18, 19, 20]. The results of these types of studies alloweed researchers to make a lot of
progress in determining the extent of target motion, how external chest motion correlates with
target motion within the lung and early attempts at determining necessary treatment margins
to compensate for target motion. Ultimately fluoroscopic approaches fell out of favour when
studying lung target motion due to difficulty of incorporating the fluoroscopic imaging data into
the radiotherapy treatment process.
The increased availability of four dimensional computed tomography (4DCT) scans has in-
creased the viability of patient-specific approaches to motion management of lung targets. 4DCT
data sets provide clinicians with complete 3D images of the patient anatomy and target at several
different phases of a given patient’s respiratory cycle [21]. The improved contrast offered by 3D
6
CT images as compared to the 2D projection images of a fluoroscopic scan allows for a more
detailed study of the motion. As with fluoroscopy, 4DCT allows for gathering information re-
garding the patient’s breathing pattern [15]. A clearer picture of the target motion within the lung
allows for better incorporation of the target motion into the treatment plan. However, a thorough
understanding of the dosimetric impact of the organ motion must be attained before the motion
information can be used clinically.
One calculation model used to predict the dosimetric impact of target motion on the deliv-
ered dose distribution is the convolution model originally proposed by Leong [22]. This model
takes a planned static dose distribution (D0) and a probability density function (PDF) describing
the target location over time as its inputs. The model predicts the delivered dose distribution by
performing a mathematical convolution of the inputs. The result of this convolution is a dose
distribution which has been ‘blurred’ by the motion of the target (Db), thereby reducing target
dose coverage and increasing dose to organs at risk (OARs). The model can be written suc-
cinctly as: Db = D0 ⊗ PDF . An early attempt at using the convolution model in the context of
intrafraction motion was published by Lujan et. al. in 1999 [23]. The authors used fluoroscopy
to determine the 1D motion of the target in order to generate the required PDF. They showed that
incorporating organ motion into the treatment plan was important to maintain dose coverage and
that the convolution model provided an acceptable approximation to the delivered dose distribu-
tion [23]. As reported by other authors [24], the blurring effect of target motion is predominant
in regions of the dose distribution with sharp dose gradients. Since the sharp dose gradients are
typically associated with field edges, selection of appropriate target margins becomes a crucial
step in ensuring adequate target coverage. A predictive model such as the convolution model is
a valuable tool for analyzing the impact of target motion on the delivered dose distribution.
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1.4 Scope of Work
In searching for the appropriate balance it becomes clear that patient-specific approaches to target
volume definition are necessary because of the wide variation in patient anatomy, disease mani-
festation and breathing patterns. Furthermore some lung cancer patients present highly irregular
breathing patterns, characterized by large inter- or intrafraction changes to target motion ampli-
tude or cycle frequency. These patients present unique challenges with respect to modeling and
predicting the target position throughout the breathing cycle and will be less amenable to a class
solution. However, by developing margin selection guidelines that can be implemented by any
radiation treatment center, the benefits of a patient-specific approach can be attained. Therefore,
the aims of this work are as follows:
1. to investigate the breathing patterns of radiotherapy patients using 4DCT
2. to apply a model of the dosimetric impact of lung motion on the delivered dose distribu-
tions resulting from intrafraction breathing motion
3. to experimentally verify the model predictions using radiochromic film and a dynamic
anthropomorphic thorax phantom
4. to establish a set of guidelines for selecting motion compensating treatment margins on a
patient-specific basis.
1.5 Outline of Thesis
The relevant photon interactions contributing to absorbed dose and radiobiological principles for
EBRT of lung tumours is reviewed in Chapter 2. Chapter 3 reviews the staging and classification
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of lung tumours along with treatment techniques, methods for quantifying lung target motion
and the margin recipes currently available in the literature. In Chapter 4, a detailed review of
the convolution model and its inputs is presented. This includes an analysis of the assumptions
implicit to the model as well as an analysis of the implications of using the model in the context
of intrafraction motion. Chapter 5 discusses the experimental verification of the convolution
model. The procedures surrounding the use of gafchromic film and a dynamic thorax phantom
are detailed. Chapter 6 discusses the details of the motion simulation study that was performed, as
well as its results and interpretation. Chapter 7 contains a sensitivity analysis of the convolution
model as applied to Gaussian dose profiles and motion PDFs. By using Gaussian functions as
the basis of the sensitivity analysis, an analytical approach becomes feasible. Finally, Chapter
8 offers a summary and the conclusion of the study, as well as a look at some potential future
work.
There are two Appendices included in this thesis as well. Appendix A details work that was
presented at the Canadian Organization of Medical Physicists annual scientific meeting in 2013.
This work extends the idea of the effective dose gradient due to motion and applies it to the
concept of adaptive radiotherapy. The result is a proposal for a tool that would assist radiation
therapists with patient setup and treatment decision making. Appendix B details the MATLAB
code used to perform the simulation study that is detailed in Chapter 6.
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Chapter 2
Photon Interactions, Absorbed Dose and
Radiobiology
2.1 Introduction
A thorough understanding of the physical action of radiation and the subsequent chemical and
biological effects has allowed for the development of radiation therapy for treating cancers. Al-
though modern treatment centres now exist which offer radiation therapy using protons and other
heavy ions, X-rays and electrons are still the most common form of radiation used in clinics to-
day.
X-rays that enter a patient’s body have a probability to interact with the tissues based mainly
on the energy of the X-ray, the tissue composition and the amount of tissue in the X-ray path.
X-rays that do interact with the patient’s body will transfer some or all of their energy to the
atoms and electrons comprising the tissue. When electrons absorb energy from the X-rays they
may in turn be ejected from their orbits, thereby leaving the associated atom ionized; or a bound
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electron within the atom may move to a new orbit, thereby leaving the atom in an excited state.
Any ejected electrons will also travel through the tissue, interacting with other atoms and causing
the ejection of more electrons from their bound states. These further interactions cause more
ionizations and the process repeats until all the energy of the initial electron has been dissipated
or absorbed by the tissue. The energy that is absorbed by the tissue per unit mass is referred to
as the ‘absorbed dose’ and is measured in terms of the SI unit of Gray (Gy) [3], defined as the
energy absorbed per unit mass of absorbing material (J/kg). The amount of energy absorbed by
a given mass of tissue is an indirect measure of the biological damage caused to that tissue by
the radiation.
The ionization of atoms in the patient’s tissue is the first step in a chain of events that can
ultimately lead to cell death. This chapter aims to deal with a description of photon interactions
relevant to radiotherapy and the radiobiological principles at play when treating cancers. A more
detailed discussion of radiotherapy for the treatment of lung cancers specifically is offered in
chapter 3.
2.2 Photon Interactions
2.2.1 Linear Attenuation Coefficient
The attenuation of a photon beam entering a medium is described by the Beer-Lambert law
(Equation 2.1)
I(x) = I0e
−µx. (2.1)
In this formulation, I is the intensity of the photon beam at a depth x into the medium, I0 is
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the initial intensity of the beam and µ is the linear attenuation coefficient of the medium, often
described in terms of the units cm−1. The linear attenuation coefficient itself depends on the
material composition and photon energy. The law can also be written in terms of the ‘mass
attenuation coefficient’ described by
I(x) = I0e
−(µ/ρ)ρx, (2.2)
where ρ is the density of the medium and (µ/ρ) is identified as the mass attenuation coef-
ficient (typically expressed in units of cm2/g). The mass attenuation coefficient describes the
ability of a medium to attenuate photons independent of the material density. The quantity ρx
is known as the ‘mass thickness’ with units usually expressed as g/cm2. The Beer-Lambert
law gives a description of the overall attenuation of a photon beam, but does not delve into the
specifics of the photon interactions.
The attenuation coefficient plays a key role in X-ray CT imaging. The 3D images recon-
structed from CT data are displayed in terms of the Hounsfield Units (HU) scale. The HU scale
is a linear transformation of the linear attenuation coefficient scale such that pure water has a
value of 0 HU , and air (at standard temperature and pressure) has a value of −1000 HU . The
HU value of a given linear attenuation coefficient [25] is determined by
HU =
µ− µwater
µwater − µair × 1000. (2.3)
Since CT images are displayed in HU, the quality of a CT image can be interpreted based
on the variance of the HU values within a region of the imaging subject known to have constant
density. The lower the HU variance, the better the image quality. The role of CT images and
the importance of their quality in context of radiotherapy treatment planning for lung cancers is
discussed thoroughly in chapter 3.
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2.2.2 Basic Photon Interactions
Photon interactions with matter are understood to occur through one of eight possible pathways.
Those interactions are:
1. Thomson scattering (Elastic scattering)
2. Rayleigh scattering (Elastic scattering)
3. Raman Scattering (Inelastic scattering)
4. The photoelectric effect
5. Compton scattering
6. Pair production
7. Triplet production
8. Photonuclear interactions
The probability of any one of these interactions taking place depends on a myriad of param-
eters. The most important of the parameters are the photon energy and the atomic number (Z)
of the medium. For the typical atomic number of soft tissue (Z ' 7) and the photon energies
commonly used in the diagnosis and treatment of cancers, the most relevant interactions are:
Rayleigh scattering, the photoelectric effect, Compton scattering and pair production. The plot
in Figure 2.1 shows the mass attenuation coefficients for the relevant photon interactions with
soft tissue, as adapted from Bushberg’s book ‘The essential physics of medical imaging’ [26].
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Figure 2.1: A plot of the mass attenuation coefficient versus photon energies for soft tissue
(Z ' 7). The photoelectric effect, Compton scattering and pair production are the dominant
processes in the diagnosis and treatment of cancers. This image appears in Bushberg’s book
‘The essential physics of medical imaging’ [26].
Each of these interactions has a role to play in the attenuation of an X-ray photon beam.
However, Rayleigh scattering is an elastic process that results in the interacting photon changing
direction without imparting any energy to the medium. Therefore, Rayleigh scattering is not
considered an important interaction in the context of radiotherapy. The other three dominant
processes are discussed in more detail in the following sections.
2.2.3 Photoelectric Effect
In the case of photoelectric interaction, an inner shell electron of the absorbing medium com-
pletely absorbs the incoming photon [4]. The initial energy of the recoiling photoelectron (Kpe)
is calculated by taking the difference between the incident photon energy (hν) and the work
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function of the bound electron (|W |) as shown in Equation 2.4. The photoelectron then proceeds
through the medium as a directly ionizing particle.
Kpe = hν − |W | (2.4)
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Figure 2.2: A schematic representation of a photoelectric event. Redrawn from Radiobiology for
the Radiologist [3].
2.2.4 Compton Effect
In the case of a Compton scattering event, the incoming photon interacts with a loosely bound
outer-shell electron of the absorbing material [4]. This electron absorbs a portion of the incoming
photon’s initial energy and is ejected from the atom. The law of conservation of energy can be
used to determine the scattering angles of both the recoil electron and photon. The various
quantities involved are related by the equations shown below, where m0 is the rest mass of the
electron and T is the energy transferred from the incoming photon to the recoil electron. The
recoil electron proceeds through the material and acts as a directly ionizing particle while the
recoil photon goes on to further interact with the medium.
The energy of the scattered photon is can be expressed by
hν ′ =
hν
1 + ( hν
m0c2
)(1− cos(φ)) . (2.5)
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The electron scattering angle is given by
cot(θ) = (1 +
hν
m0c2
)(tan(
φ
2
)). (2.6)
The conservation of energy dictates that
hν = hν ′ + T. (2.7)
Compton scattering is by far the most important photon interaction in the context of radiother-
apy. As seen in Figure 2.1, the likelihood of Compton scattering events dominates the other
interactions in soft tissue for photon energies ranging from ∼ 80 kV to ∼ 12 MV .
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Figure 2.3: A schematic representation of a Compton scattering event. Redrawn from Radiobi-
ology for the Radiologist [3].
2.2.5 Pair Production
Pair production can occur when a high energy photon (≥ 1.022 MeV) interacts with the nucleus
of an atom. The photon is transformed into a positron and an electron. On average the energy is
shared equally between the two particles. As the positron slows down in an absorber it will likely
undergo an annihilation event with an electron in the absorber. The annihilation event destroys
both the positron and the electron in favor of two photons headed in opposite directions with
equal energy (hν ′ = hν ′′ = m0c2 = 511 KeV ).
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Figure 2.4: A schematic representation of a pair production and annihilation event. Redrawn
from The Physics of Radiology [4].
2.3 Absorbed Dose
Each of the photon interactions described above result in the liberation of energetic electrons. As
these electrons travel through a medium, they transfer their energy to the medium via Coulomb
force interactions. The absorbed dose is defined as the energy transferred to an absorbing medium
per unit mass of the medium. This can be described as
D =
∆E
∆m
. (2.8)
The energy absorbed by a medium can cause ionizations, atomic excitations or break chemi-
cal bonds. The resulting chemical changes can disrupt biological processes and ultimately result
in cell death. This sequence of events is displayed in Figure 2.5.
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Figure 2.5: A flow chart tracking the scales and processes associated with radiation damage.
As a charged particle proceeds through the absorbing medium it will typically undergo many
interactions before dissipating all of its energy and coming to rest. The absorbed dose delivered
to the medium in any given volume can be determined by summing all the energy left behind
by all the charged particles which passed through the volume and dividing by the mass of the
medium within the given volume.
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2.4 Radiobiology
Radiobiology is the study of the action of ionizing radiations on living things [3]. Shortly after
the discovery of X-rays by Ro¨ntgen in 1895, the first biological effects of radiation were docu-
mented by Becquerel. He left a container of radium in his vest pocket and noticed erythema and
ulceration develop on his skin roughly two weeks later. Over the course of the following century,
the entire theory of radiobiology was developed by a huge number of contributors. A detailed
understanding of radiobiology has allowed for the refinement of radiotherapy treatments and the
exploitation of certain effects to improve treatment outcomes.
2.4.1 Mechanism of Cellular Damage
The DNA strand is the main target within a cancer cell that clinicians aim to damage with ra-
diation therapy treatments [3]. By causing disruptions or breaks to the DNA, the cell will fail
to reproduce and ultimately die, thereby limiting the growth of the cancer. The most effective
form of damage to the DNA is known as a double strand break (DSB). In the case of a DSB, a
disruption to each of the two phosphorus backbones of the DNA strand occurs within a distance
of approximately ten base pairs from one another. A DSB is very difficult for the cell to repair
and usually results in cell death. Other less lethal forms of damage are single strand breaks (SSB)
and base damage. In the case of a SSB only one of the DNA backbones is disrupted. In the case
of base damage, the DNA backbone remains intact but a base-pair will have been the subject of
an ionization or chemical disruption. Most cells are very efficient at repairing SSBs and base
damage, and these type of DNA damage do not reliably result in cell death.
DNA strand breaks can be measured using a technique known as Pulsed-field Gel Elec-
trophoresis (PGFE) [3]. This technique separates the DNA fragments of irradiated cells by
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applying a pulsed electromagnetic field which pulls the fragments through a porous gel [27].
Large DNA fragments do not travel through the gel as easily as smaller fragments under the
force of the pulsed field, allowing them to be separated from one another. These experiments
show that as the radiation dose delivered to the cell increase, more DNA fragments and smaller
DNA fragments are produced [28].
There are two main mechanisms known to cause these breaks to the DNA strand via deliv-
ered radiation. In the first case the DNA strand is directly ionized by a charged particle. The
ionized DNA strand becomes chemically reactive at the location of the ionization event and new
chemical bonds can form, thereby disrupting the DNA backbone. This is the dominant mecha-
nism of damage for radiations with high linear energy transfer (LET). The second case is known
as indirect ionization. In this situation a molecule (typically a water molecule) in the surround-
ing medium is ionized or disrupted itself, either by direct or indirect radiation. The ionized or
disrupted water molecule, known as a hydroxyl radical, is highly chemically reactive. If this
reactive molecule diffuses within the vicinity of the DNA strand within its short lifetime, it will
react with the DNA backbone causing a strand break.
2.4.2 Linear Energy Transfer
Linear energy transfer (LET) is the amount of energy transferred by a charged particle to the
surrounding medium per unit length of path. LET is defined by the Equation below, where dE is
the average energy locally imparted to the medium as it travels a distance dl [3]
LET = dE/dl. (2.9)
LET is usually discussed in terms of the units keV/µm of unit density material. It should be
noted that energy imparted by a charged particle as it travels through a medium occurs at discrete
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locations along the track of the particle. As such, the LET of a given particle is an average of
the energy imparted to the medium over the length of the particle track. The LET of a given
particle depends on the particle energy, particle charge and the density of the medium. In Table
2.1 adapted from Hall [3] the LET of various particles and energies is shown for comparison.
Radiation LET (keV/µm)
Cobalt-60 γ-rays 0.2
250-kV X-rays 2.0
10 MeV protons 4.7
150 MeV protons 0.5
2.5 MeV α particles 166
2 GeV Fe ions (space radiation) 1000
Table 2.1: LET values for various particles and energies in water. Adapted from Radiobiology
for the Radiologist [3]
Due to the dependence of LET on the particle energy, the LET varies as the particle imparts
its energy to the medium along its track. In the case of high energy protons (≥ 150 MeV ) the
LET as the particle enters water is approximately 0.5 keV/µm. As the particle loses energy the
LET increases, with a sharp peak reaching approximately 100 keV/µm at the end of the particle
track. This peak is known as the Bragg peak. Although all charged particles exhibit a sharp peak
in LET at the end of the track, only heavy ions show the characteristic peak in dose deposition
due to a more predictable path. Light charged particles, such as electrons, travel along a torturous
pathway with many changes in direction [29]. This means that the sharp dose deposition due to
the Bragg peak does not occur at a predictable depth or location.
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2.4.3 Linear-Quadratic Model of Cell Survival
Radiotherapy treatments are prescribed in terms of an absorbed dose, measured in Gray (Gy), to
the target volume. The absorbed dose is an indirect measure of damage caused to the tissue by
the energy deposited from charged particles. As the absorbed dose in a target volume increases,
the likelihood of causing a SSB or a DSB increases, thereby increasing the chances of causing
cell death. Radiobiological cell survival studies typically look to relate the absorbed dose to
fraction of surviving cells. These cell survival studies have resulted in a model of cell survival
known as the linear-quadratic (LQ) model, first proposed by Douglas and Fowler in 1976 [30].
The equation governing the LQ model is defined as
S = e−αD−βD
2
. (2.10)
In this formulation of the model, S is the fraction of surviving cells, D is the absorbed dose
and α & β are tissue specific parameters describing the ‘early’ and ‘late’ response of the tissue
to the absorbed dose. The α and β parameters of the LQ model describe the sensitivity (ease of
cell killing) of a given cell line to a single fraction of low and high dose radiation respectively.
α describes the initial slope (low dose region) of the survival curve, and can be interpreted as
the cell’s susceptibility to DNA damage from a single charged particle track. β describes the
quadratic component (curvature, final slope) of the survival curve in the high dose region. β
can be interpreted as the cell’s susceptibility to DNA damage from two unique charged particle
tracks. A sample survival curve for normal and cancerous tissue is shown in Figure 2.6. f
22
Figure 2.6: An example of normal and cancerous cell survival curves predicted by the LQ model.
The normal cells have α = 0.088 and β = 0.032 for a ratio of α/β = 2.75, the cancer cells have
α = 0.204 and β = 0.020 for a ratio of α/β = 10.4
The ratio α/β describes the cell’s insensitivity to dose fractionation. In other words, the sur-
vival of cells with a low α/β (' 3) is strongly dependent on the fractionation scheme. These
tissues are known as ‘late responding’ tissues and include the lung and spinal cord [3]. On the
other hand the survival of cells with a high α/β (' 10) is weakly dependent on the fractionation
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scheme. These tissues are known as ‘early responding’ tissues and includes skin and bone mar-
row cells. The therapeutic advantage in radiotherapy is attained by exploiting this difference in
fractionation sensitivity and by delivering lower absorbed dose to the healthy tissue.
One feature of the LQ model that is not borne out in actual cell survival data is the continu-
ously bending nature of the curve. In reality, the cell survival curve would have a final straight
segment on a log-linear plot starting around the seventh decade of cell killing. This empirical
data is not well predicted by the LQ model. However, in the range of doses typically delivered
as a daily fraction in radiotherapy, the LQ model does a reasonably good job of predicting cell
survival [3].
2.4.4 The Four ‘R’s’ of Radiobiology
The effectiveness of fractionated radiotherapy can be explained by appealing to the ‘4 R’s’ of
radiobiology: reoxygenation, repair, redistribution, and repopulation. Each of these concepts
pertains to the cells of tissues undergoing irradiation and, along with the mechanisms for cell
damage, form the basis for understanding radiobiology and cell survival in the context of radio-
therapy.
Reoxygenation
The oxygenation of a cell’s environment is described by the partial pressure of the oxygen content
in the surrounding medium, with high oxygenation refering to a partial pressure of oxygen. The
role of oxygenation in radiobiology was first investigated in detail by Mottram in the 1930’s
[31]. He was able to show that small tumours were more radiosensitive than large tumours
due to oxygenation. Mottram also suggested fractionation in order to exploit the oxygenation
effect. Later, work done by Read in the 1950’s resulted in quantitative measurement of the effect
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of oxygen concentration [32]. The role of oxygenation is typically understood in terms of the
oxygen enhancement ratio (OER). The OER is simply the ratio of the radiation doses required to
achieve the same biological outcome with the cells under hypoxic and aerated conditions [3].
The idealized understanding of the relation between oxygen concentration and radiosensitiv-
ity is shown in Figure 2.7 below. Starting from a relative radiosensitivity of 1 for the completely
anoxic scenario, the radiosensitivity quickly rises in the presence of oxygen. With oxygen ten-
sion of about 3 mm Hg (corresponding to about 0.5% oxygen) the radiosensitivity doubles, and
at oxygen tension of 30 mm Hg the relative radiosensitivity is about three times higher than the
anoxic scenario. There is little gain in radiosensitivity for situations with oxygen tension higher
than 30 mm Hg.
Figure 2.7: An idealized plot of the OER vs. Oxygen tension as shown in Radiobiology for the
Radiologist [3]. The OER quickly increases from 1 for anoxic cells to approximately 3 when the
Oxygen tension reaches about 30 mm Hg. The presence of molecular Oxygen ‘fixes’ radiation
damage, causing it to become permanent.
It is hypothesized that this increase in radiosensitivity occurs due to oxygen fixation [3]. The
damage caused to DNA due to indirect action of radiation is typically easily repaired by the
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cell, especially in anoxic situations. However, molecular oxygen readily reacts with the site of
damage on the DNA strand, causing the damage to be permanent. Therefore, when molecular
oxygen is available to react with damage to the DNA, more permanent damage to the DNA
occurs, resulting in more cell death and greater radiosensitivity.
Reoxygenation is the process by which hypoxic tumour cells become oxygenated after a tu-
mour receives a dose of radiation. This process occurs due to the usual structure of a tumour
mass. The organization of cells in a tumour is haphazard (compared to healthy tissue) and there-
fore the transfer of nutrients throughout a larger tumour is poor. This results in ‘typical’ tumour
structure with three layers: a layer of aerobic cells surrounding a layer of hypoxic cells which
in turn surround a necrotic core at the center of the tumour. After irradiation, the aerobic cells
on the exterior of the tumour will be preferentially killed due to increased radiosensitivity. As
these cells die off and are removed by bodily systems, oxygen is able to penetrate deeper into the
tumour, thereby reoxygenating previously hypoxic cells. When the next fraction of radiotherapy
is delivered, the previously hypoxic cells will now be more radiosensitive due to reoxygenation.
With repeated delivery of fractionated radiotherapy, the reoxygenation effect can be exploited to
increase cell killing for an equal delivered dose.
26
Figure 2.8: A depiction of the reoxygenation process as shown in Radiobiology for the Radi-
ologist [3]. The oxygenated cells on the exterior of the tumour are more radiosensitive and are
preferentially killed. As the previously hypoxic cells become reoxygenated, their radiosensitivity
increases, making them more susceptible to radiation damage during the next treatment fraction.
Redistribution
Redistribution in the context of radiobiology refers to the distribution of cells across the various
stages of the cell cycle. For mammalian cells, the cell cycle, as shown in Figure 2.9 is divided
into four phases labeled: M ,G1, S,G2. M is the ‘mitosis’ phase during which the cell is actively
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dividing in two. S is the ‘synthesis’ phase during which the cell is synthesizing a replicate DNA
strand. The ‘G1’ and ‘G2’ phases are gaps in the cell cycle during which the cell appears inactive
in terms of growth and division events.
Figure 2.9: A depiction of the cell cycle adapted from Radiobiology for the Radiologist [3]. Cells
progress through the cycle at different rates depending on cell type, and can become blocked in
a given phase due to environmental conditions. Cells are most radiosensitive during mitosis (M)
and least radiosensitive near the end of synthesis (S).
The radiosensitivity of the cell varies as it progresses through the four phases of the cell cycle.
It is generally accepted that cells are most sensitive during the M phase and least sensitive close
to the end S phase [3]. The increase in sensitivity during M phase is likely due to the complex
and intricate process of mitosis being interrupted. The resistance shown in late S phase is likely
due to the availability of the homologous recombination repair pathway, which is discussed in
more detail in the following subsection.
The distribution of cells across the stages of the cell cycle is uniform for a typical population
of healthy growing cells. However this uniform distribution can be disrupted by delivering a
radiation dose to the cells. Cells in the radiosensitive phase of the cell cycle will be preferentially
killed by a dose of radiation, resulting in the remaining cells being more heavily concentrated in
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the radioresistant phases. The remaining cells will then proceed through the cell cycle, naturally
redistributing themselves into more radiosensitive phases one again. This redistribution acts to
sensitize the cell population to a future dose of radiation.
Repair
Radiation damage to cells can be classified in one of three categories: lethal damage, poten-
tially lethal damage (PLD) and sublethal damage (SLD). Lethal damage is irreparable and leads
directly to cell death by definition, PLD is damage that is subject to influence by the local en-
vironmental conditions the cells face after irradiation, and SLD is damage that can be reliably
repaired by the cell over the course of hours under normal conditions [3].
Lethal radiation damage to cells usually takes the form of DSBs. However there are two
processes by which the cell may attempt to repair a DSB, known as homologous recombina-
tion repair (HRR) and nonhomologous end joining (NHEJ) [3]. HRR is a very reliable repair
mechanism that uses an undamaged DNA strand as the template for repair of the broken DNA
strand. This repair pathway occurs most frequently in the late S or G2 phase of the cell cycle.
The NHEJ repair pathway for DSBs does not require an undamaged template. Instead, the repair
mechanism is able to identify the broken ends of the DNA strand, prepare the ends for repair,
‘bridge’ the broken ends with the required base pairs and then reattach the broken ends through
the process of ligation. While both pathways result in the reliable repair of DSB, they are not
perfect and can occasionally lead to faulty repairs resulting in chromosomal aberrations. These
aberrations may ultimately cause cell death or hereditary disease.
PLD is damage that would usually cause cell death, but may be overcome under certain local
environmental conditions of the cell. The general consensus is that PLD can be repaired when
the conditions for cell growth are poor [3]. In this situation, the cell will not be likely to undergo
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the taxing process of mitosis. Instead the cell’s resources can be put towards the necessary DNA
repair. This form of damage was described by Little et al. [33] in an in vitro experiment. The
group showed that a greater fraction of cells survive replating if they are held in a stationary
state (poor growth conditions) for at least 6 hours post irradiation as compared to the fraction of
cells that survive replating immediately after irradiation. It was later shown that the rate of repair
and repair pathways involved in the in vitro experiment are comparable to the in vivo situation.
Although the existence of PLD is widely accepted, its role in radiotherapy is not generally agreed
upon [3].
SLD is damage that would usually be repaired by the cell. The repair of SLD can be observed
in experiments that divide a given radiation dose into two fractions spaced apart in time. Shown
in Figure 2.10 is a plot of the surviving fraction of cells versus the time interval between two
equal doses of radiation adapted from Elkind et al. [34]. By allowing for as little as 30 min-
utes between irradiations, the surviving fractions is appreciably higher. After about two hours
between fractions, the gain in cell survival plateaus. The increase in cell survival in the approxi-
mately two hours post irradiation is understood to be due to the repair of SLD. The hypothesis is
that cell survival is decreased by compounding multiple events that would normally result in SLD
on their own. Therefore, by allowing time between fractions, SLD is repaired before multiple
SLD events can be accumulated in the same region of the DNA strand.
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Figure 2.10: A plot of the surviving fraction of cells after two doses of radiation separated in
time (7.63 Gy followed by 7.95 Gy). The data are adapted from the experiments performed by
Elkind et al. [34] with Chinese hamster cells incubated at 24 ◦C. The surviving fraction increases
rapidly when the time between doses allows for SLD repair.
Repopulation
Repopulation simply refers to the growth of new cells, whether cancerous or normal, over the
course of a radiotherapy treatment. Work done by Fowler et al. showed that extra radiation dose
is required to counteract the proliferation of new cells [35]. However, it is necessary to consider
the effect of repopulation in the context of the early and late responding tissues discussed earlier.
Early responding tissues in humans with a high α/β ratio are triggered to start proliferating
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within a few weeks of the start of a fractionated radiotherapy regime. As a result the extra
dose needed to compensate for this proliferation is not required initially, but does increase over
time. On the other hand, late responding tissues will not begin proliferating within the typical
6 − 8 week time frame of a fractionated radiotherapy regime. Therefore, as stated by Hall
[3] ‘prolonging overall time within the normal radiotherapy range has little sparing effect on late
reactions but a large sparing effect on early reactions’. This must be balanced with the knowledge
that excessive prolongation of the fractionation scheme could allow for the tumour cells to begin
proliferating during the treatment.
2.4.5 Tumour Control Probability and Normal Tissue Complication Prob-
ability
Tumor Control Probability (TCP) as originally described by Munro et al. [36] is defined as
the probability that the elimination of all tumour cells has been achieved. Webb et al. [37]
later derived an expression for TCP based on the survival of cells exposed to a uniform dose of
radiation. Where the number of surviving cells is given by the familiar LQ model (the quadratic
term is omitted while considering the typical radiotherapy fraction size of ' 2 Gy)
S = e−αD. (2.11)
The probability of eliminating all the tumour cells is then simply given by
TCP = e−S. (2.12)
When the TCP is plotted as a function of dose, the resulting curve is sigmoidal in nature with
increasing dose resulting in an increased probability of tumour control. However, increasing
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the dose is also associated with an increase in normal tissue complication probability (NTCP).
Perhaps the most popular model of NTCP was developed by Lyman [38] and expanded upon by
Burman et al. [39]. The basis of the so-call LKB model of NTCP is an error function and four
parameters defined by the following equations:
NTCP =
1√
2pi
∫ t
−∞
e−t
2/2dt, (2.13)
ν = V/Vref , (2.14)
t =
D − TD50(ν)
(m× TD50(ν)) , (2.15)
TD(ν) = TD(1)× ν − n. (2.16)
The parameter ν is defined as the fraction of the organ irradiated (or the proportion relative to
a reference volume), D is the dose, TD50 is the tolerance dose resulting in a 50% complication
probability, n is the parameter governing the volume dependence of the complication probability
and m is the parameter governing the slope of the curve (at 50% complication probability).
It should be noted that when the NTCP is plotted as a function of dose, it is monotonically
increasing [39]. Therefore any increase in dose to the healthy tissues of the patient will increase
the probability of complication. Similarly, when NTCP is plotted as a function of the partial
volume of the irradiated tissue, it is also monotonically increasing [39]. Therefore, any increase
in the volume of normal tissue being irradiated to a given dose will also increase complication
probability. These two considerations are at the heart of treatment planning. The ideal treatment
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plan balances the delivery of the prescribed dose to the target volume with the volume and dose
of irradiated normal tissues.
When plotted together versus the delivered dose, both the TCP and NTCP appear as sigmoidal
curves separated along the dose axis. Figure 2.11 shows the plot in a hypothetical situation. A
given dose will result in a given probability for NTCP and TCP. The difference in the relative
responses of the tissues to a given dose is termed the ‘therapeutic advantage’. The outcomes
of radiotherapy treatments can be improved by increasing the therapeutic advantage. The TCP
and NTCP curves can be shifted along the dose axis through several means, such as: the action
of any of the 4 R’s, by radiosensitizing the tumour with a chemical agent or by increasing the
radioresistance of the OARs.
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Figure 2.11: A hypothetical plot of the TCP and NTCP sigmoid curves. The difference in relative
response for a given delivered dose is defined as the ‘therapeutic advantage’. Radiotherapy
treatment outcomes can be improved by increasing the therapeutic advantage through means
such as exploiting the 4 R’s, or the addition of radiosensitizing drugs.
2.5 Summary
EBRT for lung cancers is offered with X-rays in the MV energy range. These photons typically
interact with human tissue via the Compton effect, however the photoelectric effect and pair
production are also important photon interactions in the context of absorbed dose and radiother-
apy. No matter the interaction pathway, photons act to liberate electrons from their bound states.
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These free electrons are responsible for the deposition of all the energy comprising the absorbed
dose to tissue. The energy absorbed by the tissue will result in ionizations to the constituent
atoms and molecules of the tissue. These ionized atoms and molecules are chemically reactive.
When the DNA itself is ionized, or a atom/molecule nearby the DNA is ionized, they will become
chemically reactive. The result of the chemical activity can be a break in the backbone strand of
the DNA molecule. In the cases where this damage is irreparable, the result is often cell death.
The study of radiobiology has allowed for the honing of radiotherapy techniques. The four
‘R’s’ of radiobiology (Reoxygenation, Redistribution, Repair and Repopulation) form the ba-
sis of our understanding of the biological outcomes associated with the delivery of a specific
dose. The study of the survival rate of cells exposed to radiation has lead to the commonly used
Linear-Quadratic model of cell survival, which has often served as the basis of tumour control
probabilities (TCP) and normal tissue complication probabilities (NTCP). The study and under-
standing of photon interactions and radiobiology forms the basis of modern radiotherapy.
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Chapter 3
Review of Radiation Therapy for Lung
Cancers
3.1 Introduction
Each tumour site presents with its own unique challenges for the planning and delivery of exter-
nal beam radiation therapy (EBRT). Usually, the need to limit dose to the OARs in the region of
a given tumour will pose the biggest challenge to delivering a high dose to the tumour. However,
organ motion also presents challenges to the accurate delivery of EBRT. Although any given
treatment site may be susceptible to organ motion (both interfraction and intrafraction), the res-
piratory motion of the lungs causes displacement of lung tumours greater than that routinely seen
at any other treatment site.
The treatment of lung cancers with EBRT is also complicated by challenges with accurate
dose calculation. Due to differences in tissue density between healthy lung tissue and a tumour
within the lung, it is difficult to model the dose, especially in the interface region. Furthermore,
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the relatively low density of lung tissue allows for increased lateral electron disequilibrium which
is not typically an important consideration at other treatment sites.
Many approaches have been developed by researchers and clinicians to deal with the chal-
lenges of EBRT for lung cancers. This chapter aims to discuss lung cancer in the context of
EBRT, approaches to quantifying lung target motion and approaches to accounting for that mo-
tion in treatment planning and delivery. Finally, a closer look at the margin recommendations
made by other authors in the literature is provided.
3.2 Classification of Lung Cancers
Lung cancer is the leading cause of cancer death in Ontario for both men and women. Approx-
imately 1 in 4 cancer deaths in Ontario result from lung cancer [40]. Therefore, the prevention
and treatment of lung cancers is a high priority for clinicians in the provincial health system.
There exists many different types of lung cancer, but they can be broadly classified into small
cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) groups.
SCLC represents approximately 15% of lung cancer cases but also account for 25% of lung
cancer deaths [41]. These cancers are typically much more difficult to treat due to rapid cell
division and the propensity to metastasize early in the development of the disease. SCLC are
most often found centrally within the lung, usually originating in the bronchi. Cigarette smoking
is implicated as the cause of up to 95% of SCLC cases [42]. The treatment regime for SCLC
is dependent on the stage of the disease, but will usually be a combined modality treatment of
chemotherapy and radiation therapy. The metastatic potential of SCLC means that surgery is not
typically offered for treatment of SCLC. Limited stage disease (confined to a single lobe of the
lung) has much better survival rate than extensive disease, with a 5-year survival rate of limited
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stage SCLC patients of 20%. The long term survival rates for patients diagnosed with extensive
SCLC is very low, with the median survival length in the range of 8 to 10 months.
NSCLC comprises the other 85% of lung cancer cases [43]. NSCLC does not typically grow
or metastasize as quickly as SCLC. As such, NSCLC is seen as more treatable and has better
survival rates (5-year survival of approximately 15%). Cigarette smoking is again the most com-
mon cause of NSCLC, although environmental factors such as air pollution are implicated in up
to 11% of cases in some regions [43]. Surgery is the mainstay treatment for NSCLC with com-
plete resection and wedge resection frequently being offered. Almost 70% of patients initially
present with locally advanced or metastatic disease, and for these people chemotherapy in combi-
nation with surgery is typically offered. Radiation therapy for NSCLC patients is conventionally
offered in a regime of 60 Gy delivered in 30 daily fractions. The Radiation Therapy Oncology
Group (RTOG) performed a phase 3 trial for locally advanced, non-resectable NSCLC which
resulted in local failure rates of 27%. However conventional radiation therapy alone results in a
median survival of 10 months and 5-year survival rate of only 5% for this group. New radiation
therapy techniques, such as stereotactic body radiation therapy for treating early stage NSCLC
has shown promise, with one trial offering local control to 87.2% of patients [44].
3.3 Staging of Lung Cancers
The diagnosis and staging of lung cancer is a key step in determining the appropriate treatment
regime. A computed tomography (CT) scan of the chest is most often used in the initial diagnosis
of lung cancer. Additional testing, such as a complete blood cell count and electrolyte panel
can be used to discriminate between SCLC and NSCLC. Since CT has limited ability to detect
microscopic metastatic disease, radionuclide scans such as positron emission tomography (PET),
are also being used as part of the modern diagnosis of lung cancer. PET scans allow for the
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detection of the highly active cells typical of cancers and can be used to detect the metastatic
activity that may be missed by a CT scan. Ultimately it is a combination of tests that leads to the
diagnosis and staging of lung cancer. The stages of lung cancer are classified by TNM system,
where a score is assigned to each of: T - the size and location of the tumour, N - the lymph
node involvement and M - the metastatic state of the disease. The stages and TNM scores are
described below as defined by the System for Staging Lung Cancer [45]. Later stage cancers
have a worse prognosis.
Stage IA (T1N0M0) & IB (T2N0M0): These are the earliest stages which are commonly
diagnosed. The N0 and M0 designations refer to the fact that there is no apparent lymph node
involvement or metastatic spread of the disease. The T1 designation is for cancers which are
≤ 3 cm in their greatest dimension. T2 tumours have at least one of the following characteristics:
dimension > 3 cm, limited involvement with the main bronchus, have caused a partial collapse
of the lung or have caused obstructive pneumonitis. Lung cancers in stage IA and IB are most
commonly treated with surgical resection. Patients in this stage who are not amenable to surgery
may benefit from stereotactic radiosurgery.
Stage IIA (T1N1M0) & IIB (T2N1M0, T3N0M0): Stage II lung cancers are also most com-
monly treated with surgery and chemotherapy. The N1 designation denotes spread of the disease
into the ipsilateral peribronchial and hilar lymph nodes. The T3 designation is for tumours of
any size that are invading the structures surrounding the lung such as the: chest wall, diaphragm,
pericardium. A T3 designation would also be given to a tumour causing a complete collapse of
the lung.
Stage IIIA (T3N1M0, T1/2/3N2M0) & IIIB (T4N0/1/2M0, T1/2/3/4N3M0): Patients diag-
nosed with stage III lung cancers have poor prognosis with 5-year survival rates in the 6-9%
range. The N2 designation is for mediastinal and/or subcarinal lymph node involvment while the
N3 designation is for contralateral lymph node involvement. The T4 designation is for tumours
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of any size that involve the critical surrounding organs such as the: heart, mediastinum, great
vessels, trachea, esophagus or vertabrae. A tumour would also be classified as T4 in the case
of multiple ipsilateral tumour nodules. Treatment for stage III lung cancer will typically be a
combined modality approach, however in some cases the only option is for palliative treatment
(often including radiation therapy) to relieve suffering.
Stage IV (Any T, Any N, M1): Any lung cancer that has metastasized to a distal region of
the body (M1) is given a stage IV classification. These patients have the worst prognosis with
5-year survival of approximately 1%. Palliative treatment would be offered to these patients in
most cases, as a curative approach will most likely fail.
3.4 Radiotherapy of Lung Cancers
There are many considerations that must be taken when delivering radiotherapy to any cancer
site within the body, including the dose prescription and delivery technique, dose to OARs and
our ability to employ accurate dose calculation algorithms. Lung cancer presents some unique
challenges in these areas due to the natural radioresistance of lung cancer cells, the location of
the cancer within the body relative to other organs, the physical density of lung tissue and lung
motion due to respiration.
When radiotherapy is indicated for the treatment of lung cancer, the most common treatment
regime being offered today is to deliver 60 Gy in 30 daily fractions (2 Gy per fraction) to the
treatment volume. This regime was developed and tested by the RTOG in a phase III dose
escalation trial published in 1995 [46]. Ultimately this standard of care was shown to limit
local failure rates to approximately 27%. However, since that time many other approaches have
been tested for lung cancers at various stages. One such approach for earlier stage cancers is
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known as stereotactic body radiation therapy, which delivers up to 18 Gy per fraction in as
few as 3 fractions [44]. In this case the authors reported high rates of local control (97.6%
at 3 years), 55.8% survival at 3 years and only moderate treatment related toxicity. Different
treatment regimes are routinely being tested for lung cancers of different stages, with new options
becoming available as technology improves.
3.4.1 Organs at Risk
No matter what treatment regime is selected to treat a lung cancer, careful consideration must
be given to the dose being delivered to the OARs. The location of the lungs within the chest
put several critical structures in the vicinity of lung cancers, such as the: heart, spinal cord,
and esophagus. The skin, ribs, breast (in women) and the lungs themselves are also at risk for
radiation damage during treatment. The dose constraints to each of these OARs is dependent
on the fractionation scheme, the toxicity endpoint, the rate at which the endpoint is met and the
use of other treatment modalities. As a result many dose constraint recommendations have been
published, with the data from Emami et al. [47], QUANTEC [48] and various RTOG protocols
most commonly referenced. Table 3.1 summarizes the dose constraints to the common lung
radiotherapy OARs.
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OAR Volume (%) Dose Toxicity Rate Toxicity Endpoint
Heart [49] Mean < 26 Gy < 15% Pericarditis
Spinal cord [50] Max < 50 Gy 0.2% Myelopathy
Esophagus [51] Mean < 34 Gy 5− 20% Grade 3+ esophagitis
Lung [48] Mean < 20 Gy < 20% Pneumonitis
Lung [48] V20 < 30% < 20% Pneumonitis
Table 3.1: Dose constraints for various OARs common to lung EBRT. The data presented here
are taken from the QUANTEC series published in 2010. These constraints represent guidelines
as specific constraints depend on many patient specific factors.
Modern imaging and planning tools allow for the selection of X-ray beam angles to avoid
many of these structures by providing an accurate and detailed map of the patient anatomy and
its position relative to the treatment beam. As a result, major complications from radiation side
effects are less frequent than in the past and the most common form of toxicity found in pa-
tients is radiation pneumonitis of the lungs [52]. Radiation pneumonitis is an early complication
characterized by the development of a dry cough and shortness of breath. The late complication
associated with pneumonitis is known as fibrosis. Fibrosis is a scarring of the lung tissue as a re-
sult of radiation damage. This damaged lung tissue becomes more dense, less flexible and much
less effective at exchanging gases between the atmosphere and blood. Radiation pneumonitis
and fibrosis leads to a further shortness of breath in patients who already typically have trou-
ble breathing due to their condition. In 2010 a comprehensive review of radiation toxicity was
published under the name QUANTEC. In considering radiation damage to the lung, the authors
pointed to the mean lung dose (MLD) as the best predictor of radiation pneumonitis [48]. They
recommended limiting the MLD to ≤ 20 − 23 Gy as well as limiting the percentage of lung
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volume receiving ≥ 20 Gy to ≤ 30− 35% (V20 ≤ 30− 35%).
3.4.2 Dose Calculation in Lung
Absorbed dose calculation for targets in the lung is complicated by the changes in tissue density
along the path of the X-ray beam as it enters the body, travels through lung tissue and arrives at
the tumour. As X-rays travel across the interface between tissues of heterogeneous density (such
as the soft tissue surrounding the lungs and the low density lung tissue) the interaction probability
changes. When going from higher density tissue to lower density tissue, the probability of photon
interactions within the tissue drops, and as a result fewer electrons are liberated. This abrupt
change in interaction probability complicates the dose calculation. As the X-rays travel from
low density lung tissue into the higher density tumour mass, an abrupt change in interaction
probability will again occur at the interface. Many clinical dose calculation algorithms have a
difficult time modeling the dose at the interface regions due to their calculation methods. Some
popular algorithms are discussed below.
During regular clinical operation, dose distributions are calculated within commercial treat-
ment planning software (TPS). Varian’s Eclipse TPS uses the Analytical Anisotropic Algorithm
(AAA) which is convolution-superposition (CS) based algorithm for photon dose calculation
[53]. While the fine details of the dose calculation algorithm are proprietary, the basis of the
algorithm is public knowledge [54]. The CS algorithm is a model based algorithm, which means
it calculates the dose directly in a model of the patient (from a CT data set). In order to calculate
the dose at a given point, the CS algorithm first requires data regarding the energy fluence of the
specific beam of interest. From the energy fluence and the mass attenuation coefficient provided
by the CT data set, the total energy released in matter (TERMA) is calculated within the patient
model. The dose calculation is then performed by taking the mathematical convolution of the
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TERMA with a dose spread kernel. The dose spread kernel describes the dose distribution re-
sulting from a narrow photon beam in water and is originally calculated using Monte Carlo (MC)
methods. The result of the convolution is then superimposed with the convolutions performed at
other points within the patient model to determine the final dose distribution.
The CS dose calculation algorithms are advantageous because they give reliable results under
most conditions with reasonably short calculation times. However, CS algorithms have been
shown to provide inaccurate results in situations with low tissue density, high energy beams and
tissue inhomogeneities depending on the size of the beam and the beam energy [55]. Of particular
interest to lung is the problem of lateral electron disequilibrium. Due to the low density of lung
tissue, the path length of a given electron traveling through lung will be longer than that of an
electron in unit density material (the basis of the CS algorithm). As a result, electrons may travel
much further laterally (perpendicular to the beam direction) in lung than is actually accounted
for by the dose spread kernel in the CS algorithm. Electrons which travel outside the beam
profile will deposit their energy in unintended structures. This generally leads to CS algorithms
underestimating dose to surrounding healthy tissue in the lung and overestimating dose in the
target volume. Furthermore, since the dose spread kernel does not account for heterogeneities in
the mass attenuation map of the patient, the CS model is prone to dose calculation errors at the
interface of heterogeneous tissues.
In order to circumvent these issues and achieve highly accurate estimates of absorbed dose,
other calculation methods must be employed, namely MC methods. MC simulations track the
path and energy deposition of a huge number of virtual particles in order to determine absorbed
dose in a given volume. By relying on a very large sample size of simulated particle interactions,
MC simulation offers accurate dose calculations at the expense of large computing power. MC
work published in 2012 [56] shows that in some extreme circumstances, electron disequilibrium
can contribute to large differences (up to 20%) in the dose calculated with typical CS algorithms.
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Other groups have shown that for small lung targets (stage I), commonly used dose calcula-
tion algorithms (AAA and AcurosXB) underestimate the dose by approximately 12%, while the
difference is much smaller (0.8%) for stage III lung targets [57]. While MC dose calculation
is generally considered the ‘gold standard’ for dose calculation, the slow calculation times and
large computing power required have prevented MC from being used in regular clinical settings.
3.5 Quantifying Target Motion in the Lung
Treating lung cancers with EBRT is further complicated by the motion of the lungs caused by pa-
tient respiration. If conventional imaging, treatment planning and treatment delivery techniques
are used, motion induced complications in the treatment process arise at each stage. Webb pub-
lished a thorough review of motion effects and treatment techniques in radiation therapy [58]. In
order to adequately compensate for this motion and deliver a successful treatment, a thorough
understanding of the motion is required. The least invasive approach to measuring target motion
in the lung is with medical imaging techniques, namely fluoroscopy, CT, and magnetic resonance
imaging (MRI).
Initial attempts at quantifying target motion in the lung were performed using fluoroscopic
imaging. Fluoroscopy uses continuous exposures of X-rays to generate sequential 2D digital
images of the patient anatomy. While fluoroscopic images usually suffer from low contrast,
the low density of healthy lung tissue (relative to other soft tissues) makes it feasible to detect
and delineate lung cancers in fluoroscopic images. One early attempt at quantifying lung target
motion was published by Ekberg et al. [18]. The authors studied the motion of lung targets
using an electronic portal imaging device (EPID) to detect motion on the treatment unit. They
ultimately used their data to make margin recommendations as well.
In 2003 Vedam et al. [20] published an article quantifying the predictability of diaphragm
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motion. The authors used fluoroscopy to track the position of the diaphragm while having pa-
tients (1) breathe freely, (2) breathe with audio prompting, and (3) breathe with video prompting.
The authors found that free breathing patients have diaphragm position variability similar to that
of patients receiving video prompting and less variability than patients receiving audio prompt-
ing. This confirmed the earlier results of Mageras et al. who performed a similar study [59].
Although it is generally considered that lung target motion is greatest in the superior-inferior
(SI) direction within the patient, target motion does occur in all three principal directions. Due
to the 2D views provided by fluoroscopic approaches, it is impossible to measure displacements
in all three directions from a single set of images. The ability to measure target displacement in
3D is one of the major advantages offered by CT and MRI patient scans. The details of 4DCT
scans are discussed later in this chapter, but it is important to note some contributions made to
quantifying target motion in the lung that have been made with 4D scans.
A work published by Shirato et al. [11] used 4DCT scans with implanted fiducial markers to
detect tumour speed and location using 4DCT. The use of fiducial markers reduces uncertainty
associated with delineating target volumes with low contrast images. However, implanting fidu-
cial markers is an invasive procedure that may not be well tolerated by all patients. Bissonnette
et al. [60] investigated interfraction and intrafraction using respiration-correlated cone beam CT
(rcCBCT). They were able to assess how target motion changed during treatment by acquiring
rcCBCT images before daily treatment, at the midpoint of the treatment and the end of treatment.
They showed no statistical difference in tumour motion magnitude over the course of a treatment
delivery of the patients studied. Shirato et al. studied 21 patients and were able to detect tumour
displacement and speed in each of the three principal directions by using 4DCT. In a work pub-
lished by Mageras et al. [61] the authors were able to detect the motion of lung tumours without
the use of fiducial markers. The authors noted that some tumours followed a trajectory which
included some hysteresis. Mageras et al. also derived some margin recommendations from their
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study of lung target motion. Finally, a detailed work analyzing the motion of lung tumours using
MRI was published by Plathow et al. in 2004 [62]. The authors were able to study the 3D motion
of targets in each of the different lobes of the lung. Plathow et al. concluded that tumours in the
lower lobes moved significantly more than tumours in the upper lobes. They were also able to
establish the fact that regions of the lung which are involved in the disease are less mobile than
the healthy regions of the lung.
Many other authors have also studied the motion of targets in the lung and have reported
valuable data regarding the ranges of amplitude and direction of displacement. A summary of
select published results is presented in Table 3.2. Some of the results in the summary table are
divided into the region of the lung where the tumour is located. Due to the mechanics of the
breathing motion, targets in the lower lobes of the lungs are more susceptible to motion.
Perhaps the most important point to note about target motion in the lung is that there is a
wide range of motion presented by different patients. As can be seen in Table 3.2, there have
been many studies performed, all with different values recorded for the amplitude of motion.
This reinforces the need to measure and verify tumour motion in the lung on a patient-by-patient
basis.
3.5.1 Breathing Traces and Correlation to Target Motion
Taking a recording of a given patient’s breathing pattern is an important step toward adapting
the radiotherapy treatment to their specific anatomy. This issue has been tackled by many au-
thors using several different approaches. The most common approaches involve measuring the
displacement of the exterior chest wall while the patient is in the treatment position. This can be
accomplished using different technologies such as an elastic belt with embedded pressure sensor
(e.g. AZ-733V Respiratory Gating System from Anzai Medical Co., Tokyo, JP) [65, 66], or with
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Direction of Target Motion
Author & year SI AP LR
Ekberg 1998 [18] 3.9 (0-12) 2.4 (0-5) 2.4 (0-5)
Engelsman 2001 [19]
(2-6) Upper lobe - -
(2-9) Lower lobe - -
Seppenwoolde 2002 [9] 5.8 2.5 1.5
Murphy 2002 [63] 7.0 (2-15) - -
Sixel 2003 [10] (0-13) (0-5) (0-4)
Plathow 2004 [62]
4.3 (2.6-7.1) Upper lobe 2.8 (1.2-5.1) 3.4 (1.3-5.3)
7.2 (4.3-10.2) Middle lobe 4.3 (1.9-7.5) 4.3 (1.5-7.1)
9.5 (4.5-16.4) Lower lobe 6.1 (2.5-9.8) 6.0 (2.9-9.8)
Shirato 2006 [11] 10.7 8.8 8.2
Liu 2007 [15] 13.4 5.9 4.0
Suh 2008 [64]
3.7 Upper lobe
- -
8.0 Lower lobe
Table 3.2: Average (or ranges) of lung target motions reported in millimeters along the principle
body directions: superior-inferior (SI), anterior-posterior (AP), left-right (LR).
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an infrared marker block placed on the patient’s chest and a stationary wall mounted camera. An
example is the Real-time Position Management (RPM) system from Varian Medical Systems,
Inc., Palo Alto, CA)[67, 68, 69] which was used to gather the breathing trace data used in this
thesis work.
Varian’s RPM system can be installed in a CT simulation suite to offer respiratory correlated
4DCT scans, or in treatment unit to offer gated treatments. The RPM system consists of an
infrared light source and digital camera (figure 3.1), a reflective marker block (figure 3.2), hard-
ware to allow for interfacing between the RPM system and the diagnostic/therapeutic equipment
as well as the associated software [70]. The system can take recordings of the patient breathing
cycle by using the camera to measure the movement of the marker block placed on the patient’s
chest. The RPM system samples the marker block position at a rate of 30 Hz and is capable
of detecting marker block excursions as small as 1 µm as indicated by the data recorded in the
output file. The RPM system interfaces with a CT scanner or treatment unit to use the breath-
ing trace data to gate treatments in real time or to to offer respiratory correlated CT scans with
retrospective data sorting.
Figure 3.1: A depiction of the RPM infrared light source and camera as seen in the Varian RPM
reference guide [70]. The infrared light source surrounds the camera lens. The monitor is used
for patient feedback.
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Figure 3.2: A depiction of the RPM infrared marker block as seen in the Varian RPM reference
guide [70]. The markers reflect the infrared light from the camera source. In order to offer
accurate measurement, the infrared signal from the reflective block must be the strongest signal
in the room.
In order to provide information regarding the location of a target within the patient, any ex-
ternal surrogate system will rely on the correlation between the reading of the surrogate and the
internal phase of the respiratory cycle. Hoisak et al. [8] showed that the reliability of this correla-
tion varies from day to day among patients. The difference between the breathing phase and the
target motion phase can be quantified with a phase angle difference. Redmond et al. [71] found
average changes in the phase angle between the target motion and surrogate of 13.2% and 14.3%
compared to the initial 4DCT during subsequent rescans. Redmond et al. also confirmed the
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results of Hoisak et al. regarding the reliability of the correlation from day to day. Importantly,
Redmond et al. [71] showed that the target volume excursions remained stable at subsequent
rescans. Redmond et al. also point out that the correlation of the external surrogate to the target
motion is an important issue for gated treatments, as a drift in the phase angle could easily result
in a geographic miss of the delivered radiation.
The recordings generated from these methods offer insight into the patients breathing pattern
in terms of the regularity of the amplitude and frequency of the breaths being taken. An example
of a regular breathing trace recorded using the RPM system is shown in figure 3.3 while an
irregular breathing trace is shown in figure 3.4. A patient with a regular breathing pattern will
typically spend slightly more time at the full exhale phase of the breathing cycle, while irregular
breathers cannot be consistently described in any broad manner.
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Figure 3.3: An example of a regular breathing pattern recorded with Varian’s RPM system. The
amplitude of the motion and the frequency of the breathing is consistent across multiple breaths.
These breathing traces offer data which can be used in many ways by clinicians. Ultimately, it
is a recording of the breathing trace that allows for reconstruction of 4DCT image data sets. The
breathing traces can also be used to guide clinical decision making such as treatment technique
or margin selection, which will be discussed later. As can be seen in the plot of the irregular
breathing pattern (3.4), it is not necessarily easy to predict future breathing motion based on a
given breathing trace. This is especially true in the case of lung cancer patients who frequently
have trouble with respiration due to their condition. As a result, it is important to use the breath-
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ing trace with caution when involving the data in clinical decision making. Purdie et al. [72]
described using cone beam CT images acquired at the immediately prior to treatment, and during
treatment, to reduce setup error and assess intrafraction changes in tumour position.
Figure 3.4: An example of an irregular breathing pattern recorded with Varian’s RPM system.
The amplitude of the motion and the frequency of the breathing are inconsistent across multiple
breaths, while the baseline for motion can also been seen to drift.
3.5.2 Computed Tomography of Lung Cancers in Motion
Using CT imaging to determine the position of tumours is a key step in the process of delivering
EBRT. In order to acquire a clear and accurate representation of the patient many trade-offs
have to be made between parameters such as image resolution, absorbed dose to the patient,
image noise, field of view and scan time due to the physical limitations of the system. Acquiring
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CT images of the lung is further complicated by the motion of the structure during imaging.
Due to the image reconstruction process used to generate 3D CT datasets, any motion which
occurs during image acquisition of a conventional CT scan will cause motion artifacts in the final
image. Figure 3.5 shows an example of a motion artifact at the bottom of the lung, appearing
as a structure with a wavy edge. This type of artifact causes problems in the planning process
because it makes delineating structures more difficult and can also compromise dose calculation,
depending on the calculation algorithm being used. As a result, different approaches to imaging
lung targets in motion have been developed.
Figure 3.5: An example of a CT image artifact caused by organ motion during image acquisition.
Such artifacts compromise the treatment planning process and need to be avoided.
One such approach to reducing image artifacts is known as a ‘slow scan’. By operating the
CT scanner in a slow method, such that the couch position remains constant across at least one
full breathing cycle, the entire range of target motion during the breathing cycle can be captured
on each slice of the CT image. A slow scan can also be achieved by averaging several CT scans of
the same patient together [73]. The advantage of the slow scan is that the entire range of tumour
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motion is captured in the final image, although this comes at the expense of slightly increased
dose to the patient and additional blurring due to motion of other structures in the image.
Breath-hold techniques can also be used during CT simulation to reduce respiratory motion
artifacts. CT breath-hold techniques require the patient to hold their breath in order to reduce
artifacts due to respiration. Alternatively the patient may be guided through the breathing cycle
with audio or visual prompts. A work published by Hanley et al. [74] was one of the first
to investigate breath-hold CT scans in the context of radiotherapy for the lung. The authors
compared free breathing scans to breath-hold scans and found that they were able to reliably
reduce the margin of uncertainty associated with the target motion by using deep inspiration
breath-hold (DIBH) during CT simulation. Hanley et al. found that DIBH allowed for an up to
30% reduction in the volume of lung receiving 25 Gy during a 75 Gy treatment.
A final technique used to compensate for lung target motion is the use of maximum intensity
projections (MIP). A MIP is an image (or 3D data set) comprised of the ‘maximum intensity’
values of several individual scans. In the case of a CT MIP, each voxel contains the maximum
electron density of the corresponding voxels in the individual scans. Underberg et al. [75] used
3 separate CT images to generate MIPs for lung EBRT: a full inspiration, full exhalation and
a midventilation scan. By combining the images into a MIP, the full range of tumour motion
becomes apparent. The tumour volume as it appears on the MIP then forms the target volume on
which the treatment planning is performed.
No matter the scanning technique used, the ultimate goal is to generate an image which is
anatomically accurate with an acceptably low amount of noise. Image noise is quantified by
determining the standard deviation of the pixel intensity of an image of a uniform subject (e.g.
a cylindrical water phantom)[25]. Within a uniform region of interest (ROI) of a 2D image, the
image noise can be characterized by
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σ =
√
1
N − 1
∑
i,jROI
(fi,j − f¯)2, (3.1)
where fi,j are the individual pixel intensities, N is the total number of pixels included in the
sum and f¯ is the average pixel intensity calculated by
f¯ =
1
N
∑
i,jROI
fi,j. (3.2)
The pixel intensity is simply the Hounsfield unit (HU) value associated with the given pixel.
Since the HU is a rescaling of the measured linear attenuation coefficient (described in equation
2.3), the image noise is ultimately dependent on the standard deviation of the measured linear
attenuation coefficients of the subject. Ford et al. [76] showed that for an idealized CT scanning
system with isotropic voxel size, the variance in measured linear attenuation coefficient of a
cylindrical object is given by
σ2µ =
pi2
12∆x2nangN
. (3.3)
In this context ∆x is the voxel side length, nang is the number of projection views used in
the reconstruction and N is the number of photons absorbed per projection, per detector. The
number of photons absorbed, N , is ultimately dependent on many parameters of the scanner
design and X-ray tube operation. N is can be determined by
N =
ΦI∆tnWHηe−µd
L
, (3.4)
where Φ is the fluence rate per unit tube current at the detector plane, I is the tube current,
∆t is the exposure time per view, n is the number of detector elements per view, W is the
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aperture width, H is the slice thickness, η is the quantum efficiency of the detector, µ is the
linear attenuation coefficient of the subject, d is the diameter of the subject and L is the number
of reconstruction bins in the image.
Given that the image noise is inversely dependent on the number of photons absorbed by the
detectors (N ), the best way to reduce image noise is to increase the value of N . This can be
achieved by the appropriate manipulation of any of the parameters which comprise N . However,
any increase in the value of N will necessarily increase the effective dose to the patient. This is
the ultimate trade off for CT image quality: if you wish to reduce image noise while maintaining
all other image parameters (e.g. contrast, resolution, scan time), you must increase the dose to
your subject. In a clinical situation, the balance that must be struck is between acceptable image
quality and dose to the patient.
4DCT for Imaging Lung Cancer
Another approach which is growing in popularity as the required technology becomes more
widespread is the use of 4DCT scans. A 4D scan generates multiple (typically 8-10) complete
datasets of the patient, each corresponding to a different phase of the breathing cycle. This
approach offers the benefits of increased contrast (as compared to a slow scan) and the avoidance
of motion artifacts in the images. The datasets may be viewed in sequential order, thus offering
a short movie of the target motion due to respiration.
Modern CT hardware is required to generate a 4DCT scan. These scanners have very fast
gantry speeds (on the order of 1 second per rotation) which allows the machine to acquire a
complete view of the patient in less than the time required for a typical breathing cycle (on the
order of 3 seconds per cycle). The acquired image views must be sorted according to when they
were acquired during the breathing cycle. This is accomplished with the aide of the recorded
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breathing trace. An early description of the procedure for acquiring a 4DCT scan correlated to
respiratory motion was published by Ford et al. [77]. The images can be sorted according to the
phase of the breathing trace during which they were acquired [78], or according to the amplitude
(position) of a surrogate marker during the breathing cycle [79]. 4D scans come at the expense
of increased dose to the patient and increased workload for the clinical resources [77]. Due to
the rapid acquisition times, the individual phased images will typically have more image noise
as compared to a conventional scan. However, the additional positional information gained by
this method is very valuable during treatment planning.
A 4DCT is similar to a conventional CT scan in most regards. The image data is acquired and
reconstructed in the same overall manner. However, in the case of 4DCT, the X-ray projection
data is recorded along side the patient’s breathing pattern and additional X-ray projections are
acquired to use in a post-processing procedure. After acquiring the data from the scan, the X-ray
projections are sorted into groups depending on which point of the breathing cycle the projection
data was captured. Each of these groups of data are then used to reconstruct an image of the
patient corresponding to the given portion of the breathing cycle. A typical 4DCT scan will
reconstruct 8 − 10 image data sets which can then be viewed in sequence to offer insight into
the given patient’s intrafraction motion. The image sorting is typically done in one of two ways:
phase binning or amplitude binning.
A phase binned acquisition, as depicted in Figure 3.6, sorts the images according to the
angular phase of the breathing cycle. This approach has been discussed by many authors [80, 81,
82, 83] and is the most common approach to 4DCT image reconstruction. Each full breathing
cycle is divided into the desired number of segments and the projection data is grouped according
to which segment it was acquired in. A full image data set is then reconstructed for each segment.
This approach is ideal for a patient exhibiting a regular breathing frequency and amplitude.
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Figure 3.6: An idealized breathing trace broken into 10 phase segments for data binning prior to
image reconstruction.
An amplitude binned acquisition, as depicted in Figure 3.7, sorts the images according to
the amplitude of the breathing trace recorded at the time of data acquisition. Although less
popular than the phase binning approach, amplitude binning has still seen widespread discussion
in the literature [84, 85, 86, 87]. The entire breathing trace is divided into the desired number
of amplitude segments and the projection data is grouped according to which segment it was
acquired in. As before, a full image data set is reconstructed for each segment. This approach
can be beneficial when the subject being imaged is exhibiting an irregular breathing pattern [87].
60
Figure 3.7: An idealized breathing trace broken into 10 amplitude segments for data binning
prior to image reconstruction.
For the purposes of this work there are three particular phases of the breathing cycle which
are of interest. The first is the ‘peak inhalation’ phase (bin 1 in the amplitude sorting scheme,
bin 3 in the phase sorting scheme). During this phase the patient is just finishing the inhalation
of air. In a regular breather there is typically very little pause at the moment of peak inhalation
before exhalation begins. At the moment of peak inhalation the lungs reach their full capacity
and any target within the lung will be at an extreme position within its motion cycle. In the
most common scenario of superior-inferior motion, this corresponds to the most inferior position
the target will reach. The second phase of interest is the ‘peak exhalation’ phase (bin 10 in the
amplitude sorting scheme, bin 8 in the phase sorting scheme). During this phase the lungs are
61
in their natural resting state and any target within the lung will again be at an extreme position
within its motion cycle. Most people will naturally pause for a moment at peak exhalation before
beginning to inhale. The accumulation of this pause over the course of several breathing cycles
is what contributes to the usual lobed feature of a regular breathing PDF.
The final phase of interest is the mean phase. This is the phase of the breathing cycle during
which the target is at its mean position during the breathing cycle. The bin corresponding to the
mean phase will depend on the given patients precise breathing trace, however it will typically
fall in bin 5 or 6 of both depicted schemes. This phase is of importance because it represents
the phase on which the treatment should be planned in order to confidently apply the margins
ultimately recommended in this work.
The technology required to perform 4DCT imaging has only become widely available within
the last 10 years. In order to acquire the image data with sufficient temporal resolution, several
advances in CT technology were required. One key advancement was the introduction of the
slip ring gantry. This gantry design eliminated the need for cables to transfer data between the
rotating detector elements and the associated computer hardware. Without the limitations of
the cables, the gantry is free to continuously rotate in the same direction. This improvement
decreases the overall time required to acquire the necessary data. Along with the introduction of
the slip ring came an increase in gantry rotation speed. Reducing the time per revolution of the
gantry had a major impact on reducing overall scan times. Another important advancement was
the introduction of helical scanning. This advancement allowed for continuous imaging of the
patient as they are translated through the CT gantry. This was an important improvement because
it drastically increased the duty cycle of the CT scanner, allowing for scans to be completed in
as little as half the time as compared to the traditional ’step-and-shoot’ approach. Finally, the
use of multiple detector rows in modern CT scanners also improves the temporal resolution by
allowing for complete scans of a given organ in fewer gantry rotations.
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All of these technological advancements served to reduce the time required to scan a patient.
The goal with 4DCT is to acquire data with sufficient temporal resolution as to be able to discern
organ motion that is occurring during the data acquisition. In the case of respiratory motion, a
typical breathing cycle takes between 2 − 3 s. It is therefore necessary to acquire a complete
set of projections in less than 2 s in order to have sufficient temporal resolution to detect the
motion. The CT scanner in clinical use at the Grand River Regional Cancer Centre is capable
of a complete gantry rotation in as little as 0.5 s. By combining the technological advances in
CT scanner design with data binning and image reconstruction, it is possible to generate useful
4DCT images. However, it should be noted that by decreasing the exposure time with fast gantry
rotations, the image quality will be degraded as per the discussion of Equations 3.1 - 3.4. This
can be overcome by making the tradeoff of increased dose to the patient. The advantages of the
additional information provided by a 4DCT scan must be weighed against the risks associated
with this extra dose by the physician.
One of the key pieces of information provided by a 4DCT scan is the amplitude of target
motion during the breathing cycle. The breathing trace data recorded by Varian’s RPM system is
actually the vertical position of a reflective marker block placed on the chest of a patient during
the 4DCT scan [59]. While this data gives us accurate information regarding the frequency and
baseline of the breathing cycle, the recorded amplitude does not correspond to the amplitude of
the target motion in general. Therefore the breathing trace amplitude as recorded by the RPM
system cannot be assumed equal to the amplitude of the motion of the target. In order to use the
breathing trace data to generate a PDF describing the motion of the target within the patient, the
amplitude of the marker block motion must be normalized to the amplitude of the target motion
as revealed by the 4DCT scan. After this normalization is performed, the renormalized breathing
trace can then be said to be representative of the motion of the target within the patient. This
procedure was recommended by Richter et al.[2] in order to generate accurate 1D PDFs of target
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motion and is used in this thesis.
3.6 Treating Lung Cancers in Motion
Clearly defined treatment volumes play a key role in the delivery of EBRT. The description of
these volumes was standardized by the International Commission on Radiation Units and Mea-
surements (ICRU) Reports 50 and 62 [88, 89]. These reports defined several volumes which are
used to prescribe and report photon beam radiotherapy. The Gross Tumour Volume (GTV) is the
main clinical target representing the bulk of the solid tumour, it is easily discernible on a CT scan.
The Clinical Tumour Volume (CTV) includes the GTV and some additional surrounding volume
to account for the microscopic spread of the disease which is known to occur clinically. This
microscopic spread is not typically visible in CT images. The Planning Target Volume (PTV)
includes the CTV and some additional surrounding volume to account for treatment uncertainties
such as organ motion and setup error. ICRU Report 62 also defined an Internal Target Volume
(ITV) which represents the movement of the CTV relative to other structures in the patient. The
ITV was defined because target movement due to internal organ motion such as respiration or
organ filling, is extremely difficult for the clinician to control. In the cases where an ITV is
defined, the PTV typically surrounds the ITV to account for setup uncertainties associated with
positioning the patient on the treatment unit. The treatment volumes are illustrated in Figure 3.8.
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Figure 3.8: An illustration of the treatment volumes defined by ICRU Reports 50 and 62. These
standardized volumes allow for consistent prescription and reporting of photon radiotherapy
across clinics around the world.
There is always a trade-off to be made between the confidence that a given volume covers
the intended structure, and the size of that volume. In order to minimize the NTCP associated
with a given radiotherapy treatment, the treatment volumes should be kept as small as possible.
However, if the treatment volumes fail to cover the intended target and the resulting treatment
also fails, then the radiotherapy has not been successful and the risks associated with delivering
the absorbed dose have not been balanced with the intended benefits.
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3.6.1 Breath Hold Techniques
Various treatment techniques have been developed in the context of moving targets in the lung
that attempt to minimize the treatment volumes while still ensuring confidence in the delivered
dose coverage. One such group of approaches is known as ‘breath-hold techniques’. There
are many different breath-hold techniques which take advantage of different technologies while
delivering the radiotherapy treatment [12]. The simplest approach involves coaching the patient
to perform repeatable deep inspiration [90]. The treatment beam is only turned on when the
patient’s respiration is paused at the full inhale phase. A similar technique reported by Wong et al.
in 1999 [91] used a medical device to suspend the patient breathing and achieve similar results.
Finally, respiratory motion can be controlled by forcing the patient to perform only shallow
breathing, thereby limiting target motion. This approach can be achieved with an abdominal
compression plate. In one study, lung target motion was reduced from a range of 8−20mm to 2−
11mm using this technique [92]. While breath-hold techniques have been used successfully, not
all patients are amenable to their use. Lung cancer patients often have compromised respiration,
and so forcing new breathing patterns onto patients can be difficult for them to achieve. The
treatment planning process for breath-hold techniques starts with an evaluation of the tumour
motion [92]. If the tumour motion is deemed too large (usually > 5 mm [92]) then a breath-hold
technique may be indicated. In this case a free-breathing CT image is acquired along with a
motion limited CT image acquired while implementing a breath-hold technique. The treatment
planning is performed on the motion limited CT while the free-breathing CT image provides a
reference for treatment planners. The clinical target volume is delineated on the motion limited
CT, and the appropriate margins are added. At the time of treatment, verification imaging is
performed to reduce any setup errors and ensure the patient is positioned as they were during the
motion limited CT scan. After the patient setup is complete, the treatment is delivered. Breath
hold techniques provide simple cost effective means for reducing target motion.
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3.6.2 Gated Radiotherapy
Another treatment technique used to reduce the impact of lung target motion is ‘gated radiother-
apy’. Gated treatment takes advantage of the delivery technology to turn the treatment beams
on while the target is in a specific location (the ‘gate’), and off as the target leaves that location.
By developing a treatment plan for the target in a specific location, the treatment volumes can be
reduced. Gated treatment can be achieved by using external markers such as a camera or pressure
belt [93] to determine the breathing phase. The treatment delivery is then delivered at a consistent
phase of the breathing cycle. Gated treatment can also take advantage of internal markers such as
an implanted fiducial marker. The position of the marker is then tracked with fluoroscopic X-ray
imaging. One such study showed a reduction in target motion from 5.5− 15.9 mm during beam
off time to less than 5.3 mm during beam on time using this technique [94]. This level of motion
reduction offers a clear advantage towards reducing treatment volumes, however they come at
the expense of increased use of clinical resources, more quality assurance testing and surgical
intervention in some cases. The treatment planning process for gated radiotherapy begins with a
gated CT scan. This is typically accomplished by triggering the CT acquisition based on the sig-
nal of an external surrogate [12]. The image data gathered during the gated CT scan then forms
the basis for the treatment plan. The target volumes are delineated on the gated CT image and the
remainder of treatment is planned as usual. At the time of treatment, verification imaging needs
to be performed to ensure accurate patient setup and to verify that the signal from the external
surrogate is correlated to the target motion as expected. The treatment is delivered by gating the
delivery beam to match the gating performed during the planning CT. Special care must be taken
to ensure that the phase angle between the external surrogate signal and target motion remains
consistent with the phase angle at the time of the planning CT. If there is an undetected change
in the phase angle, it is possible for the treatment beam gate to be consistently triggered when
the target is outside the intended treatment volume.
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3.6.3 Real Time Target Tracking
The latest development in the treatment of targets in motion is that of ‘real time target tracking’
techniques. These techniques seek to monitor the position of the target in real time and adjust the
relative position of the treatment beam such that the target continues to be irradiated throughout
the motion. The target motion can be tracked using implanted fiducial markers [95], or external
surrogates [96]. It has been noted that the correlation between target position and the signal
from an external surrogate may not always remain constant, as a result this information may
need to be updated throughout the treatment [97]. The repositioning of the treatment beam
can be accomplished with conventional modern radiotherapy equipment by using the multi-leaf
collimator (MLC) [98, 99] or the treatment couch [100]. Robotic radiosurgery equipment such
as the CyberKnife developed by Accuray (Accuray, Sunnyvale, CA, USA) have been designed
with target tracking in mind. The main obstacle to implementing real time target tracking is in
balancing the additional imaging dose to the patient while still obtaining the necessary data to
accurately track the target in motion. The quality assurance of such techniques also presents a
difficult challenge, and as such have yet to see wide spread clinical acceptance. A method for
planning real time target tracking treatments was described by Keall et al. [101]. This process
begins with the acquisition of a 4DCT scan. The treatment is planned on each phase of the 4DCT
data set. Keall accomplished this by generating a typical treatment plan on the peak inspiration
phase image. The plan was then transferred to each of the other phases using automated tools
within the treatment planning software to define the treatment volumes. At the time of delivery,
the patient setup is verified with further imaging. During the treatment delivery, the MLC is
varied dynamically such that the beam aperture follows the treatment volume that was defined
on each phase of the 4DCT scan. This is accomplished with a feedback loop which includes the
signal of an external surrogate used to track the target motion. As with gated treatment delivery,
particular care needs to be given to the phase angle between the surrogate signal and the target
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motion as seen on verification imaging before treatment delivery.
3.6.4 Motion Encompassing Techniques
The most widespread technique used to treat targets in motion are ‘motion encompassing’ tech-
niques. These methods seek to define treatment volumes which encompass the motion of the
target in order to ensure adequate absorbed dose is delivered. Motion encompassing techniques
can be implemented at the imaging and/or treatment planning stages of radiotherapy.
At the imaging stage, motion encompassing techniques can be implemented by taking ad-
vantage of different CT scanning protocols. Researchers have developed different methods for
detecting the range of motion of a given target using CT scans. As discussed earlier, slow scans
allow time for a complete cycle of a given periodic target motion to be represented in each slice
of a CT data set [73]. This type of image allows treatment planners to define an ITV encom-
passing the target motion, to which additional margins may be added to generate the final PTV.
Maximum intensity projections can also be used to define the range of target motion [75]. This
requires ‘fusing’ two CT images, one taken at maximum inhale and the other at maximum exhale
phases of the breathing cycle. The fused image shows the extent of motion and can be used to
define the ITV. 4DCT scans can also be used to determine the extent of target motion in order
to define an ITV [15, 102]. Work by Admiraal et al. showed that little to no additional margin
is often required when defining a PTV from an ITV [103]. It has also been shown that these
approaches to defining the ITV offer favorable results in terms of reliable dose coverage as com-
pared to adding a standard margin to each patient [104]. This emphasizes the benefits of a patient
specific approach to margin selection. However, treating the entire volume represented by the
extent of motion may add unnecessary dose to surrounding healthy tissue [105].
At the planning stage, there are several approaches which can be used to select treatment
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margins. Probabilistic approaches to motion encompassing volumes have been developed. Per-
haps the most widely known formula is that of van Herk et al. [13]. The van Herk formula
recommends margins to retain a certain percentage of the target dose for a certain percentage of
the patient population. For example, in order to retain 80% of the target dose to 90% of the pop-
ulation a margin of 0.4σbr should be added to compensate for motion, where σbr is the standard
deviation of the breathing motion. In order to retain 95% of the target dose to 90% of the patient
population a margin of 0.7σbr is recommended [13]. This work was a seminal contribution to
the ideas of margin selection as van Herk et al. justified their margin recipes by analyzing the
motion and dose coverage of a large population of patients. By recommending margins based on
the standard deviation of systematic and random errors of populations of patients, a reliable un-
derstanding of the range of required margins can be assessed. However, as this was a population
based approach, these margins will not satisfy every patient. The population based recommen-
dation will overcompensate for some patients and undercompensate for others by its nature. A
patient specific approach to margin selection would still offer the best compromise between TCP
and NTCP.
Other authors have attempted to compensate for variations in the breathing cycle during the
planning stage. Heath et al. [16] took a probabilistic approach to optimizing lung treatment
plans with breathing variations by optimizing an objective function which includes variations
in dose due to motion and lung density changes [106]. Heath et al. [16] showed that dose
coverage to the target volume was not improved with this approach as compared to margin-based
mid ventilation compensation approaches, however some reduction in the dose to the OARs was
noted. This result emphasizes the fact that typical variations in breathing patterns do not have
large effect on the delivered dose distribution, as compared to the breathing motion itself.
Since motion encompassing techniques are the most widely used motion compensating treat-
ment methods, they present the largest opportunity for improving dose delivery to targets in
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motion. One of the major aims of this research thesis is to present a method for selecting treat-
ment margins which compensate for a patient’s specific breathing and target motion. By offering
a patient specific approach, the optimal margin can be selected on a case by case basis to en-
sure that the treatment volumes are still being covered by an acceptable absorbed dose, while
minimizing the additional radiation received by the surrounding healthy OARs.
3.7 Summary
Lung cancers are classified into the categories of small cell lung cancer (SCLC) and non-small
cell lung cancer (NSCLC) according to the cell morphology. The vast majority of lung cancers
are caused by smoking, although other environmental conditions (e.g. smog and Radon expo-
sure) have also been implicated. Lung cancers have poor survival rates worldwide and pose a
significant challenge to clinicians.
The radiotherapy of lung cancers is complicated by challenges involving calculating the dose
distribution. Many dose calculation algorithms have difficulty accounting for the tissue inhomo-
geneity common in the lung, which can lead to dose errors. Furthermore, the motion caused by
respiration poses an additional challenge to the accurate delivery of radiotherapy. Several ap-
proaches to quantifying lung target motion have been developed by researchers using tools such
as fluoroscopy and 4D imaging techniques. In this thesis the images and data gathered during
a 4DCT scan are used to identify the mean phase of motion. The respiratory motion can the be
compensated for with additional treatment margins. This approach does come at the expense of
increased dose to OARs.
Knowledge of the target motion patterns has lead to the development of several techniques
for the delivery of radiotherapy to the lung. Gated radiotherapy turns the beam on only when
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the target is in a specific location. Real time target tracking techniques direct the beam to follow
the target as it undergoes respiratory motion. Breath hold techniques look to reduce the amount
of motion by managing patient breathing and are often used in conjunction with gated delivery
techniques.
Perhaps the most widely used approach to lung target motion management is with motion en-
compassing techniques. These approaches seek to define target volumes which will compensate
for the motion of the target, either by estimating the position of the target using a probabilistic
approach, or by recording the extent of target motion and irradiating the entire volume. The mo-
tion encompassing technique employed in this work seeks to add additional treatment margins
based on a patients’ specific breathing pattern and target volume. Since these types of approaches
are most commonly used to compensate for target motion, they present a large opportunity for
improving patient outcomes.
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Chapter 4
The Convolution Model and its Inputs
4.1 Introduction
The convolution model employed throughout this work was originally described by Leong in
1987 [22]. At that time, the proposed use of the model was to determine the effect of random
daily patient setup errors on the originally calculated dose distribution. These setup errors oc-
cur as a natural result of treatment fractionation. As patients return for their daily fractions of
radiotherapy, they need to be positioned on the treatment couch each time. While much care
is taken in the clinic to ensure that patient positioning is accurately reproduced each day, small
variations are inevitable. The small differences in daily patient setup can manifest themselves
as a displacement of the entire patient from the originally planned position, or as a shift in the
relative locations of the organs within the patient. Changes in patient position or anatomy which
occur on a day-to-day basis (as opposed to during treatment delivery) are categorized as ‘inter-
fraction motion’. Any change in patient position or anatomy from the original plan will manifest
as deviations between the planned and delivered dose distributions. The original convolution
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model aimed to predict the extent of the changes to the dose distribution in order to allow for the
compensation of interfraction motion during treatment planning.
The convolution model has also been used to study the effect of intrafraction motion on the
delivered dose distribution. An early work assessing the convolution model for intrafraction
motion was published by Lujan et al. [23] in 1999. In that work, the authors used fluoroscopic
imaging and direct simulation to investigate the use of the convolution model for intrafraction
motion. The authors showed that the results of the convolution model predictions were very
similar to the results of a direct simulation of the dose delivered at each phase of the breathing
cycle. At the time, the authors were limited in their approach by the lack of availability of 4DCT.
It is valuable to revisit the use of the convolution model for intrafraction motion in the context of
this new technology.
Intrafraction motion is a serious challenge to targets in the lung and liver in particular. As a
result the use of the convolution model in the context of intrafraction motion as described in the
literature is focused on these two disease sites. This chapter will describe the convolution model
and its inputs in detail, as well as assess the model assumptions and review the historical use of
the convolution model in the literature.
4.2 The Convolution Model of Target Motion
The convolution model as originally proposed by Leong in 1987 [22] is given by the equation
Db(x, y, z) =
∫ ∫ ∫
D0(x− x′, y − y′, z − z′)PDF (x′, y′, z′)dx′dy′dz′, (4.1)
or succinctly as
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Db(~r) =
∫
D0(~r − ~r′)PDF (~r′)d~r′ (4.2)
Db(~r) = D0(~r)⊗ PDF (~r). (4.3)
Db(~r) represents the resulting ‘blurred’ dose distribution; D0(~r) is the static dose distribution
(as calculated a priori by treatment planning software); PDF (~r) is a probability density function
describing the position of the target over the course of all treatment fractions; and the coordinates
(x, y, z) correspond to the standard body directions of left-right (LR), anterior-posterior (AP) and
superior-inferior (SI), respectively. D0(~r) is referred to as the ‘static’ dose distribution because it
comes from a treatment plan that does not account for target motion. The plan is generated on a
static image of the patient and assumes the patient will be static while receiving their treatment.
In the context of this thesis work, the static plan would be generated on an image of the patient
at a particular phase of their breathing cycle. This is the phase of the breathing cycle which has
the target at its mean location. The model prediction, Db(~r), is referred to as the ‘blurred’ dose
distribution because the qualitative effect of the convolution is to spread (or blur) the static dose
distribution.
The Fourier transform is commonly used to treat convolutions because the convolution oper-
ation reduces to multiplication in the Fourier space. This is described in Bracewell [107] as
F−1 [F (f(x))F (g(x))] = f(x)⊗ g(x), (4.4)
where F is the Fourier transform
F (f(x)) =
∫ ∞
−∞
f(x)e−2piikxdx, (4.5)
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and F−1 is the inverse Fourier transform
F−1(f(x)) =
∫ ∞
−∞
f(x)e2piikxdx. (4.6)
Jiang et al. [24] proposed a modification to the model by first noting that the derivative of a
convolution is well defined ([108]) as:
∇Db(~r) = ∇D0(~r)⊗ PDF (~r) (4.7)
∇Db(~r) = D0(~r)⊗∇PDF (~r) (4.8)
Therefore, given a reference point ~kR3, the blurred dose can also be expressed as:
Db(~r) = Db(~k) +
∫
s
∇Db(~r)d~r (4.9)
= Db(~k) +
∫
s
[∇D0(~r)⊗ PDF (~r)]d~r (4.10)
= Db(~k) +
∫
s
[D0(~r)⊗∇PDF (~r)]d~r (4.11)
where s is the line from ~k to ~r. In the case of a straight one dimensional dose profile with
dose equal to zero (or negligibly small) at ~k, these equations can be simplified to
Db(x) =
∫
d
dx
D0(x)⊗ PDF (x)dx (4.12)
Db(x) =
∫
D0(x)⊗ d
dx
PDF (x)dx. (4.13)
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This approach of Equation 4.12 is advantageous because regions of the dose distribution with
large dose gradients are most susceptible to changes due to target motion. Therefore, taking the
gradient first will highlight regions of the dose distribution where the blurring effect is greatest.
Jiang et al. [24] also showed that the model can be formulated in terms of an integral over the
static dose distribution convolved with the spatial gradient of the PDF as shown in Equation 4.13,
however did not pursue this line of investigation in detail.
This formulation of the convolution model described in Equation 4.13 will highlight features
of the PDF which have the largest impact on the delivered dose distribution. The shape of the
PDF is largely governed by the ‘regularity’ of the breathing pattern. For the purposes of this
work, a breathing trace is considered ‘regular’ if it exhibits clear periodicity. A regular breathing
trace will show little breath-to-breath variation in breathing frequency, breathing amplitude and
baseline location (the baseline is the geometric mean location of the breathing trace). An image
of the patient while they are in the baseline phase can be obtained by selecting the appropriate
phase of a 4DCT scan. A regular breathing trace will tend to result in a PDF with two prominent
lobes, corresponding to the peak inhalation and peak exhalation phases of the breathing cycle.
This two mode shape can be seen in the PDF presented in Figure 4.2. A breathing trace is
considered ‘irregular’ if it does not exhibit stable amplitude, frequency or baseline location. An
irregular breathing trace will typically result in a PDF with a single prominent lobe and other
(minor) unique features depending on the specifics of the trace. The distinction between regular
and irregular breathing patterns remains qualitative due to the wide range of breathing patterns
exhibited by patients. Any attempt to put a strict definition on regular versus irregular breathing
will likely involve arbitrary definitions of thresholds regarding the trace parameters.
It should be noted that a property of the convolution can be used to help interpret the predic-
tions made by this model. As described by Bracewell [107], the integral of the convolution of
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two functions is equal to the product of the areas of the two functions. This can be shown as∫ ∞
−∞
f(x)⊗ g(x)dx =
∫ ∞
−∞
[∫ ∞
−∞
f(u)g(x− u)du
]
dx (4.14)
=
∫ ∞
−∞
f(u)
[∫ ∞
−∞
g(x− u)dx
]
du (4.15)
=
[∫ ∞
−∞
f(u)du
] [∫ ∞
−∞
g(x)dx
]
. (4.16)
This is important in the context of this work because the area under the PDF is unity (by
definition). This implies that the integral dose being delivered during intrafraction motion is
equal to the integral dose delivered by the same plan to a static patient. In other words, the effect
of target motion can be interpreted as a redistribution of the dose you expect to deliver to a static
target.
A careful understanding of the model inputs and the associated model assumptions is required
to make proper use of the convolution model. This model makes assumptions tied to each of
the inputs, and these assumptions must be satisfied in order for the model to make accurate
predictions. The two assumptions will be referred to as ‘shift invariance’ (connected to the static
dose input) and ‘sufficient sampling’ (connected to the PDF input). A thorough analysis of these
assumptions in the context of interfraction motion was published in two papers by Craig et al.
[109, 110]. However, it is important to re-confirm the validity of these assumptions in the context
of intrafraction motion.
4.2.1 Convolution Model Inputs - Static Dose Distribution and its Gradient
The static dose distribution used as a model input in this work was planned on a dynamic thorax
phantom. The details pertaining to the phantom, scanning procedure and planning procedure
are given in Chapter 5. Briefly: the planning followed a procedure similar to that of a patient
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undergoing radiotherapy treatment. The phantom was configured with a lung equivalent insert
that is designed to accept a piece of radiographic film for dose measurement. The phantom was
then scanned using the department’s typical thorax scanning protocol. The image of the static
phantom obtained in this scan was used to generate the static dose distribution (D0) used in the
convolution model predictions. After completing the scan, the DICOM data was sent to the
treatment planning computers. The treatment volumes were then defined on the phantom image
data set, which included a simulated GTV, CTV and PTV. The PTV was approximately spherical
in shape and had a diameter of 3.7 cm.
In order to generate the treatment plan, a simple three field, conformal technique was used.
As well as being clinically relevant, this technique also allows for simple adjustments to be made
in order to test the effect of varying field sizes and dose rates. A dose of 200 cGy per fraction
was selected in order to remain consistent with conventional conformal treatments of the lung.
Further details on the treatment plan are provided in Chapter 5.
After completing the treatment plan including the TPS dose calculation, the static dose profile
can be obtained. The Eclipse TPS offers users the ability to plot and export dose profiles along
any straight line within the patient. The exported dose profile data can then be imported into
other software, such as MATLAB or a spreadsheet program, for analysis. A dose profile through
the plan isocentre is presented in Figure 4.1.
The use of dose gradients in this motion model as described by Equation 4.12 offers an im-
portant tool for understanding the regions of the dose distribution which will be most susceptible
to changes due to target motion. The regions of the dose distribution where the gradient is small
(or zero) make little (or no) contribution to the blurred distribution that we expect to deliver in
the presence of motion. In practice this means that the penumbral regions (defined as the region
where the dose falls from 80%− 20% of the prescribed dose) of the distribution where the mag-
nitude of the dose gradients is largest, will be most susceptible to the blurring effect of target
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motion. As a result, the outer edges of the target volume are at the highest risk of losing dose
coverage as a result of target motion.
Figure 4.1: A static dose profile and its derivative taken from the treatment planned on the static
phantom. The profile is taken in the SI direction starting superior to the treatment volume, along
the length of the film insert.
In terms of treatment planning, the loss of dose coverage is the complication caused by target
motion. An appropriate treatment plan has to balance the NTCP with the TCP. In the presence
of target motion, the loss of target dose coverage represents a loss of TCP. In order to recover
the TCP by increasing target margins, the treatment plan will necessarily increase NTCP. The
presence of target motion makes striking the appropriate balance more difficult. In situations
where the target volume is directly adjacent to an OAR, it may not be possible to safely increase
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target margins in a given direction and therefore different treatment techniques may need to be
considered.
Understanding what margins are necessary to retain the desired TCP for a given dose distri-
bution and breathing pattern is one of the key motivations for this work. It is the hope that by
giving clinicians tools for margin selection, decisions can quickly and easily be made regarding
the balance of TCP and NTCP for a given treatment plan.
4.2.2 Convolution Model Inputs - Motional PDF and its Gradient
The PDFs used for this work were generated from 502 unique patient breathing traces. The
traces were recorded at the London Regional Cancer Program (London, Ontario) using the Varian
RPM system (Varian Medical Systems, Inc., Palo Alto, CA). The breathing traces were acquired
during 4DCT simulation and were originally used for 4DCT image reconstruction. The PDFs
were generated from each breathing trace using MATLAB (The Mathworks, Inc., Natick, MA) to
create a histogram of the breathing trace recorded during ‘beam on’. A PDF was then generated
from the histogram using MATLAB’s Kernel Smoothing Density Estimate routine (ksdensity).
The resulting function was normalized such that the area under the curve was unity, as required
by the definition of a PDF. A graphical depiction of this process for a regular breathing trace is
provided in Figure 4.2.
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Figure 4.2: The development of a PDF from a recorded breathing trace. Figure A is the recorded
breathing trace. Figure B is the associated histogram generated by binning the breathing trace
data. Figure C is the final PDF generated with a MATLAB routine and normalized appropriately.
Figure D shows the PDF and its gradient.
The origin of the PDF coordinate system was placed at the mean location of the recorded
positions, as suggested by other authors [1, 111]. For the purposes of the analysis performed in
this work, the breathing trace amplitudes as recorded by the Varian RPM system were assumed
to be equal to the target motion amplitude within the patient. This was done to ensure a wide
range of motion amplitudes were considered. Although the amplitude of target motion within the
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patient is not equal to the amplitude of the marker block motion in general, the breathing trace
amplitude can be renormalized [2] to the target motion amplitude as seen on 4DCT. A breathing
trace renormalized in this way is representative of one dimensional motion of the target during
breathing.
The formulation of the convolution model described by Equation 4.12 makes use of the gra-
dient of PDF for calculating the blurred dose distribution. In the case of the regular breathing
PDF depicted in Figure 4.2 the gradients with the largest magnitude surround the peak inspira-
tion and peak expiration phases of the breathing cycle. These phases correspond to the largest
displacements of target from its mean position. As a result, the largest contribution of the PDF
gradient to the blurred dose distribution is seen in these regions of large displacement. This em-
phasizes the fact that the blurring of the delivered dose distribution is predominantly influenced
by the ‘most likely’ position of the target during its motion. The rate of change of the PDF along
a given direction can then be seen as a measure of the amount of dose blurring that is expected
as a result of target motion.
4.3 The Convolution Model Assumptions
As with any physical model, certain assumptions are required to be met in order to generate
accurate predictions. Work done by Craig et al. [109, 110] described the two main assumptions
inherent to the convolution model in the context of interfraction motion: shift invariance of
the dose distribution and sufficient fractionation. In order to have confidence in extending the
convolution model to intrafraction motion, these model assumptions need to be analyzed in the
context of intrafraction motion.
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4.3.1 Assumption of Shift Invariance
The concept of shift invariance in this model is closely associated to the static dose distribution.
The assumption being made is that the static dose distribution is unchanged by changes in patient
anatomy. In other words, we assume the exact same dose distribution is being delivered to the
patient, despite any changes to the patient’s position or internal anatomy. Strictly speaking, this
assumption cannot be met as the dose deposited by charged particles depends directly on the
stopping power of the medium along the path they are traveling. Therefore any slight differences
between the patient positioning or internal anatomy at planning time, as compared to treatment
time, will result in differences between the planned and delivered dose distribution due to changes
in the stopping power along the path. However, the model is still able to provide a reasonable
approximation for most clinical situations where the changes in internal anatomy and position
are small (due to the extreme care taken by therapists during patient setup). This allows the
model to provide useful predictions even if the assumption is not strictly met.
The convolution of the static dose distribution and a motional PDF is simply a mathematical
operation and therefore care must be taken when interpreting the results in a physical situation.
For example, as pointed out by Craig et al.[109], the convolution involves shifting the dose
distribution. At the surface of the patient, there is no ‘dose’ outside the patient to shift. Therefore
additional assumptions are required when interpreting the results of the convolution model at the
surface of the patient. The effect of tissue inhomogeneity must also be considered when using
the convolution model for targets such as lung cancer. In the same work, Craig et al. showed that
the additional error in dose calculated using this method due to lung equivalent inhomogeneity
is approximately 1%. This level of accuracy is sufficient to proceed with confidence when using
the model to analyze the motion of lung targets.
Fortunately, for small changes in patient position and internal anatomy, the resulting static
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dose distribution is modified only slightly. Craig et al. [109] showed that the typical changes
in patient positioning and anatomy that are encountered on a routine basis only result in small
changes in the predicted dose distribution. Specifically, changes due to radiological path length
differences were shown to be< 0.1%. Although errors due to inhomogeneties of a ‘few percent’
were noted, these errors were localized and small compared to errors encountered due to ‘inho-
mogeneity’ at the surface of the patient. Ultimately the authors felt that the convolution model
is useful in situations where dose inhomogeneities are present, especially for plans with multiple
beams and targets at depth within the patient, which are used in this thesis work.
4.3.2 Assumption of Sufficient Sampling
The convolution model employs a PDF to describe the motion of the target during treatment. As
described by Craig et al. [110], in the strict mathematical interpretation of the convolution model
the assumption being made is that the dose is being delivered in an infinite number of fractions,
each delivering an infinitesimal dose. In the case of interfraction motion, each daily fraction
represents a single sample of the PDF describing the motion. A typical fractionated treatment
plan will deliver the prescription dose over the course of approximately 30 fractions. As a result,
the positions sampled by the anatomy during the delivery of this finite number of fractions may
not end up being representative of the PDF used to make the predictions by the convolution
model. Craig et al. showed that the average maximum dose error was 11% for the convolution
model when the effect of finite fractions was considered. Ultimately the authors warned that the
effect of finite fractions appears to have a greater impact on the delivered dose distribution than
typical plan evaluation parameters.
When using the convolution model in the context of intrafraction motion the problem of
sufficient sampling also must be considered. In this case, the motion of the target during beam
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delivery must correspond to the motion of the target used to generate the PDF. In other words,
the proportions of the positions sampled by the target while the treatment beam is on must be
substantially similar to the proportions of the positions measured a priori. In order to test this
assumption a simulation of ‘beam on sampling time’ was developed.
Each recorded breathing trace was analyzed to determine the minimum required time to
achieve sufficient sampling. This was done empirically using the Kullback-Leibler divergence
as a measure of the similarity between two probability distributions. The sufficient sampling
simulation was performed by first selecting a random point in the breathing trace as the starting
point. The trace was then broken into 0.1 s subsections beginning with the starting point, with the
trace repeating itself as necessary. A ‘sub-PDF’ was then generated from each of the new trace
subsections and the sub-PDF was compared to the PDF generated from the full trace using the
Kullback-Leibler divergence. The goal is then to determine ‘at what level of Kullback-Leibler
divergence between the two PDFs are the resulting blurred distributions substantially similar to
one another?’. To determine an empirical answer, each sub-PDF was also convolved against a
dose profile to determine the resulting blurred distribution. To evaluate the difference in dose
coverage the D95 metric was used. The D95 is the minimum dose received by 95% of the target
volume. A ratio between the D95 of each blurred dose profile from the sub-PDF convolutions
and theD95 of the blurred dose profile from the full PDF convolution was calculated. By relating
the Kullback-Leibler divergence of each sub-PDF to the relative D95 offered by each sub-PDF,
we can get an understanding of the sampling time required to achieve sufficient sampling.
As part of this simulation study, 42,347 sub-trace PDFs were generated and compared to
their corresponding full trace PDF. An arbitrary threshold Kullback-Leibler divergence value of
1 was selected to define a sub-trace PDF as ’substantially similar’ to the corresponding full trace
PDF. A histogram of the relative D95 when the Kullback-Leibler divergence is less than 1 is
presented in Figure 4.3. Of the sub-trace PDFs analyzed, 93.9% resulted in a D95 within 3% of
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the expected value after convolution (Figure 4.3). Furthermore, 94.4% of all the patient breathing
traces analyzed reached a Kullback-Leibler divergence of less than 1 within the maximum 12
seconds of sampling time used in this simulation. The minimum required sampling time to
generate a sub-PDF with Kullback-Leibler divergence less than 1 when compared to the full
PDF for each of the patient breathing trace is summarized in Figure 4.4. Although the vast
majority of breathing traces met the Kullback-Leibler divergence threshold within 12 seconds or
less, the breathing traces which are most likely to fail to meet the Kullback-Leibler divergence
threshold are traces with very large standard deviation (≥ 0.8cm).
Figure 4.3: A histogram showing the distribution of relative D95 values when comparing sub-
PDF and full PDF convolutions. All sub-PDFs included in this data had Kullback-Leibler diver-
gence less than 1 when compared to the full trace PDF.
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Figure 4.4: A histogram showing the distribution of sampling times required to generate a sub-
PDF that has a Kullback-Leibler divergence of less than 1 when compared to the full trace PDF.
As can be seen in Figure 4.4, after six seconds of beam on time, 92.8% of the breathing
traces had achieved sufficient sampling. By ten seconds of beam on time, over 99% of the
breathing traces had achieved sufficient sampling. Beam on times of six seconds or greater are
common for many types of radiotherapy treatments offered to lung cancer patients. In the case of
a conventional 3D conformal radiation treatment (3DCRT) or four field box, the typical beam will
deliver around 80− 100 monitor units (MU). Using the standard dose rate of 400 MU/min, this
corresponds to a beam on time of 12 − 15 s. By decreasing the dose rate, additional positional
sampling can be achieved in order to help ensure the sufficient sampling assumption is met.
Although modern treatment technology is trending towards higher dose rates, increasing the
dose rate has the effect of decreasing the reliability of the convolution model by jeopardizing
the sufficient sampling assumption. Additional care must be taken when using high dose rates
(> 400MU/min) if the convolution model is being employed. Regardless of the dose rate being
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employed for treatment, sufficient beam on time must be used to ensure accurate application of
the convolution model. For example, a modern flattening- filter-free (FFF) treatment beam may
be operated at a dose rate of 1200 MU/min. To ensure sufficient sampling with a 10 s beam on
time, a minimum of 200 MU should be delivered by the treatment beam.
The assumption of sufficient sampling may also be jeopardized in the case of an IMRT treat-
ment. IMRT treatments have beams which are subdivided into many segments with different
beam shapes. Each beam segment may account for as little as 10 MU , and in this case it is very
likely that the sufficient sampling assumption will not be strictly met. The problem of small beam
segments interacting with targets in motion is known as the ‘interplay effect’ and it has been an-
alyzed by several authors [112, 113, 114]. These authors report that in most cases the interplay
effect results in a negligible difference between the planned and delivered dose distributions over
the course of a conventionally fractionated treatment plan. This fact makes the application of the
convolution model to IMRT treatment plans possible, however special care should be taken to
avoid small beam segments, and ensure that a large number (∼ 30) of fractions are used, in order
to satisfy the sufficient sampling criteria.
4.4 Use of the Convolution Model to Assess Interfraction and
Intrafraction Motion
Interfraction Motion
The convolution model of interfraction organ motion has been employed by many researchers
since being proposed. Jiang et al. [24] used this model extensively to describe the effect of
prostate motion on intensity modulated radiation therapy (IMRT) plans. Furthermore, those
authors showed that the dose gradients can be incorporated into the model in order to offer a
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clearer picture of regions of the dose distribution which will be sensitive to anatomical changes.
Li et al. [115] used the convolution model to quantify the interplay effect in prostate IMRT. The
interplay effect is a term used to describe the interplay between organ motion and the delivery
of beam segments during IMRT. Li et al. performed convolutions between the dose distributions
resulting from each segment of IMRT delivery and the corresponding motion PDF of the prostate.
They showed that for individual segments large discrepancy between mean target dose could arise
(> 25%), however over the course of a 30 fraction treatment, the differences would be negligible.
Conversely, a hypofractionated treatment would be at greater risk of delivering a treatment with
a large discrepancy between the mean planned and delivered dose to the target.
The convolution model was also employed by Rosu et al. [116] to assess changes in liver
dose due to organ motion. The authors performed two convolutions: one for setup errors and
one for temporal position changes. Rosu et al. showed that the changes in liver NTCP due to
these motions ranged from +12.0% to −11.7%, and were dependent on the location of the target
within the liver. In a separate investigation, Balter et al. [117] used the convolution model to
assess the use of patient specific setup margins versus population based setup margins. They
showed that population based setup margins tended to result in higher NTCP values, and thus
that a patient specific approach could yield safer treatments.
The convolution model was also used to investigate random setup errors in the context of
the treatment of head & neck cancers. Astreinidou et al. [118] used the convolution model to
determine the treatment margins required to maintain the dose delivered to 95% of the treatment
volume, given a certain distribution of setup uncertainties. For IMRT treatments, they found a
margin of 1.5 mm, when the setup errors are normally distributed, with standard deviation of
2 mm, and a margin of 3 mm for setup errors with standard deviation of 4 mm. Siebers et al.
[119] used the convolution model to investigate the effect of patient setup on boost treatments for
head & neck cancer patients. They found that systematic setup errors caused a greater dose dis-
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crepancy then random setup errors. Therefore the dosimetric accuracy of head & neck treatments
would benefit more from methods that reduce systematic errors as opposed to random errors.
In each of these cases the researchers have used to convolution model with a Gaussian PDF
to assess the difference between the planned and delivered dose distribution in the presence of
setup errors. They all note a loss of target dose coverage as a result of the setup errors, and each
offers an approach to rectifying the loss of coverage (either by increasing the prescribed dose or
by increasing the treatment margin). Interfraction target motion is an issue for every treatment
site and the convolution model has been used repeatedly to assess its impact.
Intrafraction Motion
In recent years, the convolution model has been extended in order to describe the modification
of the delivered dose distribution which results from organ motion occurring during treatment
delivery. This type of motion is categorized as ‘intrafraction motion’. One of the original pub-
lications using the convolution model to assess intrafraction motion was published by Lujan et
al. [23]. In this study the authors compared the dose distributions that were calculated in the
static case to dose distributions predicted by the convolution model, as well as to dose distribu-
tions resulting from a direct simulation of the organ motion. The authors used an asymmetric
1D PDF to describe liver motion resulting from breathing (the fact that breathing motion results
in an asymmetric PDF was identified by Balter et al. in 1996 [120]). Lujan et al. had several
key results in their work. First, they noted that due to the finite beam-on time during a treat-
ment, the initial phase of the breathing cycle would influence the delivered dose distribution.
However, they found that over the full course of a conventionally fractionated treatment, these
phase differences would effectively cancel out. Secondly, they found that the dose distribution
calculated by direct simulation of each phase of breathing (which accounts for changes in beam
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pathlength) was nearly identical to the prediction made by the convolution model. Since the
convolution model calculations are much simpler to perform than a direct simulation, the use of
the convolution model to describe the effect of target motion is preferred.
Engelsman et al. [1] used the convolution model to investigate the displacement of iso-dose
lines due to motion in the context of lung cancer treatment. They found little to no change in
the position of iso-dose lines for target motions with amplitude less than 10 mm. However for
motions larger than 20 mm margins of 7 mm or greater need to be applied, depending on the
dose gradient in the region of interest. Engelsman et al. also showed a correlation between
breathing amplitude and the standard deviation of the breathing motion. Richter et al. [2] also
used the convolution model in the context of intrafraction lung motion. They analyzed the effect
that inhomogeneous target dose distributions had on breathing motion margins. Richter et al.
found that by increasing the prescribed dose delivered to the target volume, they could reduce the
margin required to maintain a given dose to the edge of the target. This result follows intuitively
from the concept of dose blurring described by the convolution model. The total dose delivered to
the entire patient is not affected by target motion, however the distribution of the dose is affected.
By increasing the prescribed dose, the dose blurring can be compensated for. Richter et al. also
noted a quadratic relationship between their required margins and the standard deviation of the
PDF used to describe the target motion.
An important result for the use of the convolution model for intrafraction respiratory motion
was published by George et al. [121] in 2005. In this work, the authors assessed whether or
not the total geometric error due to combined effects of interfraction motion and intrafraction di-
aphragm motion is normally distributed. The authors ultimately concluded that when assessing
populations, the combined error can be considered normally distributed. However, when individ-
ual patient measurements are acquired, diaphragm motion (and thus respiratory motion) is not
normally distributed. This is a key point because it underlines the importance of patient specific
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measurements. The use of imaging on the treatment unit at the time of treatment has helped to re-
duce setup errors. Therefore the relative importance of addressing the patient’s specific breathing
motion increases.
With the use of 4DCT scans, clinicians are now able to get more detailed information about
the target trajectory and periodicity than ever before. The focus of this work is to revisit the
intrafraction convolution approaches employed by other authors in the context of the patient
specific information available from 4DCT scans.
4.5 Example Convolutions & Analysis
In order to understand the expected results and trends that arise from the use of the convolution
model, it is instructive to assess the results of some example convolutions across a range of
breathing traces and target volume sizes. The first point to recognize is that although different
breathing traces may all share the properties of a regular breathing trace (e.g. little or no baseline
shift, consistent breathing period, consistent breathing amplitude), it is not expected that they will
result in the same blurred dose profile after convolution. Instead, the spread of the PDF along the
x-axis (position) has the most predominant effect on the resulting dose distribution. This spread
is ultimately characterized by the PDF’s standard deviation. Examples of three regular breathing
traces and their corresponding PDFs are shown in Figures 4.5 and 4.6, respectively. It should be
reiterated that the area under each PDF is equal to unity as required by the definition of a PDF.
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Figure 4.5: Examples of regular breathing traces. Despite being different from one another, each
trace could be considered regular due to stable breathing frequency, amplitude and baseline.
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Figure 4.6: The PDFs and PDF gradients corresponding to the regular breathing traces above.
Although each trace is regular in nature, the PDFs resulting from each trace are quite different
in terms of standard deviation. Figure A depicts the corresponding PDFs on the same axes to
contrast their shape. Figure B plots the gradients of each PDF.
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The convolution of each of these PDFs with a static dose distribution ultimately reveals the
effect of target motion on the delivered dose distribution. Since small targets are more susceptible
to loss of dose coverage, it is important to assess the result of the convolution on a range of target
sizes. These results for the three regular traces described in this section are shown in Figure 4.7.
Figure 4.7: Examples of blurred dose distributions resulting from the convolution of the regular
breathing trace PDFs and the dose profiles corresponding to a range of target sizes. Dashed lines
are the original static profiles, solid lines are the resulting blurred distributions. The target size
is characterized by the dose profile’s full-width-half-max (FWHM). (i),(ii) and (iii) depict the
resulting blurred distributions for the PDFs with SD of 0.12 cm, 0.5 cm and 0.96 cm respectively.
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It is clear from Figure 4.7 that as the standard deviation of a given PDF increases, so does the
amount of blurring in the resulting dose distribution. The susceptibility of small targets to large
motion is also highlighted in Figure 4.7 (iii) where both the dose coverage and maximum dose
delivered to the small target have seen a substantial drop.
The trend in the amount of blurring resulting from the convolution also holds true for irregular
breathing traces. An irregular breathing trace is typically characterized by baseline shifts, incon-
sistent breathing period and/or inconsistent breathing amplitude. As with the regular breathing
traces, a set of irregular traces are not expected to result in similar dose blurring after convolu-
tion simply based on these attributes. Again, it is seen that the spread along the x-axis (standard
deviation) of the breathing trace PDF is what best predicts the resulting blurring. Examples of
three irregular breathing traces and their corresponding PDFs are shown in Figure 4.8 and 4.9,
respectively. As with the regular breathing PDFs, the irregular PDFs are also normalized such
that the area under the curve is unity.
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Figure 4.8: Examples of irregular breathing traces. Each trace exhibits breath-to-breath irregu-
larities in at least one of: breathing amplitude, breathing frequency or baseline location.
Figure 4.10 shows the resulting convolutions of the irregular breathing traces with the same
three target dose profiles. The clear trend of increasing blurring with increasing PDF standard
deviation is again apparent in the case of the irregular breathing traces.
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Figure 4.9: The PDFs and PDF gradients corresponding to the irregular breathing traces above.
The PDFs resulting from each trace exhibit a more prominent single mode, as compared to the
regular trace PDFs. Figure A depicts the corresponding PDFs on the same axes to contrast their
shape. Figure B plots the gradients of each PDF.
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Figure 4.10: Examples of blurred dose distributions resulting from the convolution of the irreg-
ular breathing trace PDFs and the dose profiles corresponding to a range of target sizes. Dashed
lines are the original static profiles, solid lines are the resulting blurred distributions. The target
size is characterized by the dose profile’s full-width-half-max (FWHM). (i),(ii) and (iii) depict
the resulting blurred distributions for the PDFs with SD of 0.1 cm, 0.5 cm and 0.99 cm respec-
tively.
It is also important to note the relative asymmetry of the blurred dose profiles resulting from
the convolution with irregular breathing in Figure 4.10 (iii) and regular breathing in Figure 4.7
(iii). This asymmetry is best explained by looking at the gradient of the PDFs as suggested by
Equation 4.13. In the case of the large standard deviation PDFs for both regular and irregular
traces, we can plot the PDFs along with their derivatives, as shown in Figure 4.11.
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Figure 4.11: A plot of a regular and an irregular breathing trace PDF with their gradients. In
these cases, the PDFs have substantial asymmetry due to the specific breathing patterns. As a
result, the PDF gradients also have large asymmetry. The large asymmetry in the PDF gradient
is what contributes to an asymmetric blurred dose profile.
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When performing the calculation defined in Equation 4.13 it can be seen that the regions of
the d
dx
PDF (x) that are equal, or nearly equal, to zero will offer little or no contribution to the
resulting convolution. Correspondingly, regions of the d
dx
PDF (x) which are largest will make
the largest contribution to the resulting convolution. The PDF gradient highlights these regions.
In the case of Figure 4.11, a prominent asymmetry in the d
dx
PDF (x) can be seen. This feature
of the PDF gradient is not being balanced by any other features of d
dx
PDF (x) and as a result,
creates the asymmetry seen in the blurred profiles.
4.6 Summary
The convolution model has been used by many different researchers to assess the impact of
interfraction and intrafraction organ motion on the delivered dose distribution. Jiang et al. [24]
showed the model can be reformulated in terms of the static dose gradient, or equivalently, the
PDF gradient. This approach highlights the features of the inputs which have the most prominent
effect on the resulting blurred dose distribution.
The convolution model requires two inputs: a static dose distribution and a PDF describing
the target motion. In this work the static dose distribution must come from a plan generated
on an image of the patient with the target in its average position. The PDF describing target
motion is garnered from 4DCT data. Tied to these inputs are the assumptions of shift invariance
and sufficient sampling. As has been reported by other authors and investigated in this work,
the model assumptions can be met to a reasonably strong degree, providing confidence in the
modified dose predictions made by the convolution model.
The trends in target dose blurring that result from the convolution of PDFs and dose profiles
of various sizes show the impact of the PDF standard deviation and gradient of the PDF on the
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delivered dose distribution. The asymmetric nature of gradient of the breathing trace PDFs also
determines asymmetric blurring of the dose distribution.
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Chapter 5
Film Measurement Procedures and Results
5.1 Introduction
The convolution model of target motion described in Chapter 4 is most frequently used in the
context of predicting the effect of interfraction target motion on delivered dose distributions. This
type of work was done in the context of random setup errors for tumour sites such as prostate
[24, 115], liver [116, 117], or head and neck [118, 119]. However, this study looks to extend the
use of the convolution model to intrafraction motion. In order to have confidence that this model
can be used in the context of intrafraction motion, experimental measurements must be made to
verify the predictions made by the convolution model.
Radiochromic film is the dosimeter of choice for performing these verification measurements.
Film offers the best combination of spatial resolution, signal to noise ratio and ease of use for
this application. Additionally, film has the advantage of offering a dose measurement over a 2D
region of interest. This allows the user to extract dose profiles or perform dose map comparisons
with the dose predictions made by the treatment planning software. In this work there is also a
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need for comparison with dose predictions made by the convolution model itself. The film mea-
surements performed for this work were taken in a dynamic anthropomorphic thorax phantom
that was programmed to perform custom breathing motions. The details of the phantom and film
measurements are given in this chapter.
5.2 Radiochromic Film Handling
The radiochromic film used in this work was Gafchromic EBT2 (International Specialty Prod-
ucts, Wayne, NJ). This film offers several advantages over traditional radiochromic film products.
Gafchromic EBT2 film requires no processing, which eliminates the need for a darkroom and the
associated equipment and chemicals. Gafchromic EBT2 also has low energy dependence and re-
acts independently of dose rate and fractionation [122].
Gafchromic EBT2 film consists of several layers of material: a base layer (175 µm), an active
layer (28 ± 3 µm), an adhesive layer (25 µm) and a laminate layer (50 µm) as shown in Figure
5.1 [122]. The film works by undergoing chemical changes in the active layer in response to the
absorbed dose. The active layer of Gafchromic EBT2 consists of diacetylene monomers oriented
in the same direction. In response to the absorbed dose, the monomers react with one another to
form polymers. The result of this reaction is a change in the optical properties of the film, which
can then be used to assess the absorbed dose.
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Figure 5.1: A depiction of Gafchromic EBT2 film configuration as shown in the Gafchromic
EBT2 white paper published by ISP [122]. Optical density changes in the film result from poly-
merization reactions in the active layer.
Proper handling of the film includes several steps and considerations as detailed by the manu-
facturer [122], and expanded upon in the AAPM TG-55 report titled ‘Radiochromic film dosime-
try: Recommendations of AAPM Radiation Therapy Committee Task Group 55’ [123]. These
recommendations span topics regarding the handling, calibration and readout of radiochromic
film. The key recommendations made by these groups are as follows:
• The film should be exposed to the minimum possible amount of ambient light. Although
the manufacturer claims the film is stable in ambient light, the ultraviolet component of the
light can contribute to changes in optical density of the film. Andres et al. [124] showed
that a 6 hour exposure to (relatively intense) room lighting changed the optical density of
Gafchromic EBT2 by the equivalent of a 6.1 cGy dose.
• The film should be handled by touching the sides and edges of the film with careful at-
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tention paid to avoiding leaving fingerprints or other marks in the area of the film to be
used for dose measurement. Any marks or fingerprints on the film will adversely affect the
readout of the film.
• It is important to maintain a consistent orientation of the film for readout [124]. The
monomers in the active layer are anisotropic and have a specific orientation which results
in different readout values depending on the orientation of the film on the scanner bed.
• The film must be digitized at a specific time interval after irradiation due to post-exposure
changes in the film. This is because the initial polymerization reaction takes place in
approximately 30 ms, however slow changes continue to take place over the course of
hours after exposure. Andres et al. showed that a minimum of 2 hours is required, post
exposure, for the film to stabilize [124].
• The lot number and model number of the film should always be noted so that any variation
in the manufacture of the film can be accounted for, if necessary.
• Calibration of the film should use a well-characterized, uniform radiation field.
• The calibration should be performed over the range of dose values expected to be measured
experimentally.
For this work, Gafchromic EBT2 film of the same batch (lot # A02181104) was calibrated
and handled according to the procedures laid out in AAPM TG-55 [123] and the recommenda-
tions of the manufacturer [122]. All the films were digitized with an Epson 10000XL flatbed
scanner (US Epson, Long Beach, CA) 22 hours after irradiation. This time frame was selected to
allow for the film to develop and to provide consistency in the handling procedure. Calibration
and analysis of the images was performed using the RIT v1.2 software package (Radiological
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Imaging Technology, Inc., Colorado Springs, CO). Careful handling and digitization of the films
used for calibration and measurement allows for dose measurements near 200 cGy to be acquired
with a relative uncertainty of ±6% [125].
5.3 Radiochromic Film Calibration
Calibration of the Gafchromic EBT2 film was performed by irradiating pieces of film to a known
dose and then reading the optical density of the films using a flatbed scanner. New pieces of film
from the same batch (or sheet) can then be used experimentally and compared to the calibration
films in order to determine dose. The film calibration was performed in a ’solid water’ phantom
setup as depicted in Figure 5.2. The setup has a source-to-surface distance (SSD) of 95 cm,
source-to-axis distance (SAD) of 100 cm and a field size of 10 x 10 cm at isocentre. This setup
mimics the absolute dose calibration geometry used by the Grand River Regional Cancer Centre
(GRRCC). The LINACs at GRRCC have been calibrated such that 1 MU delivers 1 cGy to the
centre of the field under these setup conditions.
A single piece of film was cut into 13 squares with a side length of 5 cm. The films were
labeled and their orientation relative to the original full sheet of film was noted. Each piece of
film to be used for calibration was placed in the centre of the 10 x 10 cm field (at isocentre) with
5 cm of solid water on top and 10 cm of solid water below to provide back scatter material. Each
piece of film used for calibration was irradiated once with a predetermined number of monitor
units.
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Figure 5.2: A depiction of the film calibration setup geometry. In this configuration, one monitor
unit delivers one cGy of dose to the centre of the film.
The manufacturer’s recommended analysis of the irradiated films is for a minimum of 13
dose points, including zero dose, to generate a reliable calibration curve. The dose points used
should cover the range from zero to a value at least 25% larger than the highest dose you expect
to measure with the current calibration [122]. The dose points used for this calibration were:
300, 240, 200, 160, 120, 90, 70, 50, 40, 30, 20, 10 and 0 cGy. Example calibration films scanned
together to show contrast are displayed in Figure 5.3.
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Figure 5.3: Example calibration films after irradiation. The films are shown scanned together in
order to demonstrate the colour progression associated with increased dose delivered to the film.
In order to digitize the films, the scanner was first allowed to warm up. After warming
the scanner, the films are scanned individually and are each placed on the same area of the
scanner bed by using a template to align the film. Each film is scanned using the same settings.
The scanning resolution was set to 72 DPI to balance image noise and image resolution. After
all the films were scanned, each image was imported into the RIT software for analysis. The
calibration curve is created by first selecting a region of interest on each calibration film. The
optical density data in the region of interest is averaged to determine the optical density value
which corresponds to the given dose level. The film scanner measures the amount of transmission
of light through a film and converts this analog signal into digital values with a range between 0
and 65,535 A/D units, where 0 is no light being transmitted (most dense) and 65,535 indicates
that the light is transmitted through air (least dense). The A/D units are used in the calibration
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software to generate the calibration cure. The graph of A/D units versus dose is then created
with each of the 13 data points plotted. The calibration curve was fitted to the data using a cubic
spline. The calibration data is shown in Figure 5.4. The doses delivered during experimental film
measurements can then be analyzed based on the calibration curve.
Figure 5.4: The calibration curve for Gafchromic EBT2 film used in this work. The curve
consists of 13 data points and a cubic spline fit with R2 = 0.9999.
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5.4 Anthropomorphic Breathing Phantom Film Measurements
Description of the Phantom
In order to verify the delivery of the dose distribution calculated by Eclipse v10.1 TPS (Varian
Medical Systems, Inc., Palo Alto, CA) and predicted by the convolution model, Gafchromic
EBT2 film measurements were taken in an anthropomorphic breathing phantom. The CIRS Dy-
namic Thorax Phantom, Model 008 (Computerized Imaging Reference Systems, Inc., Norfolk,
VA) used for these measurements is shown in Figure 5.5. The phantom is made of epoxy ma-
terials that are radiologically equivalent to tissue in the energy range of 50 kV to 25 MV . It is
equipped with a drive unit capable of performing target motions with sub-millimeter accuracy
and reproducibility. The phantom can accommodate different dosimeters (film, MOSFET or ion
chambers) depending on its configuration. The dimensions of the thorax phantom represent the
‘average man’ [126].
Figure 5.5: A picture of the CIRS Dynamic Thorax Phantom, Model 008. This phantom was
used for all film measurements.
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The phantom can be used in both static and dynamic modes. In the static mode, the phantom
is at rest and no target motion is used. In dynamic mode the phantom can perform many dif-
ferent motions. The phantom system comes pre-programmed with several sinusoidal ‘breathing
patterns’ to choose from. However, the phantom can also be manually programmed to replicate
custom breathing patterns with one dimensional target motion. For this work, film measure-
ments were taken in both static and dynamic modes for the verification of the delivered dose
distributions.
CT Simulation of the Phantom
A CT simulation of the static phantom was acquired at the GRRCC using a Siemens SOMATOM
Sensation Open scanner (Siemens AG Medical Solutions, Erlangen, Germany). This is a large
bore scanner capable of complete gantry rotations as fast as 0.5 s. The scanner uses a propri-
etary STRATON X-ray tube that functions with tube current in the range of 28 − 400 mA and
tube voltage of 80, 100, 120 or 140 kV . The scanner features 26, 880 detectors arranged in 40
rows and is capable of reconstructing images with isotropic voxels with side length as small as
0.33 mm [127].
The CIRS phantom was scanned using a typical departmental chest scan protocol. The chest
scan protocol used a tube voltage of 120 kV and tube current of 55 mA. The resulting dataset
is reconstructed with anisotropic voxels with axial dimensions of 0.0977 x 0.0977 cm and slice
thickness of 0.3 cm. The phantom was setup and aligned on the CT couch using the external
markers affixed to the phantom and the in room lasers for reference. Figure 5.6 is a coronal slice
at the plane of interest in the phantom CT data set used for treatment planning.
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Figure 5.6: A coronal slice taken from the CT scan of the CIRS dynamic thorax phantom con-
figured with the film insert. Note the fiducial markers which are used to align the selected dose
profiles for comparison.
After completing the scan, the reconstructed images were pushed via the network from the
CT scanner computers to the computers serving the TPS. From there the phantom images were
imported into the TPS in order to generate the treatment plan.
Treatment Planning on the Phantom
A simple, open MLC, three field plan was generated with the Eclipse TPS. The plan parameters
are displayed in Table 5.1. The beam isocentre was placed at the centre of the film insert within
the phantom. The dose rate was 400 MU/min for all beams and all couch angles were set to
0◦. The beam angles were selected in order to avoid excessive interference from the treatment
couch and the dose prescription was set to deliver 200 cGy to 99% of the PTV. The dose was
calculated using Varian’s AAA v.10.0.28 algorithm. The main reason for taking this approach
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to the treatment plan is that simple open fields result in dose profiles with the steepest dose
gradients. This makes these types of plans the most susceptible to loss of dose coverage due to
target motion. The dose profiles taken from film measurements of this plan were compared to
the dose profiles calculated by Eclipse at the same location inside the phantom.
Beam 1 Beam 2 Beam 3
Gantry Angle (deg) 315 0 45
(X,Y) Jaw settings (cm) (3.7 , 3.7) (3.2, 3.7) (3.6, 3.7)
MU 86.6 92.5 93.9
Table 5.1: A summary of the treatment plan parameters used to irradiate the phantom for static
and dynamic film measurements. The coordinate system used is the IEC convention.
In order to compare dose profiles from the TPS dose calculations to the profiles measured
on film, careful consideration must be given to geometry of the film insert. The phantom’s
film insert accepts rectangular pieces of film cut to dimensions of 13.5 x 4 cm. As can be
seen in Figure 5.6, the phantom’s film insert has pegs to allow for consistent film placement.
The pegs also serve to align both halves of the film insert, and hold them together. The film
insert also has fiducial markers placed within it to provide reference points on the CT images
for film measurement comparisons. Comparison of the measured and calculated dose profiles
was achieved by selecting a dose profile along the superior-inferior direction of the phantom
through treatment plan isocentre, in the TPS. The distance from the right edge of the film to the
selected dose profile was then recorded. After irradiating and digitizing the film, the measured
dose profile for comparison was selected by measuring the same distance from the edge of the
film, then selecting the dose profile passing through that point, parallel to the length of the film.
All dose profiles originated at the superior edge of the film.
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5.5 Film Measurements in the Static Phantom
The film measurements taken in the static mode were used to determine confidence in the re-
peatability and accuracy of the film handling and measurement procedures. These results also
serve to verify the calculations made by the Eclipse TPS environment. In order to acquire the
static film measurements, the CIRS phantom was setup on the treatment unit using the same
configuration as at the time of CT scanning. The external markers on the phantom were aligned
with the in room lasers. After aligning the phantom with the lasers the required couch shifts were
applied, such that the treatment beam isocentre was at the centre of the film insert as planned.
The couch shifts were predetermined by the TPS by comparing the location of the isocentre at
the time of the CT simulation to the location of the beam isocentre in the treatment plan.
The dose profile resulting from a static phantom film measurement is shown in Figure 5.7.
The absolute dose profiles have good agreement with the predictions made by Eclipse. In this
case, 96.1% of the measured dose points are within 3% or 3 mm of the corresponding dose
points in the Eclipse prediction. These criteria are commonly used when assessing the level of
agreement between a measured and calculated dose plane in the context of a gamma evaluation
[128], and is similar to the recommendations of Van Dyk et al. [129] for a quality assurance
threshold. The error bars represent±6% of the absolute dose, which is the error level that can be
expected with good handling techniques as determined by Hartmann et al. [125].
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Figure 5.7: A comparison of the dose profile calculated by the Eclipse TPS and the corresponding
dose profile measured on radiochromic film in the CIRS phantom in static mode.
Several such film measurements were performed over the course of this work. The resulting
dose profile comparisons consistently showed good agreement between film measurement and
dose calculation in Eclipse. The static dose profile measurements were an important part of
refining the measurement technique and building confidence in the measurement procedure and
results.
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5.6 Film Measurements in the Dynamic Phantom
Film measurements were also taken with the phantom in the dynamic mode. This was achieved
by programming the one dimensional motion of the phantom insert to replicate the motion of
selected patient breathing traces. Programming the phantom to perform a custom motion based
on a recorded breathing trace requires several steps. First, the recorded trace data needs to be
manipulated and scaled such that it is geometrically centered with a maximum amplitude of 1
and minimum amplitude of -1 (arbitrary units). The manipulated trace also needs to be smoothed
to remove any fine structure from the recorded trace. The smoothing step is necessary to avoid
damaging the phantom motion hardware. The trace manipulation and smoothing was performed
in MATLAB. The next step is to reformat the trace data such that it is readable by the motion
controlling software (Motion Perfect 2.4.4, Trio Motion Technology, Freeport, PA, USA) of
the CIRS phantom. The CIRS phantom can then be connected to the computer running Motion
Perfect via the serial port. With the custom trace data loaded on the computer, the CIRS phantom
can then be made to perform the custom motion by setting it to manual motion mode and issuing
the command to start the motion. The amplitude, A, of motion performed by the phantom is
defined by the user. The scaled breathing trace will then span the range [−A,A] when performing
the custom motion.
The film measurements taken with the phantom in the dynamic setting were used to verify the
ability of the convolution model to predict the effect of intrafraction motion on the delivered dose
distribution. Several patient breathing traces were used; some with regular repetitive breathing
and others with highly irregular breathing patterns. With the film insert in place and the phantom
set to perform the custom motion, the same three field treatment plan used for the static case
was delivered to the target. The dose profiles from the films acquired in the dynamic mode were
compared to the dose profile predictions made by the convolution model. Figure 5.9 and Figure
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5.11 present the results of two such dynamic phantom film measurements.
Figure 5.8: A) A regular breathing trace used to program the dynamic thorax phantom. C) The
PDF generated from the trace (standard deviation of 0.52 cm).
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Figure 5.9: D) Dynamic mode dose profile measurements demonstrating the applicability of the
convolution model for intrafraction motion in the case of regular breathing traces.
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Figure 5.10: A) An irregular breathing trace used to program the dynamic thorax phantom. C)
The PDF generated from the trace (standard deviation of 0.40 cm).
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Figure 5.11: D) Dynamic mode dose profile measurements demonstrating the applicability of
the convolution model for intrafraction motion for irregular breathing traces.
The selected traces were used to demonstrate that the convolution model makes valid predic-
tions for a range of breathing patterns, including regular and irregular breathers. In the case of the
regular breathing pattern (Figure 5.9), 98.9% of the measured dose points passed the 3% / 3 mm
criteria, while the measurement of the irregular breathing pattern (Figure 5.11) dose distribution
passed on 98% of dose points. The obvious discrepancy between the Eclipse calculation and the
convolution model prediction (and corresponding film measurement) is the ‘blurring’ effect of
target motion. Eclipse dose not account for target motion while performing the dose calculation.
These results underscore the needs for target motion management.
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5.7 Summary
These experimental measurements were necessary to verify the validity of the convolution model
in the context of intrafraction motion, and to assess the use of the margin recommendations made
in this work. The results show good agreement between the TPS calculations and film measure-
ments taken in the static phantom, which gives confidence in the film handling and measurement
procedures. The dynamic mode film measurements have good agreement with the predictions
made by the convolution model for both regular and irregular breathing patterns.
These experimental results indicate that under most circumstances the convolution model
makes valuable predictions regarding the effect of motion on the delivered dose distribution. The
confidence developed in the accuracy of the motion model justifies larger scale simulation and
analysis of the effect of breathing motion on the delivered dose distribution. The results of such
an analysis could be used to identify trends in the resulting dose coverage, which could then
inform intrafraction motion management strategies.
Film measurement procedures such as these could provide an effective QA procedure for
measuring dose profiles with patient specific breathing patterns measured during 4DCT scans.
This verification could be done on a plan-by-plan basis to provide clinicians confidence that
increased margins are justified and offer an effective means for compensating for target motion.
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Chapter 6
Motion Simulation Study
6.1 Introduction
Confidence in the reliability of the convolution model for intrafraction target motion has been es-
tablished by performing radiochromic film measurements as described in Chapter 5. These static
and dynamic mode film measurements provide the basis for further analysis on the effect of tar-
get motion by analyzing the predictions of the convolution model on a larger scale. Ultimately,
one of the aims of this work is to generate margin predictions which can be used by clinicians
while making treatment planning decisions. In order to accomplish this aim, we need to analyze
the effect of target motion on the delivered dose distribution under a wide range of conditions.
Specifically we want to analyze a variety of breathing patterns and target sizes in order to estab-
lish trends that can be used to make margin recommendations. Computational simulation of the
target motion allows for the rapid data generation and analysis required to identify these trends.
The motion simulations generated in this work were performed in MATLAB using standard
MATLAB routines and custom code. As discussed in chapter 4, the convolution model requires
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the input of a motional PDF obtained from a 4DCT scan and a static dose profile. The motional
PDFs were generated from each of 502 unique patient breathing traces. The traces used in this
work were recorded from patients undergoing clinical 4DCT scans over a four year period at
the London Health Sciences Centre. The static dose profiles were obtained by first generating
a simple treatment plan on a CIRS Dynamic Thorax phantom (described in chapter 3) in the
Eclipse treatment planning software. Static dose profiles along the appropriate directions were
then exported from the treatment plan and used in the MATLAB simulation. The results of the
simulation described in this chapter and film measurements described in chapter 5 were published
in the Journal of Applied Clinical Medical Physics [130].
6.2 MATLAB Simulation Process
The effect of motion on the delivered dose distribution as predicted by the convolution model was
simulated for each of the 502 patient breathing traces on a set of static dose profiles generated
from targets ranging from 2-10 cm in diameter. An in house MATLAB program was used to
perform the convolutions and analyze the dose coverage offered by the resulting blurred dose
profiles. The main dose coverage metric used to assess the effect of the target motion was the
D95. The D95 is defined as the minimum dose received by 95% of the target volume. This metric
is akin to a point on a dose-volume histogram (DVH) and is used to assess the quality of the dose
coverage offered by a given treatment plan. Other dose coverage metrics such as the equivalent
uniform dose andD99 were also assessed. Below is the pseudo code description of the simulation
process:
• IMPORT list of static dose profile files
• FOR EACH static dose profile file:
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– compute dose coverage metrics of the static profile
• IMPORT list of breathing trace files
• FOR EACH breathing trace file:
– extract positional data recorded during beam-on
– compute breathing trace statistics (breathing amplitude, length of data recording)
– generate histogram of recorded breathing trace positions
– generate normalized PDF from histogram
– compute PDF statistics (standard deviation, mean, skewness, kurtosis)
– place PDF origin at the PDF mean
– perform convolution of PDF with EACH static dose profile
– compute dose coverage metrics of the blurred dose distribution
Having simulated the outcomes of target motion based on a wide variety of breathing traces
and target sizes, the data must be analyzed to identify trends and correlations that can be used to
justify margin recommendations.
6.3 PDF Statistics
It is useful to look at some descriptive statistics summarizing the breathing traces (and corre-
sponding PDFs) used in the simulation study. Figure 6.1 shows the distribution of the total time
recorded for each breathing trace. It should be noted that all traces are comprised of data recorded
over a minimum of 24.5 s with the median recording time of 77.9 s. Given that a typical breath-
ing cycle is approximately 3 s, recording the breathing trace on this time scale ensures that a
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minimum of 8 breathing cycles are captured during the recording period. This gives time for any
breathing irregularities to manifest, which is a necessary requirement for a useful and reliable
breathing trace.
Figure 6.1: A histogram detailing the distribution of breathing trace recording times. The mini-
mum and maximum recording time were 24.5 s and 119.5 s respectively. The median recording
time was 77.9 s and the average recording time was 78.8 s.
The breathing amplitude and breathing trace standard deviation are also important parame-
ters for making margin recommendations. Figure 6.2 and Figure 6.3 display histograms of the
breathing amplitude and PDF standard deviation for all the breathing traces used. The amplitude
is determined by referencing the maximum displacement recorded by the marker block. The
standard deviation is calculated according to
s =
(
1
n− 1
n∑
i=1
(xi − x¯)2
)1/2
, (6.1)
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where s is the standard deviation, xi are the recorded positions, x¯ is the average position and
n is the total number of data points.
Figure 6.2: A histogram detailing the distribution of breathing trace amplitudes. The minimum
and maximum amplitudes were 0.13 cm and 2.30 cm respectively. The median amplitude was
0.66 cm and the average amplitude was 0.73 cm.
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Figure 6.3: A histogram detailing the distribution of breathing trace standard deviations. The
minimum and maximum standard deviations were 0.057 cm and 1.13 cm respectively. The
median standard deviation was 0.31 cm and the average standard deviation was 0.34 cm.
It should be noted that the positions (and amplitude) recorded for the breathing trace are in
fact the positions of the marker block, used as part of Varian’s RPM system, on the patient’s
chest. Although the breathing trace positions and amplitude recorded this way are not equal to
the positions or amplitude of the target motion in general, the trace can be normalized according
to the amplitude of motion determined in a 4DCT scan. Once the trace has been normalized, it is
representative of the 1D motion of the target. The breathing traces used for this simulation study
were not normalized in this manner (as would be required when applying the results of this work
clinically), however the raw trace information provides a wide range of breathing amplitudes and
trace patterns for study here.
The relationship between the PDF standard deviation and breathing amplitude is also perti-
nent. As can be seen in Figure 6.4 there is a clear correlation between the amplitude and standard
deviation. Intuitively this is the expected result; as the amplitude of the motion increases, so too
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does the standard deviation (often interpreted as the ‘average distance from the average’ of the
data points). The slope of the best fit line is approximately 0.46 (R2 = 0.864), indicating that the
value of the standard deviation is approximately 46% of amplitude. This is similar to the result
identified by Engelsmann et al. [1]. Although the amplitude accounts for a major portion of the
standard deviation, higher order features of the PDF (such as skewness and kurtosis) also make
contributions to the PDF standard deviation.
Figure 6.4: A plot showing the relationship between the PDF standard deviation and the breathing
amplitude.
6.4 Target Volume Dose Coverage
In order to make margin selection recommendations, it is useful to know the loss of target cov-
erage which is expected on case by case basis. This simulation study revealed that the loss of
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target D95 is predictable, based on the patient’s specific PDF standard deviation. Figure 6.5
demonstrates the relationship between the expected loss of target D95 (in terms of the ratio of the
static and blurred D95 values) and the standard deviation of the breathing pattern. These results
are in line with data presented by other authors [2, 1] regarding the predictive power of the PDF
standard deviation with regards to the target dose coverage. The D95 was used to assess dose
coverage because this metric is often used in the clinic to evaluate whether a given treatment
plan offers acceptable coverage. Other dose metrics could be used in principal, the D95 was
selected for its relevance to clinicians.
Figure 6.5: A plot of the relative D95 (blurred D95 to static D95) versus PDF standard deviation.
As the amount of motion increases, so t0o does the loss of target dose coverage.
The next assessment was to determine how much target D95 can be recovered by incremen-
tally increasing the beam width. The incremental increase in beam width was achieved by adding
the additional beam width to the center of the static dose profile, leaving the dose gradients in the
penumbral regions of the profile unchanged. This approximation allowed for rapid assessment
of the additional beam width required to recover the lost dose coverage.
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Using MATLAB code (included in Appendix B) an iterative process was used to determine
the necessary additional beam width:
• A blurred dose profile is calculated based on a static dose profile and a given PDF.
• The relative D95 of blurred profile is calculated.
• If the relative D95 is less than 1, the width of the original static dose profile is increased (as
described above). If the relative dose profile is greater than or equal to 1, then the iterative
process stops.
• The blurred dose profile is re-calculated based on the wider static dose profile and the same
PDF.
• The relative D95 of the new blurred profile is calculated and the process repeats.
Once the iterative process has stopped, the additional beam width required to recover the
lost D95 is recorded. Shown in Figure 6.6 is a plot of the additional beam width required to
completely recover lost D95 due to dose blurring caused by target motion. The fit equation
y = 18.582x2 + 2.234x describes the data set well (R2 = 0.984).
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Figure 6.6: A plot of the additional beam width required in the direction of motion to compensate
for loss of target D95 vs. PDF standard deviation. The additional beam width should be applied
in the direction of motion.
For example, suppose a given patient presented with a breathing trace whose PDF has a stan-
dard deviation of 0.4 cm. After referencing Figure 6.6 or using the fit equation, it is determined
that an additional 3.9 mm of beam width is required to compensate for the target motion.
6.5 Effect of Target Size
It is necessary to consider the role of target size when trying to compensate for motion and deliver
a specific D95 to the target. As the size of the target along the direction of motion increases, so
133
does the width of the dose profile (defined as the full-width-half-max [FWHM] of the profile)
required to adequately cover the target. As the FWHM of the dose profile increases, the relative
contribution of the penumbral region of the profile to the overall dose profile, decreases. Since the
penumbral region of the profile is most predominantly affected by the convolution (compared to
the central region of the profile), smaller targets will be more susceptible to loss of dose coverage
due to motion as compared to larger targets.
In order to assess this effect, the relative D95 data resulting from the convolution of each
breathing trace was analyzed over a range of target sizes. The results of this simulation study
are summarized in Figure 6.7. As the FHWM of the various profiles increases, the given profile
becomes less sensitive to motion in terms of loss of D95. For example, the target profile with
a FHWM of 2.6 cm loses approximately 7% of its original D95 when faced with target motion
of 0.4 cm standard deviation. The same level of motion causes a loss of approximately 1.5%
of the original D95 to a target profile with a FHWM of 5.1 cm. As the target FWHM increases
beyond 5.1 cm, the changes in sensitivity to motion become small. This is due to the smaller
relative contribution of the penumbral regions to wider profiles. As a result, the D95 data for
targets with FWHM greater than 5.1 cm begins to overlap with the data for the 5.1 cm target and
was therefore omitted from Figure 6.7.
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Figure 6.7: A plot of relative D95 versus PDF standard deviation for multiple target sizes. The
sensitivity to coverage loss due to motion decreases with increasing target size. The change in
sensitivity becomes small as the FWHM of the increases beyond 5.1 cm.
The iterative process described in the previous section was extended to static dose profiles
with initial FWHM values ranging from 2.6 cm to 10.1 cm. Shown in Figure 6.8 is a plot of
the additional beam width required vs. PDF standard deviation for a range of initial static dose
profile FWHM values.
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Figure 6.8: A plot of the additional beam width required in the direction of motion to compensate
for loss of target D95 vs. PDF standard deviation. The additional beam width should be applied
in the direction of motion. This plot includes the trends for several initial static dose profile
FWHM values
6.6 Treatment Margin Recommendations
Treatment margin recommendations can be made by using the simulation results discussed above.
The margin required to maintain the planned target D95 in the presence of breathing motion with
a given standard deviation can be calculated by using fit equations from the data presented above.
The fit equations for each of the FWHM values tested are included in Table 6.1 below, where
ABW is the additional beam width required and s is the standard deviation of the PDF describing
the motion.
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Profile FWHM (cm) Fit equation of ABW data R2 of fit
2.6 ABW = 20.734s2 + 3.282s 0.9754
3.1 ABW = 19.098s2 + 3.574s 0.981
3.6 ABW = 18.582s2 + 2.234s 0.984
4.1 ABW = 18.84s2 + 1.003s 0.9819
4.6 ABW = 16.832s2 + 2.051s 0.9835
5.1 ABW = 16.561s2 + 1.537s 0.9849
5.6 ABW = 16.551s2 + 1.201s 0.9836
6.1 ABW = 16.213s2 + 1.353s 0.9856
7.1 ABW = 15.438s2 + 1.427s 0.9863
9.1 ABW = 13.531s2 + 1.977s 0.9894
10.1 ABW = 13.829s2 + 0.5121s 0.985
Table 6.1: A summary of equations describing the additional beam width (ABW) per unit stan-
dard deviation (s) for various target sizes.
A table of margin recommendations spanning a range of target sizes and target motions can
be generated using these equations. These margin recommendations are presented in Table 6.2
below.
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0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8
2.6 0.5 (mm) 1.5 2.9 4.6 6.8 9.4 12.5 15.9
3.1 0.5 1.5 2.8 4.5 6.6 9.0 11.9 15.1
3.6 0.4 1.2 2.3 3.9 5.8 8.0 10.7 13.7
4.1 0.4 1.0 2.0 3.4 5.2 7.4 9.9 12.9
4.6 0.4 1.1 2.1 3.5 5.2 7.3 9.7 12.4
5.1 0.3 0.9 1.8 3.1 4.7 6.7 8.9 11.5
5.6 0.3 0.9 1.8 3.1 4.7 6.7 8.9 11.6
6.1 0.3 0.9 1.9 3.1 4.7 6.7 8.9 11.6
7.1 0.3 0.9 1.8 3.0 4.6 6.4 8.6 11.0
9.1 0.3 0.9 1.8 3.0 4.4 6.1 8.0 10.2
10.1 0.2 0.7 1.4 2.4 3.7 5.3 7.1 9.3
Table 6.2: Summary of the recommended additional margin required (mm) to compensate for a
loss of targetD95 due to target motion. As the FWHM of the dose profiles increases, the required
margins decrease.
6.7 Motion Simulation with Clinical Plans
Three clinical treatment plans were also selected for motion simulation: a three field, a four field
and a volumetric modulated arc therapy (VMAT) plan, all of which were used to treat patients
at GRRCC. The dose profiles from these plans were convolved with the same set of breathing
traces used in the phantom plan simulation. The clinical dose profiles and target definitions that
were originally used in these plans were kept the same for the purposes of this simulation. The
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resulting loss of target coverage in the respective PTVs was recorded in order to assess the effect
of motion in clinically relevant situations.
The result of the target motion simulation on the clinical plans reinforces the notion that the
proper margin selection is an effective tool in compensating for target motion. After including
the modeled effect of target motion, the dose coverage still remained high for the majority of
breathing patterns. As shown in Figure 6.9 it is only after the target motion becomes large (PDF
standard deviation greater than 0.4 cm) that margins beyond what are typically applied should
be considered in order to maintain target D95.
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Figure 6.9: A plot of the relative D95 versus the PDF standard deviation for three clinical plans
with the phantom data for comparison. The clinical plans with typical margins selected are robust
in the face of target motion up to a PDF standard deviation of approximately 0.4 cm. For target
motion beyond this level, additional margins would be required to maintain target D95.
The clinical plans show less susceptibility to motion for two main reasons: large target size
( 5 cm FWHM) and softer dose gradients as compared to the dose profile from the phantom
treatment plan. Since the dose gradients play an important role in the loss of coverage, it is
instructive to look at the width of the penumbra in the dose profiles near the beam edge of these
plans. In the cases of the clinical three field and VMAT plans, the 80%-20% penumbra was
measured at 14 mm (Figures 6.10 & 6.11). In the case of the four field plan, the penumbra of
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the dose profile was 9 mm (Figure 6.12). In each case the dose gradient was less steep than
in the phantom plan, which had a penumbra of 8 mm. The typical clinical plan (regardless of
technique) will have dose gradients which are softer than those seen in the simple three field
phantom plans. As a result, the margin recommendations generated from the phantom plans can
be seen as a worst case scenario, and any plan with softer dose gradients will be sufficiently
compensated for by using the same margins.
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Figure 6.10: An image through the isocentre of the clinical three field treatment plan. The inset
dose profile was used as the basis of the simulations of target motion in the case of the three field
plan. The dose profile runs from superior to inferior through the center of the treatment volume
along the vertical line indicated.
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Figure 6.11: An image through the isocentre of the clinical VMAT treatment plan. This plan was
comprised of two arcs. The inset dose profile was used as the basis of the simulations of target
motion in the case of the VMAT plan. The dose profile runs from superior to inferior through the
center of the treatment volume along the vertical line indicated.
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Figure 6.12: An image through the isocentre of the clinical four field treatment plan. The inset
dose profile was used as the basis of the simulations of target motion in the case of the four field
plan. The dose profile runs from superior to inferior through the center of the treatment volume
along the vertical line indicated.
Since the size of the target plays an important role in the loss of D95, it is important to
consider the width of the dose profiles in these plans. The FWHM for the clinical three field,
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four field and VMAT plans were measured at 8.5 cm, 11.1 cm and 12.8 cm respectively. The
same trend that was identified with the study of target size can be seen in these three clinical
plans as well. However, the variation in dose gradients also plays a role in the clinical results.
The results of the phantom study are generated with very steep dose gradients resulting from
a simple three field plan with overlapping beam edges. In practice, these phantom plan dose
gradients will be as sharp as, or sharper, than what can be achieved in a clinical situation. As a
result the margin recommendations of the phantom plan can be taken as a worst case scenario,
and can be safely applied to a clinical plan which has equivalent or softer dose gradients.
The analysis of the clinical treatment plans reveals that they are rather robust in the face of
target motion. Figure 6.9 displays the loss of target D95 versus the PDF standard deviation and
also includes the phantom results of the 4.1 cm FWHM target for comparison. Images of the
dose distributions and the associated dose profiles are displayed in Figures 6.10-6.12.
The clinical plans lose very littleD95 for target motions which have a PDF standard deviation
below 0.4 cm. It is only after the PDF standard deviation is larger than approximately 0.4 cm
that the loss of target D95 becomes appreciable. This highlights the effectiveness of selecting
appropriate margins to compensate for target motion.
6.8 Example Margin Selection
Having determined recommended field margins shown in Table 6.2, it was instructive to re-
examine the dynamic phantom dose profiles measured for a small target volume and extreme
standard deviation (characteristic of a stereotactic radiosurgery case with large, irregular tumor
motion). A treatment plan for a small target (2.6 cm FWHM dose profile) was first generated
in Eclipse. The static dose profile was extracted from the treatment plan and convolved with a
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breathing trace PDF with a large standard deviation (0.8 cm) to assess the impact of target motion
on dose coverage. A new plan was then generated by adding the appropriate margin from Table
6.2 to the small target (16 mm). The phantom was programmed to replicate the motion recorded
in by the breathing trace and the new plan was then delivered to the phantom in motion. The dose
coverage offered by the new plan under motion was then compared to the original static plan in
order to validate the use of Table 6.2 for margin selection recommendations.
The results of this validation measurement are depicted in Figure 6.13 and summarized in
Table 6.3. The D95 of the target PTV increases from 75.8% of the original D95 without motion
compensation to 99.1% with motion compensation. In this case, the additional margin would
play an important role in ensuring an adequate dose is delivered to the treatment volume in the
presence of target motion. It should also be noted that by expanding the margins in this treatment
plan, it is possible that adjacent OARs could receive an increased dose. By using the margin
recommendations in Table 6.2 a clinician would be able to assess the impact of the expanded
margin on OARs at the treatment planning stage.
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Figure 6.13: A plot of dose profiles demonstrating the margin recommendations provided in this
work. The original static profile is taken from Eclipse, then convolved with the PDF. The original
static plan loses dose coverage due to the target motion. When the margin recommendation from
Table 6.2 is included in the plan, the target dose coverage is largely recovered when the treatment
is delivered in the presence of the same target motion.
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Original Static
Profile (Eclipse)
Original Profile with Motion
(Eclipse, convolved)
Profile with Added Margin &
Motion (film measurement)
D95 (cGy) 189.9 143.9 188.2
Relative D95 (%) 100 75.8 99.1
Table 6.3: Summary of the results of the margin selection example to demonstrate use of the
margin recommendations presented in this work. The D95 of the PTV is largely recovered by
including the margin recommended in Table 6.2.
For this type of situation the increase in field dimensions could compromise the dose to
adjacent organs as seen in a treatment plan with adjusted margins. A clinical decision to use
a different treatment technique, instead of simply increasing the margins, could be guided by
the treatment plan with extended margins. By assessing the treatment plan with the extended
margins in place, the clinician has the ability to compare other treatment options, to a treatment
plan with margins that will compensate for target motion.
6.9 Comparison of Margin Recipes
Since Leong [22] proposed the idea of incorporating target motion into dose calculations via the
convolution model, other authors have also assessed how the blurred dose coverage depends on
the model parameters. The works of Engelsmann et al. [1], Richter et al. [2] and van Herk
et al. [13] also identified the standard deviation of the motional PDF to be a key predictor of
changes to dose coverage. Although each group used the standard deviation to make margin
recommendations, the dose coverage metrics used as the basis for comparison are different in
each case. The differences in margin recommendations made in this work and as compared
to the above cited authors offers an interesting perspective on the trade-offs and weighting of
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outcomes that must be considered clinically when applying treatment margins to accommodate
for target motion.
6.9.1 Comparison with Engelsmann et al.
The approach detailed by Englesmann et al. [1] looks to assess how the position of the 95%
isodose line is displaced as a result of the dose profile blurring predicted by the convolution
model. In a 1D dose profile, the 95% isodose line corresponds to the point where the dose is
95% of the maximum profile dose. The location of the 95% isodose line relative to the target
PTV is used clinically to assess the quality of dose coverage offered by a give treatment plan.
By offering margin recommendations that look to preserve the location of the 95% isodose line,
the authors are looking to ensure that the abosorbed dose received by the tissue at the border of
the target volume location remains at planned level. This is in contrast to the D95 used in this
thesis (defined as the minimum dose received by 95% of the target volume), which summarizes
the dose coverage to the entire target volume. By making margin recommendations that look to
preserve the target D95, we look to ensure that the 95% of the target volume receives at least the
same dose as originally planned, after considering target motion.
A major difference in the approach Englesmann et al. used to generate the margin recom-
mendations lies in the static dose profiles used as the input to the convolution model. The authors
used an analytical expression based on the sum of Error Functions (Equation 6.2) as an approxi-
mation of a one sided dose profile only.
D(x) =
ω1erf(
x
b1
) + ω2erf(
x
b2
)
2
• 100% (6.2)
In this context the 0% dose is located at x = −∞, 50% dose at x = 0 and 100% dose at
x = ∞ [1]. It should be noted that the integral dose of this profile is infinite, and as such the
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analysis by Englesmann et al. loses the effect of conserved integral dose that is a property of the
convolution model. The result is that changes to the maximum dose, and therefore the location
of the 95% isodose line, that result from small targets undergoing motion is not captured by this
approach. As such, Engelsmann et al. do not provide margins that depend on the size of the
target being treated. The margins suggested by Englesmann el al. are summarized in Table 6.4
in comparison with the margins recommended in this work.
Standard Deviation (cm) 0.4 0.8 1.2
Englesmann et al. [1] 1 (mm) 4.5 9.5
2.6 cm FHWM 2.3 8.0 16.9*
5.6 cm FWHM 1.6 5.8 12.8*
10.1 cm FWHM 1.2 4.7 10.2*
Table 6.4: A comparison of the margin recommendations presented in this work with the recom-
mendations of Engelsmann et al. [1]. The margins from this work are taken as half the ABW
recommendations (total symmetric margin) for accurate comparison to Engelsmann et al (one
sided dose profile). For large targets, the recommended margins are similar, but for small targets
the additional margin recommended here is much larger. The values marked with an asterisk are
extrapolated values based on the equations in Table 6.1.
The margins recommended by both approaches for large targets are in fact quite similar. This
result is intuitive as the analytical expression of Englesmann et al. (Equation 6.2) describes an
’infinitely’ wide static dose profile. Since this approach loses the effect of conserved integral
dose, Engelsmann et al. are not able to properly assess the margins required for small targets. In
particular the margins recommended here for a target with FWHM of 2.6 cm are more than twice
as large as the recommendations of Engelsmann et al. The effect of target size on the required
target margin should not be overlooked.
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6.9.2 Comparison with Richter et al.
Richter et al. [2] also used the standard deviation of the motional PDF as an important predictor
in loss of dose coverage. The margins recommended by Richter et al. aim to preserve the
absorbed dose at the border of the target volume. The approach taken by the authors was to
compensate for target motion by both increasing target margin, and increasing the dose delivered
to the target. They assessed the additional margin required while also delivering 105%, 125%,
and 150% of the originally prescribed dose. Since increasing the dose delivered to the target also
compensates for the dose spillage resulting from the blurring caused by target motion, the effect
of increasing the dose to the target is to reduce the additional margin required to maintain the
dose to the edge of the target volume.
The margin recommendations from Richter et al. are summarized with comparison to this
work in Table 6.5. It can be seen in the table that the margin recommendations are similar for
medium sized targets in this case. The approach of increasing the prescribed dose allows for
smaller margins to offer the same level of dose coverage.
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Standard Deviation (cm) 0.1 0.2 0.3 0.4 0.5 0.6 0.7
P105 0.3 (mm) 0.9 1.6 2.6 3.8 5.2 6.9
P125 0.4 0.9 1.5 2.2 3.0 4.0 5.0
P150 0.3 0.5 0.8 1.2 1.5 1.9 2.2
2.6 cm FHWM 0.5 1.5 2.9 4.6 6.8 9.4 12.5
5.6 cm FWHM 0.3 0.9 1.8 3.1 4.7 6.7 8.9
10.1 cm FWHM 0.2 0.7 1.4 2.4 3.7 5.3 7.1
Table 6.5: A comparison of the margin recommendations presented in this work (profile FWHM
specified) with the recommendations of Richter et al. [2] using different prescribed doses (P105,
P125, P150). The values for the recommended margins from Richter et al. were calculated using
the formulas given in the paper. Although Richter et al. do not specify the size of the target used
to generate this data, the recommendations from both approaches are similar for medium sized
targets.
By increasing the prescribed dose, the authors effectively increase the integral dose in the
static plan. This way, the dose spillage that results from the blurring due to target motion is
partially compensated for without increasing the target margin. The potential drawback of this
approach is the large increase in dose to surrounding healthy tissue that results from the increased
dose prescribed to the target. In many cases the dose prescribed to the target volume is limited by
the dose that will also be imparted to surrounding healthy tissues. As a result, it may not always
be safe to drastically increase the prescribed dose to a target volume in order to compensate for
target motion.
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6.9.3 Comparison with van Herk et al.
In comparison with the approach detailed by van Herk et al [13], we can see that the margin
recommendations presented here are similar for some situations. Although the van Herk formula
makes no accounting for target size, we can compare the margin recommendations based on the
van Herk et al. ‘linear approximation of the random component for 95% dose coverage’. This
is a simple formula which approximates the margin required to compensate for target motion as
‘0.7σ’ where σ is the standard deviation of the motion. The approach of van Herk et al. seeks the
margin that results in 95% of the prescribed dose covering the target for 90% of patients. These
results are presented in Table 6.6.
Standard Deviation (cm) 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8
van Herk Approximation 0.7 (mm) 1.4 2.1 2.8 3.5 4.2* 4.9* 5.6*
2.6 cm FHWM 0.5 1.5 2.9 4.6 6.8 9.4 12.5 15.9
5.6 cm FWHM 0.3 0.9 1.8 3.1 4.7 6.7 8.9 11.6
10.1 cm FWHM 0.2 0.7 1.4 2.4 3.7 5.3 7.1 9.30
Table 6.6: A comparison of the margin recommendations presented in this work in comparison
with the commonly used van Herk recommendations. For small targets, the recommended mar-
gins are similar, but for larger targets D95 can be maintained with less additional margin than
suggested by van Herk et al. Since van Herk et al. only claim accurate approximation of the
formula used up to a standard deviation of 0.5 cm, the values marked with an asterisk are noted
as an extrapolation.
For small targets, the margin recommendations are similar. For larger targets, the results
computed in this study suggest less additional margin is required. The differences in margin
recommendations likely arise due to differences in the approach to the problem. The approach of
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van Herk et al. is to find margins that satisfy the majority of the population of patients studied.
However if a patient specific approach to margin selection is taken, there is opportunity for
reduced target margin for patients with larger sized targets. This can be seen in the comparison
table above where patients with small target motion (PDFSD < 0.4 cm) have smaller margin
recommendations from this work as compared to van Herk et al.
6.10 Summary
Target motion was simulated for a wide range of breathing traces and target sizes in order to
determine the loss of target dose coverage. Statistics describing the range of breathing traces
were presented. It was shown that breathing trace amplitudes in this large data set ranged from
0.13 to 2.30 cm with an average amplitude of 0.73 cm. The standard deviations of the PDFs in
the data set ranged from 0.057 to 1.13 cm with an average standard deviation of 0.34 cm.
A quadratic function used to describe the loss of target dose coverage in terms of the standard
deviation of the PDF describing the motion of the target was found to correlate strongly with the
data set (R2 = 0.9821). The size of the target along the direction of motion was also found to
influence the amount of coverage being lost, with larger targets being less susceptible to loss of
dose coverage due to motion. The recovery of target dose coverage was also found to correlate
with the PDF standard deviation, and these two trends were used to generate margin recommen-
dations. A table of margin recommendations based on the PDF standard deviation and target size
was presented in Table 6.2. These margins can be applied in a clinical situation to compensate
for the reduction of the target’s D95 due to intrafraction motion.
An example application of the use of the methodology and margin recommendation table
was presented for a small target and extreme motion. This example demonstrates how the table
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can be used to ensure adequate dose coverage of the target volume. The influence of the studied
motions on a set of clinical treatment plans was also assessed. This assessment demonstrated the
interplay between target size, dose gradient and standard deviation of the target motion.
Finally the margins recommended in this thesis were compared with published recommenda-
tions from other authors who also took advantage of the convolution model to assess the impact
of target motion on target dose coverage. The margins presented here are comparable to those
presented by other authors under some circumstances, however the inclusion of dependence on
target size presented in this thesis offers opportunity for smaller margins for some patients, as
compared to the other recommendations.
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Chapter 7
Convolution Model Sensitivity Analysis
7.1 Introduction
In this thesis a convolution technique has been applied to determine the impact of intrafraction
lung motion on absorbed dose. As shown previously, a patient specific lung PDF was derived
from 4DCT data, and the gradient of the PDF was convolved with the static dose profile to obtain
a blurred or motion-impacted dose gradient along the superior-inferior direction. The blurred
dose gradient was then integrated along the superior-inferior direction to obtain the blurred dose
profile. This technique was developed in Chapter 4 using Equation 4.8, expanded with clinical
examples in Section 4.5, and demonstrated graphically in Figures 4.7 to 4.11. Using a dynamic,
tissue equivalent phantom programmed for clinical breathing patterns and radiochromic film for
dose measurement, the convolution technique described above was validated experimentally and
the results were summarized in Chapter 5.
In Chapter 6, breathing patterns from 502 patients were used to simulate the effect of in-
trafraction motion on static dose profiles obtained from a standard treatment plan designed to
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cover targets ranging from 2-10 cm in diameter. D95 was selected as the metric for comparing
static and motion-impacted dose profiles based on clinical importance and the relative D95 was
defined as the ratio of the blurred D95 to the static D95. After analysis it was determined that rel-
ative D95 has a quadratic dependence on the standard deviation of the static dose profile and this
is shown in Figures 6.5 and 6.7 and Table 6.1. A program was written in MATLAB to calculate
the additional beam width (ABW applied to the static dose profile) that is required to restore the
high dose region impacted by lung motion. Table 6.2 shows ABW as a function of the standard
deviation of the PDF and also the FWHM of the static dose profile.
In addition to the conformal treatment plan, a 3-field, 4-field and a VMAT plan were also
analyzed with the 502 patient breathing patterns to assess impact on relative D95 and the validity
of recommended margins in Table 6.2. The results were shown in Figure 6.9 and the conclu-
sion was that Table 6.2 is valid for conformal and more complex planning techniques including
multiple beams and arcs.
In Section 6.8, the margin recommendations were tested experimentally using a treatment
plan with a single beam of FWHM = 2.6 cm and the dynamic lung phantom programmed for a
lung PDF with SD = 0.8 cm. These parameters were chosen to simulate a Stereotactic Radiation
Surgery (SRS) treatment and to test the extreme margin recommendations from Table 6.2. The
results from Figure 6.13 show that D95 is restored with the recommended margins at the expense
of lower dose spillage adjacent to the target due to a wider field. This effect is shown in Figure
7.1. The intersection points of the blurred dose profiles (with and without ABW) and the static
dose profile are highlighted in the figure with ovals.
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Figure 7.1: The D95 is restored with the additional beam width, however it comes at the expense
of lower dose spillage adjacent to the target. The intersection points of the blurred dose profiles
(with and without ABW) and the static dose profile are highlighted in the figure with ovals.
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7.2 Factors Determining the Blurred Dose Gradient
The motivation for breaking down the convolution integral as described by Equation 4.8 is a
fundamental understanding of the factors contributing to the blurred or motion-impacted dose.
Furthermore, the selection of a principal direction of motion (the superior-inferior direction in
this analysis) provides flexibility to construct the most relevant lung PDF and to make margin
adjustments tailored to a patients breathing. As shown in Figures 4.7, 4.10, 4.11, and 6.13, the
convolution-derived, blurred dose profile depends on the following parameters:
• the shape and symmetry of the PDF along r
• the standard deviation of the PDF
• the slopes of the leading and trailing edges of the static dose profile
• the FWHM and the shape of the plateau region of the static dose profile
In this chapter an analytical model is developed to explain how each of these parameters
contributes to the blurred dose profile. In general and as shown in Figure 7.2, the leading and
trailing edges of the blurred dose profile have a lower slope than the leading and trailing edges
of the static dose profile, as a result of the convolution. For field sizes < 5 cm, the peak height
of the blurred dose profile falls below that of the static dose profile in order to conserve integral
dose (also referred to as imparted energy, [4]).
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Figure 7.2: The D95 is restored with the addition beam width, however it comes at the expense
of lower dose spillage adjacent to the target. The intersection points of the blurred dose profiles
(with and without ABW) and the static dose profile are highlighted in the figure with ovals.
This is a consequence of the convolution theorem, which, applied to Equation 4.1 yields
∫
Db(~r)dr =
∫
D0(r)⊗ PDF (r)dr =
[∫
D0(r)dr
]
•
[∫
PDF (r)dr
]
. (7.1)
In this study the PDFs were normalized (i.e.
∫
PDF(r)dr = 1) and Equation 7.1 reduces to
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∫
Db(r)dr =
∫
D0(r)dr. (7.2)
In Figure 7.2 the intersection points of the blurred and static dose profiles are identified with
ovals and their projections on the r axis are shown as −r∗ and r∗ relative to the static profile
centered at the origin. These points are used to identify regions of under and overdose for the
blurred profile relative to the static profile.
For the static dose profile,
∫ ∞
−∞
D0(r)dr =
∫ −r∗
−∞
D0(r)dr +
∫ r∗
−r∗
D0(r)dr +
∫ ∞
r∗
D0(r)dr (7.3)
and similarly for the blurred dose profile,
∫ ∞
−∞
Db(r)dr =
∫ −r∗
−∞
Db(r)dr +
∫ r∗
−r∗
Db(r)dr +
∫ ∞
r∗
Db(r)dr. (7.4)
Using Equation 7.2 and subtracting components from Equations 7.3 and 7.4,
∫ r∗
−r∗
D0(r)−Db(r)dr =
∫ −r∗
−∞
Db(r)−D0(r)dr +
∫ ∞
r∗
Db(r)−D0(r)dr (7.5)
In words, Equation 7.5 states that the region of dose deficit shown in Figure 7.2 is equal to
the sum of the regions of dose spillage arising from the convolution of the static dose profile with
the PDF.
It is important to note that by adding additional margins to the static dose profile to recover
the dose deficit arising from lung motion (per Table 6.2), the dose spillage regions will also
expand. This means that the impact on the DVH for OARs adjacent to the target volume must be
assessed carefully along with the PTV coverage as part of using this methodology.
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7.3 Analytical Modeling Using Gaussian PDF Functions
Since the parameters contributing to the blurred dose gradient described in the previous section
are highly patient and treatment plan specific, it is not practical to derive a comprehensive sensi-
tivity model that applies to all cases. By employing a simpler lung PDF than observed clinically,
however, it is possible to provide an analytical sensitivity analysis that explains the basic physics.
Jiang et al. [24] used a Gaussian PDF to describe interfraction prostate motion and previously
showed the equivalence of deriving the blurred dose gradient from the convolution of a static
dose profile with the gradient of a Gaussian PDF or from the convolution of the gradient of the
static dose profile with a Gaussian PDF. This is shown in Figures 7.3 and 7.4 for PDF standard
deviations ranging from 0.2 cm to 0.8 cm.
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Figure 7.3: An example of Gaussian blurring applied to gradient of a static dose profile as de-
scribed by Jiang et al. [24]. The standard deviation of the Gaussian PDF ranges from 0.2 to 0.8
cm.
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Figure 7.4: An example of blurring a static dose profile with the gradient of a Gaussian PDF as
described by Jiang et al. [24]. The standard deviation of the Gaussian PDF ranges from 0.2 to
0.8 cm.
Due to the symmetry of both the static dose profile and the gradient of the Gaussian PDF in
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this example (Figure 7.4), the blurred dose gradient is also symmetric along with the resulting
blurred dose profiles.
From the analysis in Chapters 4 and 6 and preceding discussion, it is clear that the biggest
impact on the static dose profile will occur for narrow beam profiles (FWHM < 5 cm) and large
PDF standard deviations (> 4 mm). The following analysis provides a quantitative explanation
for this effect using separate Gaussian functions to describe the dose profile and PDF.
A normalized uni-variate Gaussian function (centered on the origin) is described by
G(r) =
1
σ
√
2pi
e−
1
2
( r
σ
)2 . (7.6)
The first partial derivative is given by
∂
∂r
G(r) =
−r
σ2
G(r) =
−r
σ3
√
2pi
e−
1
2
( r
σ
)2 , (7.7)
and the second partial derivative is given by
∂2
∂r2
G(r) =
−σ2 + r2
σ4
G(r) =
−σ2 + r2
σ5
√
2pi
e−
1
2
( r
σ
)2 , (7.8)
which will be zero when r = ±σ.
When r = ±σ the slope of G(r) will be maximized (designated by MS)
GMS =
[
∂
∂r
G(r)
]
r=σ
= − e
− 1
2
σ2
√
2pi
. (7.9)
When r = 0, G(r) will be have maximum peak height (designated by PH)
GPH = G(0) =
1
σ
√
2pi
. (7.10)
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The convolution of two normalized Gaussian functions
G1(r) =
1
σ1
√
2pi
e
− 1
2
( r
σ1
)2 (7.11)
and
G2(r) =
1
σ2
√
2pi
e
− 1
2
( r
σ2
)2 (7.12)
is given by
G3(r) = G1(r)⊗G2(r) = 1
σ3
√
2pi
e
− 1
2
( r
σ3
)2
, (7.13)
where
σ3 =
√
σ21 + σ
2
2. (7.14)
Using Equations 7.6 to 7.14, let G1(r) represent the normalized lung PDF obtained from
4DCT and G2(r) represent the dose profile along the direction of relevant lung motion, r. Be-
cause G2(r) was defined as a normalized Gaussian, it needs to be scaled by σ2
√
2pi so that the
height of the dose profile is unity (i.e. 100% or 1.0). This axis can also be scaled by absolute
dose with units of Gy. The net result is a scaled convolution Gaussian described by
G4(r) = σ2
√
2piG3(r), (7.15)
and the maximum slope of G4(r) when r = σ3 is given by
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GMS4 =
[
∂
∂r
G4(r)
]
r=σ3
=
−σ2
σ23
e−
1
2 =
−σ2
σ21 + σ
2
2
e−
1
2 . (7.16)
The maximum height of G4(r) when r = 0 is given by
GPH4 = G4(0) =
σ2
σ3
=
σ2√
σ21 + σ
2
2
=
1√
1 +
(
σ1
σ2
)2 . (7.17)
For the description ofG2(r), (i.e. the static dose profile), both the FWHM and σ2 are relevant
physical parameters. For a Gaussian function, these are related by
FWHM = 2σ2
√
2ln2, (7.18)
or
σ2 =
FWHM
2
√
2ln2
. (7.19)
From the clinical data analyzed in this thesis, the relevant range of PDF standard deviations
for lung patients was from 0.1 cm to 0.8 cm and the FWHM of the beam profile was varied
from 2.6 cm to 10.1 cm. Similar parameters were used in a spreadsheet with Equations 7.6 to
7.19 to generate data shown in Figures 7.5 to 7.13 and Table 7.2. Figures 7.14 to 7.16 were
generated from MATLAB and show static dose profiles of 1 cm and 5 cm FWHM respectively
convolved with Gaussian lung PDFs with standard deviations ranging from 0.1 cm to 1.0 cm.
The MATLAB analysis included Gaussian and rectangular static dose profiles.
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7.4 Analysis of Gaussian Convolution Model
The most important results from the analysis are shown in Figures 7.5 and 7.6. Figure 7.5 shows
that the maximum height of the blurred dose profile varies as 1
σ3
and Figure 7.6 shows that the
maximum slope of the blurred dose profile varies as 1
σ23
. The relative dependencies of both the
maximum height and maximum slope on σ1 and σ2 (or FWHM) are largely determined from
Equation 7.14 (i.e. σ23 = σ
2
1 + σ
2
2) as explained in the previous section.
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Figure 7.5: The plot of maximum blurred dose peak height versus the standard deviation of the
blurred dose profile for several static dose profile FWHM values. The PDF standard deviation
ranges from 0.1 cm to 1.0 cm. As the combined standard deviation (SD3) increases, the peak
height of the blurred dose profile decreases. As the FWHM of the static dose profile increases,
the sensitivity of the peak height to SD3 decreases.
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Figure 7.6: The plot of maximum blurred dose gradient versus the standard deviation of the
blurred dose profile for several static dose profile FWHM values. The PDF standard deviation
ranges from 0.1 cm to 1.0 cm. As the combined standard deviation (SD3) increases, the maxi-
mum dose gradient of the blurred dose profile decreases. As the FWHM of the static dose profile
increases, the sensitivity of the the maximum dose gradient to SD3 decreases.
The simultaneous 1
σ
and 1
σ2
dependencies of the maximum height and maximum slope of
the blurred dose profile respectively, reflect conservation of integral dose as shown previously in
Equation 7.2 (i.e.
∫
Db(r)dr =
∫
D0(r)dr). Stated in words, the standard deviation (σ3) of the
blurred dose profile will expand relative to the standard deviation (σ2) of the static dose profile
due to lung motion characterized by the standard deviation (σ1) of the PDF. This expansion is
given by Equation 7.18 (i.e. FWHM = 2σ2
√
2ln2). As σ1 increases for a given static dose
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profile FWHM, the maximum height of the blurred dose profile will decrease and the maximum
slope will also decrease such that the area under the blurred dose profile remains constant and
equal to
∫
Db(r)dr.
The same functional relationship between reduced peak height and reduced slope can be
derived by using a right triangle for the blurred dose profile as shown below. This example is a
simplification of the Gaussian model and is only provided for clarity.
Figure 7.7: A simplification of the Gaussian convolution model depicting the relation between
reduced peak height and reduced maximum slope for constant area.
In this example the static dose half profile is given by right triangle ABD and the blurred
dose half profile by right triangle EFD. As the peak height of the blurred dose profile is reduced
(arbitrarily) by 2/3, the base must be expand by 3/2 in order for the area of the triangles to be
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equal. For that situation, the slope of triangle EFD (relative to base FD) is given by ED/FD which
is equal to
(
2
3
)2 or 4
9
AD/BD which is the slope of the original static profile (relative to base BD).
The maximum blurred dose peak height curves in Figure 7.5 were generated from Equation
7.17. Each of the curves correspond to a different static dose FWHM ranging from 1.0 cm to
5.0 cm as shown in the legend. For each FWHM, the PDF standard deviation (σ1) was varied
from 0.1 cm to 1.0 cm. Power regression data fits were added to provide graphical verification
of the numeric analysis. As shown in Figure 7.5 the R values for each of the power regression
data fits are equal to 1 and the coefficients are the σ2 values that were calculated from integer
FWHM values using Equation 7.19.
The abscissa for both Figures 7.5 and 7.6 is labeled SD3 and corresponds to σ3 in the equa-
tions. For each of the curves in Figures 7.5 and 7.6, the range of applicable σ3 values decreases
as determined from Equation 7.14. The applicable σ3 range is defined as σ3|σ1=1.0 cmσ1=0.1 cm and is cal-
culated for each of the σ2 values corresponding to the integer static dose FWHM values. For
Figures 7.5 and 7.6, the applicable range of σ3 decreases from 0.65 cm at FWHM = 1.0 cm to
0.22 cm at FWHM = 5.0 cm.
Although the maximum height of the blurred dose profile for a given static FWHM decreases
as 1
σ3
, the maximum peak height for constant σ1 increases as FWHM increases from 1.0 cm to
5.0 cm. From Equation 7.17, the maximum peak height is given by
(√
1 +
(
σ1
σ2
)2)−1
and the
limit as σ2 →∞ = 1.
This trend can be seen from Figure 7.5 and is described using the smallest and largest values
of σ1. For σ1 = 0.1 cm (lowest clinical PDF standard deviation studied), the maximum peak
height varies from 0.973 for FWHM = 1.0 cm to 0.999 for FWHM = 5.0 cm. For σ1 = 1.0 cm
(highest clinical PDF SD studied), the maximum peak height varies from 0.391 for FWHM =
1.0 cm to 0.905 for FWHM = 5.0 cm. The explanation for the relatively large drop in maximum
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peak height for FWHM values of 1 cm and 2 cm is due to conservation of integral dose from
the convolution theorem explained previously (Equation 7.2). As the static dose profile FWHM
decreases to small values (e.g. 1 cm needed for SRS), and as the patients breathing becomes
more erratic (higher PDF standard deviation), the peak height drops below unity in addition to
an increase in the maximum slope in order to conserve the area under the blurred dose profile.
The drop in maximum peak dose height for static dose FWHM < 2.5 cm is discussed in more
detail in Section 5.
In Figure 7.6, the data for the maximum gradient of the blurred dose profile was generated
from Equation 7.6 using the same range of values for FWHM and σ1 as used to generate the
maximum peak height. Power regression data fits were also added to provide graphical verifica-
tion of the numeric analysis. Shown in Figure 7.6, the R values for each of the power regression
fits are equal to 1 and the coefficients are the σ2 values that were calculated from integer FWHM
values multiplied by e−0.5 = 0.607.
In contrast to the behavior of the maximum peak height, the maximum dose gradient for a
given static FWHM decreases as 1
σ23
, and the value of the maximum gradient for constant σ1
generally decreases with increasing FWHM. An exception to this trend occurs for σ1 ≥ 0.75 cm
as FWHM increases from 1.0 cm to 2.0 cm. For this situation as shown in Figure 7.6, there
is a small increase in the maximum blurred dose gradient which is again due to conservation of
integral dose. For the large drop in maximum peak height for FWHM = 1 cm and large σ1, there
is also a large decrease in the maximum dose gradient. As the FWHM increases from 1.0 cm
to 2.0 cm at large σ1 the maximum peak height increases and the maximum dose gradient must
increase slightly to conserve integral dose.
Derivatives of the blurred dose profiles are shown in Figures 7.8 and 7.9 for static dose
FWHM values of 2.6 cm and 5.1 cm. For both figures the derivatives are shown for σ1 values of
0.2, 0.5 and 0.8 cm.
173
Figure 7.8: The derivatives of the blurred Gaussian dose profiles generated from a static Gaussian
dose profile with FWHM of 2.6 cm and PDF standard deviations of 0.2 cm, 0.5 cm and 0.8 cm.
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Figure 7.9: The derivatives of the blurred Gaussian dose profiles generated from a static Gaussian
dose profile with FWHM of 5.1 cm and PDF standard deviations of 0.2 cm, 0.5 cm and 0.8 cm.
For the Gaussian convolution model presented in this chapter the blurred dose profiles were
derived analytically to provide a parametric sensitivity analysis. This is in contrast to the method-
ology used in the thesis where the derivatives of the lung PDF were first convolved with the static
dose profile to obtain the blurred dose gradient and then integrated along the superior-inferior (r)
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direction as described before. As shown in Figures 7.8 and 7.9, the derivatives of the blurred dose
distribution are symmetric, and, due to the peaked nature of the Gaussian static dose profile, the
transition of the derivatives from positive to negative is continuous through the origin with the
separation of the positive and negative peaks defining the blurred dose FWHM. For the Gaussian
convolution model there is no flat spot between the peaks of the blurred dose gradient as shown
in Figures 7.3 and 7.4 for a more flat static dose profile.
7.5 Table 6.2 Revisited
Table 6.2 in this thesis describes recommended margins to be applied to the static dose FWHM
in order to recover D95 that is lost due to lung motion quantified by the PDF standard deviation.
The table lists the ABW required as a function of FWHM and SD and is based on the quadratic
polynomial data fits shown in Table 6.1. The parametric boundaries of the Table 6.2 are 2.6 cm ≤
FWHM ≤ 10.1 cm and 0.1 cm ≤ SD ≤ 0.8 cm.
The recommended ABW data in Table 6.2 were plotted in Figure 7.10 as a function of the
FWHM of the static dose profile. Power regression data fits were added showing that the recom-
mended ABW varies approximately as 1√
FWHM
(for fixed PDF standard deviation). This graph
was used to extend the experimental data to FWHM < 2.5 cm. The power regression equations
are tabulated in Table 7.1.
176
Figure 7.10: Plots of the recommended additional beam width from Table 6.2 as a function of
static profile FWHM for a range of fixed PDF standard deviations. The data presented here was
used to extend the experimental data to FWHM < 2.5 cm. In general, as the FWHM of the
static profile increases, the required additional beam width decreases for a given PDF standard
deviation.
The analytical convolution model presented in this chapter provides a reasonable benchmark
for testing the recommended margins in Table 6.2. For this investigation, the analytically simu-
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PDF SD (cm) Fit equation of ABW data (mm) vs FWHM (cm) R2 of fit
0.1 ABW = 0.8903x−0.584 0.8511
0.2 ABW = 2.3039x−0.5 0.8339
0.3 ABW = 4.2274x−0.458 0.8438
0.4 ABW = 6.6367x−0.419 0.8810
0.5 ABW = 9.7082x−0.4 0.9157
0.6 ABW = 13.197x−0.381 0.9463
0.7 ABW = 17.563x−0.381 0.9547
0.8 ABW = 22.181x−0.369 0.9717
Table 7.1: A summary of equations describing the additional beam width (mm) versus FWHM
(cm) of the static Gaussian dose profiles for fixed PDF standard deviation.
lated blurred dose profile was computed using FWHM values for G2(r) and σ1 values for G1(r)
from Table 6.2 and compared with Equation 7.13 evaluated with the recommended margins ap-
plied to G2(r). The results are shown in Table 7.2 and graphically in Figures 7.11 and 7.12.
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Figure 7.11: Analytically simulated static, blurred and ABW blurred dose profiles. The original
static profile had FHWM = 2.6 cm. The ABW recommended in this case is 1.6 cm. The loss of
dose coverage and the dose recovered by the ABW shown here is summarized in Table 7.2
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Figure 7.12: Analytically simulated static, blurred and ABW blurred dose profiles. The original
static profile had FHWM = 5.1 cm. The ABW recommended in this case is 0.8 cm. The loss of
dose coverage and the dose recovered by the ABW shown here is summarized in Table 7.2
In the context of the analytical model presented,D95 has limited practicality and was replaced
with the dose deficit defined in Equation 7.5 and shown in Figure 7.2. To calculate the dose deficit
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using Equation 7.5, the intersection points r∗ and r∗ were derived as follows.
By equating the motion-modified dose profile G4(r) = σ2
√
2piG3(r) with the scaled static
dose profile G2(r) = 1σ2
√
2pi
e
− 1
2
(
r
σ2
)2
• σ2
√
2pi the intersection points are given by
σ2
σ3
e
− 1
2
(
r∗
σ3
)2
= e
− 1
2
(
r∗
σ2
)2
. (7.20)
Solving for r∗ gives
r∗ = ±σ1σ2
√
2(lnσ3 − lnσ2)
σ23 − σ22
. (7.21)
When Table 6.2 is applied to G2(r) such that FWHM = FWHM + ABW , the intersection
points of G2(r) and G3ABW (r) are given by
r∗ = ±σ1σ2
√
2(lnσ3 − lnσ2ABW )
σ23 − σ22
, (7.22)
where G3ABW (r) and σ2ABW include ABW from Table 6.2.
For clarity in Table 7.2, r* is calculated from Equation 7.21 was labeled r1∗ and r∗ calculated
from Equation 7.22 was labeled r2∗. The initial deficit integral dose resulting from lung motion
was derived from
A1deficit =
∫ r1∗
−r1∗
Do(r)−Db,ABW (r)dr, (7.23)
and residual deficit integral dose determined with recommended ABW from Table 6.2 was
derived from
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A2deficit =
∫ r2∗
−r2∗
Do(r)−Db,ABW (r)dr, (7.24)
where Db,ABW is the blurred dose with ABW.
Since the integral dose from Equation 7.23 includes the residual integral dose from Equation
7.24, the recovered dose from using the static dose profile with ABW was calculated using
RecoveredIntegralDose = 1−
(
A1deficit
A2deficit
)
. (7.25)
The results and parametric details are shown in Table 7.2.
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FWHM
(cm)
FWHM
+ ABW
σ1
(cm)
r1∗
(cm)
r2∗
(cm)
G2(r1
∗)
(Gy)
G2(r2
∗)
(Gy)
G3(0)
(Gy)
G3,ABW (0)
(Gy)
A1deficit
(Gy cm)
A2deficit
(Gy cm)
Dose
Recov-
ery(
1− A2
A1
)
1.0 1.23 0.2 0.446 0.241 0.576 0.851 0.905 0.934 0.152 0.016 0.895
1.0 1.97 0.5 0.520 0.261 0.473 0.828 0.647 0.858 0.258 0.037 0.857
1.0 3.22 0.8 0.592 0.239 0.379 0.853 0.469 0.863 0.362 0.033 0.910
2.6 2.75 0.2 1.113 0.518 0.601 0.896 0.984 0.986 0.344 0.007 0.978
2.6 3.28 0.5 1.156 0.577 0.578 0.872 0.911 0.941 0.408 0.034 0.917
2.6 4.19 0.8 1.222 0.575 0.542 0.873 0.810 0.912 0.513 0.051 0.901
3.6 3.72 0.2 1.535 0.689 0.604 0.903 0.992 0.992 0.472 0.005 0.988
3.6 4.18 0.5 1.568 0.755 0.591 0.885 0.950 0.963 0.520 0.028 0.946
3.6 4.97 0.8 1.622 0.761 0.570 0.883 0.886 0.935 0.614 0.049 0.920
5.1 5.19 0.2 2.70 0.954 0.605 0.908 0.996 0.996 0.665 0.004 0.994
5.1 5.57 0.5 2.194 1.019 0.599 0.895 0.974 0.978 0.698 0.022 0.968
5.1 6.25 0.8 2.235 1.023 0.587 0.894 0.938 0.957 0.782 0.044 0.944
10.1 10.17 0.2 4.291 1.578 0.606 0.935 0.999 0.999 1.414 0.002 0.999
10.1 10.47 0.5 4.304 1.689 0.604 0.925 0.993 0.994 1.408 0.011 0.992
10.1 11.03 0.8 4.326 1.690 0.601 0.925 0.983 0.986 1.463 0.024 0.984
Table 7.2: A summary of the parametric analysis of the Gaussian convolution model. The legend is on the next
page.
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• FWHM of the static dose profile
• FWHM + ABW added to static profile (per Table 6.2)
• SD1 is for static dose profile
• r1∗ is the intersection of blurred dose profile with static dose profile
• r2∗ is the intersection of blurred static profile including ABW with static dose profile
• G2(r1∗) is the value of static dose profile at r1∗
• G2(r2∗) is the value of static dose profile at r2∗
• G3(0) is max height of blurred dose profile at r = 0
• G3,ABW (0) is max height of blurred dose profile including ABW at r = 0
• A1deficit is integral dose lost due to target motion
• A2deficit is the integral dose lost to target motion after the field size has been increased per
Table 6.2
• Dose Recovery = 1− A2deficit
A1deficit
When ABW from Table 6.2 motion is recovered within an average of 96% ± 2.5% for
0.1 cm ≤ σ1 ≤ 0.8 cm lung PDF and 2.6 cm ≤ FWHM ≤ 10.1 cm static dose profile. This
indicates that the ABW recommendations from Table 6.2, applied to the analytical Gaussian
convolution model, provide very good general recovery of the dose deficit resulting from organ
motion within the σ1 and FWHM parameters specified. For static dose profiles with FWHM
values less than 2.5 cm however (i.e. outside of the clinical parametric boundaries of Table 6.2),
dose recovery may not be practical using an ABW technique. As demonstrated previously, this
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is due to a significant decrease in blurred dose maximum peak height and softer maximum dose
gradients arising from convolution of small static dose FWHM and large PDF SD. This extreme
is shown in Figures 7.13 to 7.15. In Figure 7.13, the ABW for FWHM = 1.0 cm was extrap-
olated from a power regression data fit shown in Figure 7.10. From Table 7.2, the recovered
integral dose for PDFSD = 0.8 cm is 0.91 which would be a problem clinically. Figures 7.14
and 7.15 show MATLAB simulations for small FWHM and large PDF standard deviations. In
Figure 7.15, the simulation is calculated for a rectangular dose pulse which is an ideal extreme
provided for comparison. A more clinical stereotactic static dose profile would be a cross be-
tween the Gaussian and rectangular profiles.
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Figure 7.13: The effect of large target motion on a static Gaussian profile with FWHM of 1 cm.
This small target is particularly susceptible to loss of dose coverage as shown by the blurred dose
profile. The ABW recommendation derived from Figure 7.10 (or Table 7.1) is still insufficient to
restore full dose coverage for this small field and large motion
.
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Figure 7.14: The effect of varying levels of target motion, represented by several PDF stan-
dard deviations, on a small field. As the amount of motion increases the dose coverage loss,
represented by the blurred dose profile, increases. The low dose spillage becomes an impor-
tant concern for small fields and large motion that may occur in the case of an SRS treatment
technique.
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Figure 7.15: The effect of varying levels of target motion, represented by several PDF standard
deviations, on an idealized square field. As the amount of motion increases, the dose coverage
offered by the blurred dose profile continues to decrease.
For static dose FWHM values less than 2.5 cm and PDF standard deviation values greater
than 0.4 cm, an alternative methodology for recovering D95 would be to individually measure
the loss in static peak dose height using individual patient data (static FWHM, PDF standard
deviation) and increase the dose prescription by the reciprocal of the relative peak height. This
needs to be done very carefully however with accurate small-field dosimetry using a dynamic
phantom and implemented with precision IGRT based quality assurance. The important point to
be raised in this section is that the recommended margins in Table 6.2 should not be used outside
of the stated parametric boundaries particularly for static dose profile FWHM values less than
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2.5 cm.
For static dose FWHM values greater than 2.5 cm and with flatter plateau regions as shown
in Figures 7.3 and 7.4, convolution with a PDF SD results mainly in a reduction of the dose
gradients at the leading and trailing edges, again conserving integral dose as described earlier.
This is shown in Figure 7.15 from a MATLAB simulation of a rectangular static dose profile with
FWHM = 5.0 cm. In this example the peak dose height does not start decreasing below 1.0 until
the PDFSD = 1.0 cm. Figure 7.16 shows the equivalent Gaussian static dose profile where the
maximum peak height starts decreasing for PDFSD = 0.5 cm due to the more peaked central
region. This comparison indicates that the Gaussian model, although very useful for developing
this sensitivity analysis, is more relevant clinically to SRS static dose profiles.
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Figure 7.16: The effect of varying levels of target motion, represented by several PDF standard
deviations, on an idealized square field. As the amount of motion increases, the dose coverage
offered by the blurred dose profile continues to decrease. Due to the peaked nature of the Gaus-
sian profile, the maximum peak height begins to decrease with PDF standard deviation of 0.5 cm,
as compared to 1 cm for the equivalent square profile.
7.6 Summary
In this chapter a sensitivity analysis was presented of the convolution methodology used in this
thesis. Using a scaled Gaussian function for the static dose profile
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with a maximum peak height of 1.0, and a normalized Gaussian lung PDF with SD = σ1
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The blurred dose profile was determined from the convolution of G1(r) and G2(r) and ana-
lyzed parametrically. The analytical solution of the blurred dose profile is also a Gaussian, and
was derived as
G4(r) = G2(r)⊗G1(r) = σ2
σ3
e
− 1
2
(
r
σ3
)2
, (7.28)
with
σ3 =
√
σ21 + σ
2
2. (7.29)
Summarizing the important results in this chapter;
1. the modified or blurred dose profile is given by the Gaussian function G4(r) with standard
deviation σ3 =
√
σ21 + σ
2
2
2. the FWHM of the modified dose profile is given by FWHM = 2
√
2ln2σ3
3. simultaneously
(a) the peak height of G4(r) varies as 1σ3 and
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(b) the maximum slope of G4(r) varies as 1σ23 such that the integral dose is conserved via∫
G4(r)dr =
∫
G2(r)dr
4. generally, and governed by conservation of integral dose,
(a) the peak height of G4(r), or a given dose profile will decrease with increasing σ1
(b) the maximum slope of G4(r), for a given dose profile, will decrease with increasing
σ1
(c) the maximum peak height of G4(r), for a given σ1, will increase with increasing
FWHM of G2(r)
(d) the max slope ofG4(r), for a given σ1, will decrease with increasing FWHM ofG2(r)
5. additional beam width recommendations from Table 6.2 work reasonably well with the
analytical Gaussian blurred dose model. When the ABW is applied to the static dose
profile for a ”‘model-specific”’ PDF standard deviation and dose profile FWHM values,
the integral dose lost due to lung motion is recovered within an average of 96%± 2.5% for
0.1 cm ≤ σ1 ≤ 0.8 cm lung PDF standard deviation and 2.6 cm ≤ FHWM ≤ 10.1 cm
static dose profiles.
6. Table 6.2 should not be used clinically for static dose profiles and PDF standard deviations
outside of the parameter boundaries specified in item 5 above. For static dose FWHM <
2.5 cm, a patient-specific dosimetry workup should be performed to determine an estimate
for the loss of integral dose due to lung motion and an optimum strategy for providing
recovery.
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Chapter 8
Conclusions
8.1 Discussion
Organ motion during the course of EBRT is a major source of geometric uncertainty in the
delivery of the prescribed radiation dose. Organ motion that occurs between fractions during
a radiotherapy treatment is known as interfraction motion. Organ motion that occurs during
treatment delivery is known as intrafraction motion. Both interfraction and intrafraction motion
need to be accounted for in order to accurately deliver the prescribed dose and achieve the best
patient outcomes. While interfraction motion can be effectively accounted for with daily imaging
on the treatment unit; compensating for intrafraction motion presents a larger challenge.
Addressing intrafraction motion continues to be a major concern for researchers and clin-
icians. Many approaches have been detailed in the literature, such as: breath-hold techniques,
gated radiotherapy, real time target tracking and motion encompassing techniques. While each of
these approaches has its advantages and disadvantages, motion encompassing techniques are the
most widely used due to the ease of implementation. Motion encompassing techniques seek to
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define a treatment volume which sufficiently covers the volume represented by the target motion.
There have also been several approaches to motion encompassing techniques described in the
literature and each one seeks to balance the need to deliver sufficient dose to the target volume
while minimizing the dose to the surrounding OARs.
In this work, a motion encompassing technique to compensate for intrafraction lung motion
was developed. This technique is based on the convolution model of target motion. The convo-
lution model seeks to describe the effect of target motion on the delivered dose distribution by
convolving a planned static dose distribution and a probability distribution describing the target
motion. The convolution model was employed in the context of modern 4DCT equipment, which
offers new tools for assessing the impact of target motion. By generating the PDF from 4DCT
data and using the gradient of the PDF to obtain the blurred dose profiles, the effect of target
motion can be compensated for directly within the treatment planning environment.
The validity of the convolution model in the context of intrafraction motion was assessed with
radiochromic film measurements in a dynamic thorax phantom. This experimental validation
used regular and irregular breathing patterns recorded from patients as the source of the motion
pattern. After experimentally establishing the validity of the model, the model was employed as
part of a large simulation study to search for trends that can be used to guide treatment margin
selection to compensate for target motion in the lung.
The simulation study consisted of the analysis of the effect of 502 different patient breathing
patterns on targets ranging in diameter from 2.6 cm to 10.1 cm. An analysis of the dose coverage
resulting from the convolution model predictions lead to margin recommendations which seek to
maintain the minimum dose received by 95% of the target volume (D95). The margin recommen-
dations, as defined in Chapter 6, are based on the standard deviation of the target motion about
its mean position, and the diameter of the target volume.
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A sensitivity analysis of the convolution model as applied to Gaussian dose profiles and
Gaussian breathing motion PDFs was presented. The sensitivity analysis of Gaussian functions
allows for an analytical approach to assess the effect of varying model parameters on the model
output. The analytical sensitivity analysis showed that the results derived in Chapter 6 have
limitations that need to be respected in extreme cases (small targets with large motion).
8.2 Summary of Key Results
The effect of target motion was investigated based on the breathing patterns recorded from 502
unique patients. The key results can be are summarized below:
• The two major assumptions of the convolution model are generally met when the model
is used in the context of intrafraction lung motion. The assumption of shift invariance was
considered in the context of intrafraction motion and meets the requirements as discussed
by other authors. The assumption of sufficient sampling in the context of intrafraction
motion was also assessed. Ultimately, sufficient sampling will be met for the vast majority
of cases given 10 s of beam on time. This was established with an empirical study of
patient breathing traces as well as a review of the convolution model limitations in the
literature.
• The accuracy of the convolution model predictions in the context of intrafraction lung
motion was established with radiochromic film measurements in a dynamic thorax phan-
tom. For both regular and irregular type breathing patterns, the convolution model makes
predictions accurate to within the 6% margin of error expected with good film handling
techniques.
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• Breathing trace amplitudes used in this study ranged from 0.13 to 2.30 cm with an average
amplitude of 0.73 cm.
• Breathing trace PDF standard deviations used in this study ranged from 0.057 to 1.13 cm
with an average standard deviation of 0.34 cm.
• A reasonably strong correlation (R2 = 0.864) was found between breathing trace am-
plitude and standard deviation, indicating that the amplitude of the motion is the most
important factor in determining the breathing trace standard deviation.
• The loss of target dose coverage (D95) is well described by a quadratic function of the
breathing trace standard deviation. This relation indicates that loss of target D95 is negligi-
ble for breathing patterns with a standard deviation of less than 0.2 cm for all target sizes
(< 1% loss of target D95). In general, the loss of target D95 begins to become appreciable
for targets undergoing motion with a standard deviation of 0.4 cm or greater.
• The additional margin required to maintain target D95 can be computed by iteratively in-
creasing the beam width in the direction of motion, and computing the new relative D95 of
the blurred profile in each instance. A table of margin recommendations derived from this
simulation was presented in Chapter 6.
• Since the target D95 is a relative quantity dependent on the size of the target volume, the
role of target size in selecting these margins cannot be ignored. The results presented in the
margin recommendation table indicate that little to no extra margin is required for many
combinations of target size and level of motion.
• Target size plays an important role in loss of dose coverage. For targets with a FWHM
of 5 cm or greater, additional margin is only required for very large target motion (with
standard deviation ≥ 0.4 cm. For targets smaller than 5 cm, more care must be taken to
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account for target motion. Small targets with large motion are by far the most susceptible
to loss of target dose coverage due to motion.
• The margin recommendations presented here can also be used to assess the trade off be-
tween target dose coverage and dose to OARs. If the margins recommended here would
cause unacceptable dose to an OAR, then the clinician can use that information do decided
whether the current treatment technique will be suitable.
• When the convolution model is applied to Gaussian PDFs and dose profiles, the results
presented in this thesis hold except for extreme cases of small targets with large motion.
8.3 Conclusion
Intrafraction target motion during external beam radiation therapy is a large source of geometric
uncertainty which has an impact on dose delivery. While technological advancements promise
new approaches to compensating for intrafraction motion, the most reliable and easiest to im-
plement of these approaches are the motion encompassing techniques. These techniques seek to
define an appropriate treatment margin to ensure the target volume receives the prescribed dose.
The expansion of treatment margins always comes at the cost of increased dose to OARs, and
so finding optimal margins is an important step in offering a successful radiotherapy treatment.
Offering patient specific recommendations for treatment margin selection allows for a fine bal-
ance to be struck between ensuring sufficient target dose and minimizing dose to the surrounding
OARs.
Intrafraction motion has the effect of ‘blurring’ the planned dose distribution causing a loss
of dose coverage to the target volume and increased dose to surrounding OARs upon treatment
delivery. The convolution model was found to accurately predict the loss of target dose coverage
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due to the blurring of intrafraction motion. By assessing the loss of dose coverage in relation
to parameters of a given patient’s specific breathing, it was found that the standard deviation of
the breathing trace PDF is a useful predictor of the loss of dose coverage. For target motions
with a standard deviation ≥ 0.4 cm care should be taken to apply additional treatment margins
as described in Table 6.2.
The size of the target volume is an important factor when considering loss of dose coverage.
Small targets (< 5 cm) are most susceptible to a loss of dose coverage, while large targets
(> 5 cm) are more robust in the face of intrafraction motion. Finally, the gradient of the patient’s
breathing trace PDF offered insights into the blurring effect caused by the motion. The rate of
change of the PDF along the direction of motion highlights the features of the patient’s breathing
trace that will make the largest impact on the blurred dose distribution. While the PDF standard
deviation predicts the dominant blurring effect, the gradient of the PDF can offer insight into
asymmetries resulting from asymmetric breathing.
The results of this work further emphasize the need for patient specific approaches to margin
selection. The interplay between target size, dose gradients, PDF standard deviation, location
of the disease relative to OARs and treatment technique leaves no room for general solutions.
The margin recommendations made in this work can be used to help guide treatment planning
decisions by revealing the additional margin required to compensate for a given patient’s specific
breathing motion and target volume. By applying the margin at the treatment planning stage, the
impact on OARs for that patient’s disease site can be assessed. This type of patient specific ap-
proach can help ensure the patient receives the optimal treatment, and hence the best opportunity
for a successful treatment outcome.
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8.4 Suggestions for Future Work
This line of research could be carried on through one of several veins of future work:
• The same approach to a motion encompassing technique could be applied to other cancer
sites susceptible to intrafraction target motion, such as the liver.
• The applicability of the model to segmented IMRT or volumetric modulated arc therapy
techniques could be assessed.
• Extending the work towards optimizing treatment margin selection based on radiobiologi-
cal considerations instead of purely physical (geometrical) considerations.
• Using the model predictions to adjust margins based on daily measured breathing patterns.
This could perhaps be extended to real time margin adjustments.
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Appendix A
Using Planned Dose Gradients and
IGRT-based Tissue Displacement Vectors
for Calculation of Cumulative
Radiotherapy Dose
A.1 Introduction
Previous emphasis in this thesis has been on the calculation of absorbed dose using the convolu-
tion of the gradient of the probability density function for lung (free breathing) and a static dose
profile obtained from the planned dose distribution. As shown, this is an effective methodology
for determining the change in the static dose profile due to patient-specific lung motion and pro-
vides a framework for selection of appropriate margins to ensure that the radiation oncologist’s
dose prescription is met. In this chapter/appendix, a methodology is presented for calculating
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the cumulative dose during radiation therapy taking into account day-to-day tissue differences
(target and organs at risk) as determined from regular (e.g. daily) CBCT images. Inter-fraction
changes in the position or shape of organs can cause geometric misses of the target or overex-
posure of critical organs during external beam dose delivery. However, not all organ motion is
necessarily cause for alarm as target volumes may move into high dose regions, while organs at
risk (OARs) may move away into safer lower dose regions. Target or OAR motion is alarming
only when the motion will ultimately result in large negative or positive changes in the planned
dose to those structures, respectively. There are several methods for assessing the differences
between the treatment day dose distribution and the originally planned dose distribution, such as
a dose difference mapping with gamma analysis [128].
The focus of this work is to present an alternative technique, taking advantage of dose gradi-
ent and tissue displacement vector information to highlight regions of a treatment plan where
dose variations will occur due to tissue displacements. The aim was to develop a software
tool which would help radiation therapists identify situations where emerging changes in pa-
tient anatomy require: (1) no action (2) repositioning the patient, or (3) re-planning the treatment
with adaptive modification of the dose distribution.
A.2 Dose Exchange Alarm for Optimal Patient Setup
By comparing the CT image obtained on the treatment day to the original CT-simulation image,
it is possible to calculate and display a vector (i.e. quiver) plot describing the displacement of any
tissue voxel. In-house code has been used to generate a tissue displacement map from contours of
the day and planning contours, using a thin-plate spline technique [131]. The deformation vector
map can then be used to assess the direction and severity of the tissue displacements relative to
dose gradients in the original planned dose distribution (i.e. no need to calculate the dose of the
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day). An example dose gradient map is show in Figure A.1, and an example quiver plot of tissue
deformation vectors is shown in Figure A.2.
Figure A.1: An example dose gradient map calculated from a 2D dose map. Tissue movement
through regions of large dose gradient is cause for concern when setting up a patient.
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Figure A.2: An example deformation vector quiver plot overlaid on an image of the original
anatomy. The vector field is used an an input to the Dose Exchange Alarm value calculation.
A.2.1 Definition of the Dose Exchange Alarm
The dose exchange alarm (DEA) requires two inputs: the tissue displacement vectors and the
planned dose gradient vectors computed using the planned dose distribution. The DEA is cal-
culated by taking the dot product between the tissue displacement vectors and the dose gradient
vectors. The resulting map is interpreted as a differential dose due to the movement of tissues as
defined by the quiver plot of tissue displacement. The overall information provided by the DEA
map can be summarized and scored using the equation:
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DEA =
√ ∑
ijk ROI
(aijk ~∇Dijk · ~dsijk − A¯)2 (A.1)
DEA =
√ ∑
ijk ROI
(Aijk − A¯)2 (A.2)
In this formulation, each voxel in the region of interest (ROI) is given an ’i, j, k’ index. The
rest of the quantities are defined as follows:
• aijk are weighting coefficients corresponding to target tissue or organs at risk. These should
be consistent with priority weights used during treatment planning.
• ~∇Dijk is the dose gradient map computed at each voxel.
• ~dsijk are the voxel displacement vectors determined from image guidance.
• A¯ is the simple average value of aijk over the region of interest.
A.3 Discussion
By minimizing the value of DEA, the necessary patient setup shifts that optimize the weighted
dose matching (as opposed to anatomy matching) can be determined and applied just prior to
dose delivery. This approach is analogous to minimizing the work done by charges that are
moved within an electric field.
DEAopt 7→ f(δx, δy, δz, δθ, δφ) (A.3)
MIN(DEA) = f(δx?, δy?, δz?, δθ?, δφ?), A¯ = 0 (A.4)
224
The DEA value alerts the therapist to either large tissue excursions through small dose gradi-
ents, or short tissue excursions through large dose gradients. This will help identify differences
in patient setup or anatomy which result in potentially critical changes in the dose delivered to
prescribed targets or OARs based on tissue movement through the planned dose landscape.
The workflow chart in Figure A.3 summarizes how the alarm tool would be used prior to
delivering a daily fraction. The patient has their initial setup, followed by image guidance to
correct any major shifts. The DEA is then computed to assess internal tissue deformation. Min-
imizing the DEA as a function of rigid-body transformations produces an optimal set of patient
setup shifts.
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Figure A.3: An example workflow chart describing the use of the DEA during the delivery of a
single fraction of a radiotherapy treatment.
Finally, the therapists apply the secondary shifts and rotations resulting from the optimization
and DEAopt is compared to the relevant re-planning threshold value for the given treatment site.
It should be noted that in general the DEAopt will not be equal to zero and that the minimum
value of the DEA will change on a daily basis in accordance with the current state of the patient
anatomy. This is described with an example shown in Figure A.4.
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Figure A.4: A schematic plot of the optimized DEA values over the course of several fractions
of a radiotherapy treatment. The optimized DEA will not be zero in general. The re-planning
threshold varies throughout the treatment. In this example three optimized DEA violations of the
threshold were permitted before triggering a re-plan at fraction 7.
The decision to re-plan a treatment would need to consider several factors, such as: the treat-
ment site, the treatment objectives, the severity of the mismatch between the fractional dose dis-
tribution and the planned dose distribution, and the proportion of the full treatment prescription
remaining to be delivered.
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A.3.1 The Role of Deformable Image Registration
The DEA technique relies on a set of vector fields generated by an image registration algorithm.
Basic image registration algorithms seek to register the image by applying simple shifts and
rotations to images. These algorithms are known as rigid-registration algorithms. Deformable
image registration (DIR) adds a layer of complexity to the image registration algorithm by also
allowing for deformations of the image as well as the standard rigid registration shifts. While
DIR algorithms show promise for more accurate image registration, much work is still to be
done validating their results. Tissue displacement vector fields generated by accurate DIR would
provide the best basis for the DEA.
Mencarelli et al. [132] compared a b-spline-based DIR algorithm with a rigid-registration
algorithm on sets of planning CT data sets and CBCT data sets of patients acquired at a later
date. They reported poor precision for the DIR results in tumour tissue in particular. Mencarelli
et al. caution the use of DIR for monitoring tumour changes in adaptive procedures.
Zhong et al. [133] compared the performance of two DIR algorithms (Demons and b-spline)
using phantom images of different body sites. Their results suggest that the accuracy of both
algorithms was highly sensitive to the DIR parameter selection at each site. Therefor DIR results
need to be closely scrutinized on a case by base basis.
Yeo et al. [134] assessed the accuracy of dose-warping based on the results of DIR by com-
paring to measurements made in a deformable dosimetric gel phantom. They reported very good
agreement between DIR dose-warping and measured dose for simple open filed plans and small
magnitude deformations. The agreement was markedly worse for more complex treatment plans
and large deformations. The authors suggest that the DIR dose-warping is feasible, but that
results should be carefully scrutinized before clinical application.
In each case, the authors find that DIR can offer accurate results under the right set of con-
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ditions. However, in many practical cases the combination of conditions (e.g. body site, DIR
parameter selection, magnitude of deformation) make the reliability of DIR results suspect. This
is currently a major hurdle to the routine clinical use of DIR, with many research groups around
the world focused on the problem. As DIR algorithms are refined, their potential for use in the
DEA improves.
A.4 Future Work
Ultimately the DEA approach could provide an on-line alarm display to be employed by radiation
therapists at the treatment unit. The therapists would be able to easily identify whether or not
the current patient setup or anatomy warrants further setup adjustment or call for adaptive dose
re-planning.
This appendix provides a proof-of-concept methodology for calculation of cumulative dose
using IGRT data and dose gradients obtained from the original treatment plan. The limitations of
the methodology include the simplicity of the dot product computation (first order calculation)
and the accuracy of the displacement vectors determined form voxel-to-voxel DIR. Based on
recent literature, generating reliable results from DIR algorithms still poses a large challenge.
Additional work is in progress, in conjunction with researchers at the London Health Sciences
Center to derive a site-specific constrained registration algorithm that will provide more accurate
displacement vector solutions.
Future work also includes using this alarm as part of multi-fraction treatment simulations
in order to determine the tumour site-specific threshold values for the DEA. These simulations
could also be used to assess the ability of the weighted dose matching to steer the cumulative
dose distribution towards convergence to the prescribed treatment objectives. More computer
programming work is also necessary to extend this 2D proof of principle to 3D.
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Appendix B
MATLAB Code
Included in this appendix is the MATLAB code used to process the dose profiles and breathing
traces analyzed in this thesis. The code is available from the author as an electronic .m file or
packaged as a stand-alone application with a graphical user interface.
B.1 MATLAB code
1 %%%%%Start a timer to measure the total time of simulation%%%%%
2 t1=tic;
3
4 %%%%%Create Output File with Headings%%%%%
5 write=fopen('STDvsMargin_70mm.txt','a');
6 fprintf(write,'%s\t %s\t %s\t %s\t %s\t %s\r','Filename','PDF STD','DoseProf1D90','DoseProf1D95','DoseProf1D99','margin');
7 fclose all;
8
9 %%%%%Import The List of Static Dose Profiles%%%%%
10 proflisting=dir('C:\Documents and Settings\stkfoste\Desktop\redo\doseprof');
11
12 %%%%%%%
13 %This loop performs the following actions on each static dose profile:
14 %- extracts the dose profile data from the txt file (assumes Eclipse export format)
15 %- interpolates dose points for finer detail after convolution
16 %- detects the 95% dose point inferiorly and superiorly and sets them as
17 %PTV boundaries
18 %%%%%%%
19 for kk=3:size(proflisting,1)
20 %Save the profile name in a structure
21 profname.(strcat('a',num2str(kk)))=strrep(proflisting(kk,1).name,'.txt','');
22 %Import file data into a dummy variable (doseprofa)
230
23 doseprofa=importdata(strcat('C:\Documents and ...
Settings\stkfoste\Desktop\redo\doseprof\',proflisting(kk,1).name),'\t',8);
24
25 %Save the dose and position data in seperate vectors, stored in a
26 %structure
27 doseprof.(profname.(strcat('a',num2str(kk)))).origdist=doseprofa.data(:,1);
28 doseprof.(profname.(strcat('a',num2str(kk)))).origdose=doseprofa.data(:,2);
29
30 %Generate and save the interpolation grid based on the imported position data
31 doseprofdisttrans=min(doseprof.(profname.(strcat('a',num2str(kk)))).origdist):0.001:max(doseprof.(profname.%LINE BREAK
32 (strcat('a',num2str(kk)))).origdist);
33 doseprof.(profname.(strcat('a',num2str(kk)))).dist=doseprofdisttrans';
34
35 %Interpolate the dose data and save the spatial sampling rate
36 doseprof.(profname.(strcat('a',num2str(kk)))).dose=interp1(doseprof.(profname.(strcat('a',num2str(kk)))).%LINE BREAK
37 origdist,doseprof.(profname.(strcat('a',num2str(kk)))).origdose,doseprof.(profname.(strcat('a',num2str(kk)))).dist);
38 doseprofstepsize=mean(diff(doseprof.(profname.(strcat('a',num2str(kk)))).dist));
39
40 %Detect the center of the dose profile (location of the center of the dose data)
41 traceCenter=round(size(doseprof.(profname.(strcat('a',num2str(kk)))).dose,1)/2);
42
43 %Set the maximum dose. This variable used to find PTV edges.
44 %Swap the comment on the two lines below to use a fixed dMax, or
45 %the maximum dose detected in the profile.
46 dMax=200;
47 %dMax=max(doseprof.(profname.(strcat('a',num2str(kk)))).dose)
48
49 %Determine and save the location of the PTV edges
50 dynPTVinf=dsearchn(doseprof.(profname.(strcat('a',num2str(kk)))).dose(1:traceCenter),dMax*0.90);
51 dynPTVsup=dsearchn(doseprof.(profname.(strcat('a',num2str(kk)))).dose(traceCenter:end),dMax*0.90)+traceCenter;
52 doseprof.(profname.(strcat('a',num2str(kk)))).PTVinf=dynPTVinf;
53 doseprof.(profname.(strcat('a',num2str(kk)))).PTVsup=dynPTVsup;
54
55 %%%%%Optional Profile Plotting Output%%%%%
56 % figure
57 % plot(doseprof.(profname.(strcat('a',num2str(kk)))).dist,doseprof.(profname.(strcat('a',num2str(kk)))).dose);
58 end
59
60 %%%%%Import List of Breathing Traces%%%%%
61 %listing=dir('C:\Documents and Settings\stkfoste\Desktop\redo\traces');
62 listing=dir('C:\Documents and Settings\stkfoste\My Documents\MATLAB\Organized Traces\Processed');
63 %%%%%Start the progress bar%%%%%
64 hh=waitbar(0,'Please Wait...');
65
66 %%%%%This is the main loop%%%%%
67 %%%%%
68 %This loop performs the following:
69 %- Import a breathing trace file (.vxp file - from Varian's RPM system)
70 %- Extract the portion of the breathing trace recorded during 'beam on'
71 %- Generate a PDF using the 'beam on' position data
72 %- Convolve the PDF against each imported static dose profile
73 %- Calculate the D95 of the static and blurred dose profiles
74 %- Save pertinent data in a structure
75 %%%%%
76 for m=3:size(listing,1)
77 %for m=3:5
78
79 %Read the breathing trace .vxp file, save data in a dummy variable (filedata)
80 mm=listing(m,1).name;
81 file=strcat('C:\Documents and Settings\stkfoste\My Documents\MATLAB\Organized Traces\Processed\',mm);
82 qwe=fopen(file);
83 filedata=textscan(qwe,'%f %f %f %d %d %c %d', 'HeaderLines', 10, 'Delimiter',',');
84 fclose(qwe);
85
86 %Save a vector with the recorded marker block position from imported data
87 btrac=filedata{1,1,1};
88
89 %Save a vector with the recorded beam on flag from imoported data
90 beamon=filedata{1,5,1};
91
92 %Set loop counter to 1 (k)
93 k=1;
94
95 %Instantiate empty vector for saving recorded positions during 'beam on'
96 btraca=zeros(5000,1);
97
98 %Loop through filedata, saving only positions recorded during 'beam on' in
99 %a dummy variable (btraca)
231
100 for n=1:size(beamon)
101 if beamon(n,1)<=0
102 else
103 btraca(k,1)=btrac(n,1);
104 k=k+1;
105 end
106 end
107
108 %Save pertinent portion of dummy variable in usefule variable (btrace)
109 btrace=btraca(1:(k-1),1);
110
111 %Determine the geometric center of the breathing trace
112 btracecent=(max(btrace)-min(btrace))/2;
113
114 %Center the breathing trace
115 btracecentered=btrace-(ones(size(btrace,1),1)*(max(btrace)-abs(btracecent)));
116 %plot(btracecentered)
117 %Calculate some breathing trace statistics
118 pdfmean=mean(btracecentered);
119 pdfstd=std(btracecentered);
120 % pdfmean=mean(btracecentered);
121 % pdfstd=std(btracecentered);
122 % pdfkurt=kurtosis(btracecentered);
123 % pdfamp=max(btracecentered);
124 % pdfskew=skewness(btracecentered);
125 % pdfmaxloc=btracecentrange(1,dsearchn(normpdfa,max(normpdfa)));
126 % pdfmax=normpdfa(dsearchn(normpdfa,max(normpdfa)),1);
127 % diffnormpdf=diff(normpdfa);
128 % diffpdfamp=max(diffnormpdf);
129 % diffpdfmean=mean(abs(diffnormpdf));
130 % diffpdfstd=std(diffnormpdf);
131 % diffpdfkurt=kurtosis(diffnormpdf);
132 % diffpdfskew=skewness(diffnormpdf);
133 % diffpdfmaxgrad=max(abs(diffnormpdf));
134 % diffpdfmaxgradind=dsearchn(diffnormpdf,diffpdfmaxgrad);
135 % diffpdfmaxgradloc=btracecentrange(1,diffpdfmaxgradind);
136
137 %Save a vector of position data slightly longer than the range of
138 %positions covered by the breathing trace, used to help fit the PDF
139 btracecentrange=min(btracecentered)*1.3:doseprofstepsize:max(btracecentered)*1.3;
140
141 %Generate the PDF and normalize the area under the curve
142 pdf = ksdensity(btracecentered,btracecentrange,'support',[min(btracecentrange) max(btracecentrange)],'width',0.2);
143 normpdfa = pdnorm(btracecentrange',pdf');
144
145 %Save pertinent data in a structure (beamo)
146 filename=strrep(mm,'.vxp','');
147 beamo.(strcat('a',filename)).PDFmean=pdfmean;
148 beamo.(strcat('a',filename)).PDFstd=pdfstd;
149 beamo.(strcat('a',filename)).FullPDF=normpdfa;
150 beamo.(strcat('a',filename)).PDFdist=btracecentrange;
151
152 %%%%%Optional PDF Plotting Output%%%%%
153 %figure
154 %plot(btracecentrange,normpdfa);
155
156 %%%%%Convolution sub-loop%%%%%
157 %%%%%
158 %This loop performs the following:
159 %- Convolves the PDF against each imported breathing trace
160 %- Aligns convolved profile to static profile by shifting according to
161 %PDF mean (Linear shift-invariance property of the convolution)
162 %- Calculates the D95 of the static and blurred profiles
163 %- Saves pertinent data to a structure (beamo)
164 %%%%%
165 pdfdataarray = [pdfstd];
166 for gg=3:size(proflisting,1)
167
168 %Perform convolution
169 pdconv=conv(doseprof.(profname.(strcat('a',num2str(gg)))).dose,normpdfa','same');
170
171 %Determine original static profile plot area for normalization purposes
172 doseprofarea=getplotarea(doseprof.(profname.(strcat('a',num2str(gg)))).dist,doseprof.(profname.%LINE BREAK
173 (strcat('a',num2str(gg)))).dose);
174
175 %Create a vector of position data for the convolved profile,
176 %shifted by the PDF mean
177 convdistend=(size(pdconv,1)-1)*doseprofstepsize;
232
178 convdist1=(0:doseprofstepsize:convdistend)';
179 convdist=convdist1-ones(size(convdist1,1),1)*pdfmean;
180
181 %Determine the plot area of the blurred profile for normalization
182 %purposes
183 convprofarea=getplotarea(convdist,pdconv);
184 %convprofarea=getplotarea(doseprof.(profname.(strcat('a',num2str(gg)))).dist,pdconv);
185 arearatio=doseprofarea/convprofarea;
186
187 %Save the static and blurred dose profiles and corresponding
188 %positional data in the beamo structure
189 beamo.(strcat('a',filename)).(profname.(strcat('a',num2str(gg)))).convprofile=pdconv*arearatio;
190 beamo.(strcat('a',filename)).(profname.(strcat('a',num2str(gg)))).convposition=convdist;
191 beamo.(strcat('a',filename)).(profname.(strcat('a',num2str(gg)))).staticprofile=doseprof.%LINE BREAK
192 (profname.(strcat('a',num2str(gg)))).dose;
193 beamo.(strcat('a',filename)).(profname.(strcat('a',num2str(gg)))).staticposition=doseprof.%LINE BREAK
194 (profname.(strcat('a',num2str(gg)))).dist;
195
196 %%%%%Optional Blurred and Static Profile Plotting Output%%%%%
197 % figure
198 % plot(beamo.(strcat('a',filename)).(profname.(strcat('a',num2str(gg)))).staticdist,beamo.%LINE BREAK
199 (strcat('a',filename)).(profname.(strcat('a',num2str(gg)))).staticprofile, 'color', 'black');
200 % hold all
201 % plot(convdist,beamo.(strcat('a',filename)).(profname.(strcat('a',num2str(gg)))).convprofile,'color','red')
202 % hold off
203
204 %Calculate and save the D90, D95 & D99 of the static profile. This is done by
205 %numerically ordering all dose values within the PTV and selecting
206 %the value at the 95th percentile.
207 origPTVinf=doseprof.(profname.(strcat('a',num2str(gg)))).PTVinf;
208 origPTVsup=doseprof.(profname.(strcat('a',num2str(gg)))).PTVsup;
209 origtargetdose=doseprof.(profname.(strcat('a',num2str(gg)))).dose(origPTVinf:origPTVsup,1);
210 npercent=round(size(origtargetdose,1)*0.1);
211 nfpercent=round(size(origtargetdose,1)*0.05);
212 nnpercent=round(size(origtargetdose,1)*0.01);
213 orderOTD=sort(origtargetdose);
214 origD90=orderOTD(npercent,1);
215 origD95=orderOTD(nfpercent,1);
216 origD99=orderOTD(nnpercent,1);
217 beamo.(strcat('a',filename)).(profname.(strcat('a',num2str(gg)))).staticD90=origD90;
218 beamo.(strcat('a',filename)).(profname.(strcat('a',num2str(gg)))).staticD95=origD95;
219 beamo.(strcat('a',filename)).(profname.(strcat('a',num2str(gg)))).staticD99=origD99;
220
221 %Calculate and save the D90, D95 & D99 of the blurred profile. This is done by
222 %numerically ordering all dose values within the PTV and selecting
223 %the value at the 95th percentile.
224 convPTVinf=origPTVinf+round(pdfmean/doseprofstepsize);
225 convPTVinfvalue=convdist(convPTVinf,1);
226 convPTVsup=origPTVsup+round(pdfmean/doseprofstepsize);
227 convPTVsupvalue=convdist(convPTVsup,1);
228 convtargetdose=beamo.(strcat('a',filename)).(profname.(strcat('a',num2str(gg)))).%LINE BREAK
229 convprofile(convPTVinf:convPTVsup,1);
230 convnpercent=round(size(convtargetdose,1)*0.1);
231 convnfpercent=round(size(convtargetdose,1)*0.05);
232 convnnpercent=round(size(convtargetdose,1)*0.01);
233 orderCTD=sort(convtargetdose);
234 convD90=orderCTD(convnpercent,1);
235 convD95=orderCTD(convnfpercent,1);
236 convD99=orderCTD(convnnpercent,1);
237 beamo.(strcat('a',filename)).(profname.(strcat('a',num2str(gg)))).convD90=convD90;
238 beamo.(strcat('a',filename)).(profname.(strcat('a',num2str(gg)))).convD95=convD95;
239 beamo.(strcat('a',filename)).(profname.(strcat('a',num2str(gg)))).convD99=convD99;
240
241 %Calculate and save the relative D90, D95 & D99
242 relD90=convD90/origD90;
243 relD95=convD95/origD95;
244 relD99=convD99/origD99;
245 beamo.(strcat('a',filename)).(profname.(strcat('a',num2str(gg)))).relD90=relD90;
246 beamo.(strcat('a',filename)).(profname.(strcat('a',num2str(gg)))).relD95=relD95;
247 beamo.(strcat('a',filename)).(profname.(strcat('a',num2str(gg)))).relD99=relD99;
248 pdfdataarray=cat(2,pdfdataarray, relD90);
249 pdfdataarray=cat(2, pdfdataarray, relD95);
250 pdfdataarray=cat(2, pdfdataarray, relD99);
251 %%%%%Optional Blurred and Static PTV Profile Plotting Output%%%%%
252 % figure
253 % plot(origtargetdose,'color','black')
254 % hold all
255 % plot(convtargetdose,'color','red')
233
256 % hold off
257
258 %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
259 %%%%%Set the value of various variables used in the following
260 %%%%%'while' loop%%%%%
261
262 doseprofdose=doseprof.(profname.(strcat('a',num2str(kk)))).dose;
263 traceCenter=round(size(doseprofdose,1)/2);
264 newRelD95 = relD95;
265 p=1;
266 inc=p*10;
267 origdist=doseprof.(profname.(strcat('a',num2str(kk)))).origdist;
268 doseprofdist=doseprof.(profname.(strcat('a',num2str(kk)))).dist;
269 convprogression=[newRelD95];
270 %%%%%
271 %This loop performs the following:
272 %- Incrementally increases the beam width by adding additional dose
273 %points to the centre of the dose profile (this is called the
274 %recommended profile)
275 %- Convolves the recommended profile with the PDF
276 %- Calculates the D95 of the blurred recommended profile
277 %- If the convolved D95 is less than the original D95, the loop repeats
278 %with a larger increment added to the orignal profile
279 %- Saves pertinent data to a structure (beamo)
280 %%%%%
281 while newRelD95 < 0.9999
282 %Set the incremental increase in profile width
283 inc=p*10;
284
285 %Add this increment to the middle of the original profile
286 recProfinf=doseprofdose(1:traceCenter);
287 recProfAdded=ones(inc,1)*doseprofdose(traceCenter,1);
288 recProfsup=doseprofdose(traceCenter:end);
289 recProf=cat(1,recProfinf,recProfAdded,recProfsup);
290
291 %Generate a vector of positions for the recommended profile and
292 %center it
293 recProfAddedDisttrans=max(origdist):doseprofstepsize:(max(origdist)+(inc*doseprofstepsize));
294 recProfAddedDist=recProfAddedDisttrans';
295 recProfDista=cat(1,doseprofdist,recProfAddedDist);
296 recProfDist=recProfDista-ones(size(recProfDista,1),1)*(inc/2)*doseprofstepsize;
297
298
299 %Perform the convolution of the recommended profile with the
300 %PDF
301 Newpdconv=conv(recProf,normpdfa','same');
302
303 %Determine original static profile plot area for normalization purposes
304 Newdoseprofarea=getplotarea(recProfDist,recProf);
305
306 %Create a vector of position data for the convolved recommended profile,
307 %shifted by the PDF mean
308 convdistenda=(size(Newpdconv,1)-1)*doseprofstepsize;
309 convdist1a=(0:doseprofstepsize:convdistenda)';
310 convdista=convdist1a-ones(size(convdist1a,1),1)*(pdfmean+((inc/2)*doseprofstepsize));
311
312 %Determine the plot area of the blurred profile for normalization
313 %purposes
314 Newconvprofarea=getplotarea(convdista,Newpdconv);
315 arearatio=Newdoseprofarea/Newconvprofarea;
316 Newconvprofile=Newpdconv*arearatio;
317
318 %%%%%Optional plotting of the static and blurred recommended
319 %%%%%profiles
320 %figure
321 %plot(convdista,Newconvprofile,'color','green','DisplayName','Recommended Blurred Profile')
322 %plot(recProfDist,recProf,'color','blue','DisplayName','Recommended Static Profile')
323
324 %Calculate the D95 of the recommended blurred profile
325 NewconvPTVinf=dsearchn(convdista(1:(traceCenter+(inc/2))),convPTVinfvalue);
326 NewconvPTVsup=dsearchn(convdista((traceCenter+(inc/2)):end),convPTVsupvalue)+(traceCenter+(inc/2));
327 Newconvtargetdose=Newconvprofile(NewconvPTVinf:NewconvPTVsup,1);
328 Newconvnfpercent=round(size(Newconvtargetdose,1)*0.05);
329 NeworderCTD=sort(Newconvtargetdose);
330 NewconvD95=NeworderCTD(Newconvnfpercent,1);
331
332 %Update the value of the variable to be checked by the 'while' loop
333 newRelD95=NewconvD95/origD95
234
334
335 %Update the counter for incremental increase in dose profile
336 %width. Large increments when the relative D95 is far from 1
337 %speed up the simulation
338 if newRelD95 <0.9
339 p=p+75
340 elseif newRelD95 <0.95
341 p=p+50
342 elseif newRelD95 <0.98
343 p=p+20
344 elseif newRelD95 <0.99
345 p=p+10
346 elseif newRelD95 <0.992
347 p=p+5
348 else
349 p=p+1
350 end
351 % p=p+1
352 end
353
354 %Calculate the recommended margin based on the final increment
355 margin=inc*doseprofstepsize*10;
356
357 %Save margin information to write to output file
358 pdfdataarray=cat(2, pdfdataarray, margin);
359
360 %Save the recommended static and blurred profiles and their
361 %associated position data
362 beamo.(strcat('a',filename)).(profname.(strcat('a',num2str(gg)))).recprofile=recProf;
363 beamo.(strcat('a',filename)).(profname.(strcat('a',num2str(gg)))).recposition=recProfDist;
364 beamo.(strcat('a',filename)).(profname.(strcat('a',num2str(gg)))).recoConvprofile=Newconvprofile;
365 beamo.(strcat('a',filename)).(profname.(strcat('a',num2str(gg)))).recoConvposition=convdista;
366 end
367
368 %%%%%Save output data in a .txt file for export%%%%%
369 ffb=fopen('STDvsMargin_70mm.txt','a');
370 fprintf(ffb,'%s\t %g\t %g\t %g\t %g\t %g\r',filename, pdfdataarray);
371 fclose all;
372
373 %%%%%Update the progress bar
374 waitbar(m / (size(listing,1)))
375 end
376
377 %%%%%Close the progress bar
378 close(hh)
379
380 %%%%%Output total simulation time
381 toc(t1)
235
